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Abstract 
 
Muscular dystrophies are a diverse group of genetic diseases characterized by 
progressive muscle weakness and deterioration with wide variability in severity and affected 
muscle groups. Some of the more devastating muscular dystrophies result from the absence 
of components of the dystrophin-glycoprotein complex (DGC). Disruption of the DGC 
compromises sarcolemmal integrity in striated muscle, leading to increased myocyte injury 
and death. These forms of muscular dystrophy often feature both skeletal muscle wasting 
and marked cardiomyopathy. The most common of these muscular dystrophies is Duchenne 
muscular dystrophy (DMD), caused by mutations in the dystrophin gene that result in the 
loss of this large membrane-stabilizing protein. DMD features a childhood onset and leads to 
premature death at ages ranging from the teens into the 30’s, often from cardiorespiratory 
failure. DMD is an X-linked disorder, and is usually inherited from carrier mothers who also 
face a high risk of cardiomyopathy.  
Sarcoglycanopathies are a rarer group of autosomal recessive Limb Girdle muscular 
dystrophies (LGMD) that arise from mutations in the sarcoglycan genes, sometimes leading 
to an aggressive Duchenne-like disease course in patients of both sexes. The 
heterotetrameric sarcoglycan complex is a key component of the DGC, and its loss induces 
significant myocyte pathology that can trigger childhood disease onset and premature death. 
Muscles and hearts devoid of the sarcolgycan complex display hallmark dystrophic 
pathology, including muscle wasting, loss of ambulation, and a high incidence of lethal 
dilated cardiomyopathy.  
The work presented here is driven by efforts to quantify the susceptibility of 
dystrophic hearts to acute injury caused by increased cardiac workload, and to understand 
the contribution of angiotensin signaling to dystrophic heart injury. It describes the following 
key findings: 1) angiotensin receptor blockers (ARBs) can markedly reduce acute injury in 
dystrophin-null and sarcoglycan-null mouse hearts; 2) female mouse hearts lacking the 
sarcoglycan complex are significantly protected compared to male hearts, and do not derive 
the same benefit from ARBs; and 3) mosaic expression of dystrophin in the heart results in 
elevated vulnerability to injury that is modulated by factors besides dystrophin levels. This 
work suggests that angiotensin signaling plays an exaggerated role in dystrophic heart injury 
through mechanisms that may be sex-dependent, and that earlier and more consistent use 
of angiotensin-blocking therapies has the potential to limit dystrophic cardiomyopathy. 
Furthermore, it reveals that dystrophic hearts may continue to show significant vulnerability 
in the context of gene therapies that restore partial dystrophin expression.  
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CHAPTER 1: INTRODUCTION 
Cardiac Pathophysiology and the Future of Cardiac Therapies in Duchenne 
Muscular Dystrophy* 
1. Overview 
Muscular dystrophies are a diverse group of rare genetic diseases characterized 
by progressive skeletal muscle wasting. Many different molecular mechanisms underlie 
this loss of healthy muscle tissue, leading to wide variability in severity and affected 
muscle groups. Some of the more devastating muscular dystrophies are those that 
develop due to the absence of components of the dystrophin-glycoprotein complex 
(DGC), resulting in compromised sarcolemmal integrity in skeletal muscle and the heart. 
These forms of muscular dystrophy feature both skeletal muscle wasting and marked 
cardiomyopathy. The most common form of muscular dystrophy is Duchenne muscular 
dystrophy (DMD), which arises due to mutations in the dystrophin gene that result in the 
complete absence of this large protein that functions in stabilizing the myocyte 
membrane. Without dystrophin scaffolding the cytoskeleton to the sarcolemma, the 
mechanical and molecular infrastructure of the cell is significantly compromised. This 
gives rise to a variety of downstream pathogenic mechanisms, culminating in disease 
characteristics that include striated muscle degeneration, fibrosis, loss of motor function, 
and death due to cardiorespiratory failure. 
With advancements in life-prolonging symptomatic therapies like ventilatory 
support, a greater proportion of patients with severe forms of muscular dystrophy survive 
long enough to develop heart failure, increasing the need for interventions that can 
ameliorate heart disease in this population [1–3]. In the 21st century, heart failure is a 
leading cause of death in DMD, with many patients reaching adolescence or adulthood 
and displaying symptoms of dystrophic heart disease without receiving cardiac therapy 
[2,4]. To address this issue, the most current guidelines released in 2015 recommend 
that DMD patients start therapy with ACE inhibitors (ACEIs) or angiotensin receptor 
blockers (ARBs) by 10 years of age or sooner, based on mounting evidence that early 
stages of cardiac deterioration may have already begun [5,6].  
Currently, there is great excitement in the muscular dystrophy community as new 
therapeutic approaches are reaching the clinics. While the overall efficacy of these new 
therapies will be measured in ongoing clinical trials, most of these trials lack detailed 
                                               
* Under review for publication in the International Journal of Molecular Sciences  
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cardiac end-points, and some of these approaches are known to have relatively poor 
efficacy in the dystrophic heart. Given the critical role of the heart in the disease process 
and quality of life, this review will focus on current understanding of cardiac involvement 
in DMD and detail how current and future therapies may delay or prevent the onset of 
heart failure in DMD patients.   
 
2. Genetic Basis 
One of the earliest recognized features of DMD was its X-linked mode of 
inheritance, which greatly aided in the identification of the genetic locus that was 
responsible for the disease. The DMD gene is the largest known human gene at 2.4 Mb, 
producing a 14 Kb mRNA transcript from 79 exons. Several internal promoters and 
variable splicing give rise to a wide variety of dystrophin isoforms that are expressed in 
striated and smooth muscle, brain, retina, and kidney, [7]. This vast size and complexity 
likely contribute to higher probability of a mutation interfering with the gene product. 
Deletions are the most common type of dystrophin mutation underlying DMD, accounting 
for over 70% of all mutations and often causing a change in the reading frame that 
produces a premature stop codon [8,9]. The next most common types of DMD mutation 
are insertions and point mutations, also usually resulting in a premature stop codon and 
the termination of protein synthesis [8,9]. DMD is most often passed down via the X-
chromosome from a mother that has one mutated copy of the gene (carrier) to male 
offspring, but also has a relatively high rate of de novo mutations accounting for roughly 
1/3 of all cases [8,9]. Because DMD is an X-linked disease, it affects almost exclusively 
males, with an incidence of approximately 1 in 5,000 live male births [10,11]. 
Conversely, mutations that still allow for a truncated dystrophin to be produced 
and trafficked to the sarcolemma result in the overall milder Becker muscular dystrophy 
(BMD). With an incidence of about 1 in 18,500 male births, BMD is much rarer than 
DMD due to its roots in dystrophin mutations that preserve the open reading frame, 
allowing for a partially functional protein product [9]. BMD displays wide phenotypic 
variation, ranging from very severe DMD-like disease to very mild muscle weakness. 
This phenotypic variation depends on the specific regions of dystrophin that are lost as a 
result of the BMD-causing mutation [12,13]. Accordingly, analysis of the relationship 
between the underlying mutation and resulting phenotype in BMD has been instrumental 
in shaping our understanding of dystrophin’s structure and the function of its various 
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domains. In fact, identification of some BMD-causing mutations that produced extensive 
deletions in the central domain but result in a very mild disease course has led to the 
development of multiple truncated but functional micro-dystrophins as gene therapy 
candidates currently in clinical trials.   
 
3. Clinical Manifestation 
Duchenne muscular dystrophy was first described in the early 19th century by 
Italian physicians Gaetano Conte and L. Gioja. In the 1830’s, they reported on two 
brothers displaying progressive muscle weakness in the face of paradoxical hypertrophy, 
with the older brother dying with an enlarged heart, and the younger eventually losing 
the ability to move [14]. Brothers afflicted by debilitating muscle deterioration along with 
hypertrophy in the absence of neurological deficits were again described in 1852 and 
1853 by Edward Meryon and William J. Little, respectively [14]. However, the most 
detailed account was delivered in the 1860’s by Guillaume-Benjamin-Amand Duchenne, 
who provided photos, drawings, and detailed descriptions of 13 of his own patients who 
shared these characteristics of muscle wasting, progressive muscle weakness 
accompanied by pseudohypertrophy, and premature death [14].  
Initial clinical symptoms tend to be noticed around 3-5 years of age, and typically 
include apparent muscle weakness and fatigue in the legs and pelvic region, causing an 
abnormal gait, lordosis, and use of Gowers’ maneuver. The gastrocnemius eventually 
develops pseudohypertrophy, resulting from accumulation of fatty and fibrotic tissue 
combined with slower atrophy than in the thigh muscles [15]. Elevations in serum levels 
of creatine kinase (CK), an enzyme typically retained within muscle fibers in healthy 
tissue, are detectable in newborns with muscular dystrophy at levels around 10-fold 
higher than in healthy newborns [10]. As children with DMD grow and reach a 
symptomatic age, serum CK is further elevated to about 50-100 times of the healthy 
level as myofiber contents leak out of increasingly damaged muscle cells. Since 
dystrophin also plays a role in the brain and affects cognitive function, cognitive 
or neuropsychiatric impairment present in roughly 1/3 of all cases [16,17]. 
Histopathological evaluation of patient muscle biopsies reveals central nucleation 
indicative of ongoing muscle regeneration, along with fibrosis, myocyte necrosis, fatty 
accumulation, and immune cell infiltration.  
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Cardiac functional assessment via echocardiography shows systolic and diastolic 
dysfunction as the disease progresses. Declines in ejection fraction (EF) to <50% can be 
seen as early as 9-10 years of age, and ejection fraction may drop as low as 25-30% 
later in the course of the disease [18]. Cardiac magnetic resonance imaging (CMR) may 
be used to detect declining myocardial strain as an index of cardiac dysfunction before 
the onset of measurable ejection fraction deficits [19]. In combination with late 
gadolinium enhancement (LGE), cardiac MRI can also be used to identify fibrotic 
scarring in the heart, which appears ahead of cardiac dysfunction [18]. This LGE+ 
fibrosis tends to be localized sub-epicardially, appearing in some patients even before 
10 years of age and in the majority of patients after 15 years of age, and increases in 
LGE are correlated with age and declining ejection fraction [18,20]. Cardiac troponin 
(cTn) elevations can be intermittently detected in patient serum, serving as a biomarker 
of sporadic periods of myocardial destruction [21–23]. Heart rhythm abnormalities are 
also present in a significant portion of patients, usually in the form of sinus tachycardia, 
and may be related to myocardial fibrosis in the cardiac conduction system [7]. 
As the disease progresses, atrophy of posture muscles often leads to scoliosis, 
and further muscle wasting and contractures result in wheelchair dependence around 
adolescence. Cardiac dysfunction usually progresses into dilated cardiomyopathy with 
extensive fibrosis, shown to be present in essentially all patients over 18 years of age, 
and eventually heart failure sets in [3,24]. Historically, death usually occurred by 20-25 
years of age from cardiorespiratory failure, but advancements in respiratory and 
pharmacological interventions have the capacity to extend lifespans into the 30’s and 
early 40’s with diligent clinical management [1,25].   
 
4. Pathophysiological Mechanisms of Dystrophic Cardiomyopathy 
4.1. Membrane Instability 
Membrane fragility has often been viewed as the primary defect in DMD, 
precipitating multiple secondary pathophysiological mechanisms that lead to myocyte 
death. In healthy myocytes, rather than distributing diffusely throughout the sarcolemma, 
dystrophin localizes in a striated pattern that reflects its association with costameres 
[26]. Costameres are a sub-sarcolemmal network that mechanically couples the 
extracellular matrix (ECM) to the Z-disc of the sarcomere through the DGC and 
cytoskeletal γ-actin, with dystrophin playing a central role in this mechanical linkage [27]. 
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Dystrophin’s N-terminal region binds filamentous γ-actin and extends to the sarcolemma, 
where its C-terminus joins with the transmembrane β-dystroglycan. β-dystroglycan’s 
extracellular domain binds to the heavily-glycosylated α-dystroglycan, which in turn links 
to the ECM through laminin. β-dystroglycan also associates with the transmembrane 
sarcoglycan complex, which plays its own major role in sarcolemmal stability. This 
assembly comprises the DGC, and this axis of force transmission and stabilization from 
the contractile apparatus to the ECM is broken when dystrophin is not expressed. It is 
worth noting that dystrophin loss precipitates the depletion of the majority of the DGC in 
skeletal muscle, but cardiac muscle retains most of the other DGC components in the 
absence of dystrophin [28,29]. 
Without functional dystrophin, the sarcolemma becomes fragile and displays 
significant leakiness under increased workload on the myocyte. Serum biomarkers of 
this increased cellular permeability include elevated levels of CK, the bulk of which is 
attributable to skeletal muscle, and cTn from the myocardium [21,22,30]. Further 
preclinical evidence of major membrane disruptions is readily detectable in dystrophic 
hearts and muscle by Evans Blue dye or endogenous IgG entry into the myocytes, 
indicating where the sarcolemma was compromised enough to permit influx of serum 
proteins. These assays reveal markedly higher susceptibility to cardiac and skeletal 
myocyte injury in dystrophic animals lacking dystrophin compared to healthy controls 
[31–33]. 
Studies using genetic models have substantiated a pivotal role for membrane 
integrity in cardiomyocyte preservation and dystrophic cardiomyopathy. Dysferlin, MG53, 
and thrombospondin 4 (Thbs4) have been identified as important players in membrane 
repair and maintenance. Ablation of any of these genes in dystrophin-null or 
sarcoglycan-null animals has been shown to worsen their cardiac and skeletal muscle 
pathology [34–38]. In fact, primary dysferlin deficiency is associated with muscular 
dystrophy in animal models and human patients (Miyoshi Myopathy and LGMD2B) 
characterized by mild-moderate muscle weakness and infrequent cardiac dysfunction 
[39]. On the other hand, overexpression or exogenous delivery of MG53 or Thbs4 have 
been shown to attenuate the severity of myocyte pathology in dystrophic animal models 
[37,40,41]. 
In an effort to limit muscular dystrophy and dystrophic cardiomyopathy by 
patching the sarcolemma, multiple groups have turned to synthetic amphiphilic 
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copolymers, chiefly poloxamer 188 (P188), as a potential therapy. P188 works to reduce 
leak in biological membranes by partitioning into the hydrophobic region exposed when 
the lipid bilayer tears, as demonstrated by molecular simulations [42,43]. Work in cells 
has yielded convincing evidence of marked reductions in membrane leak following P188 
treatment, and dystrophic animal studies with P188 have reinforced the concept of 
membrane disruption as a major driver of dystrophic pathology [44–47]. Specifically, 
dystrophic dogs and mdx mice showed significant amelioration of various disease 
indices following P188 treatment, including improved cardiac histopathology and 
reduced myocyte force drop. Accordingly, a human trial is currently being initiated to test 
the safety and efficacy of P188 therapy in DMD patients [48]. 
 
4.2. Calcium Dysregulation 
A major feature of homeostatic disruption that stems from high membrane 
permeability is the erosion of ion gradients, which contributes to including increased 
intracellular calcium levels. In addition to passive calcium leak through membrane tears, 
a number of ion channels and calcium handling proteins may play a role in the 
elevations in cytosolic calcium concentrations found in dystrophic myocytes. 
Cardiomyocytes from mdx hearts display high diastolic calcium levels, augmented 
calcium influx in response to stretch, altered calcium transient kinetics, and changes in 
calcium-handling protein expression, activation, or post-translational modifications 
[45,49,50]. 
Aside from passive calcium entry through the leaky membrane, transient receptor 
potential (TRP) channels and L-type Ca2+ channels (LTCC) may be allowing excessive 
calcium entry into dystrophic cardiomyocytes [51]. TRP channels, including TRPC1, 
TRPC6, and TRPV2 are thought to participate in the augmented stretch-stimulated 
cation influx observed in mdx cells, and have been shown to be overexpressed and/or 
hyperactive in dystrophic myocytes [51–54]. Notably, inhibition of TRPC1 and TRPV2 
showed a benefit in mdx cardiomyocytes at baseline and under osmotic stress by 
reducing Ca2+ accumulation [50,53]. Other studies have shown enhanced calcium influx 
through the L-type Ca2+ channel in cardiomyocytes from mice lacking just dystrophin or 
both dystrophin and utrophin, and linked this change to delayed inactivation of the LTCC 
[51,55–57]. 
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Excess diastolic calcium found in dystrophic cardiomyocytes may also come from 
the sarcoplasmic reticulum (SR) in addition to extracellular sources. Ryanodine 
receptors (RyR2) and the sarcoplasmic/endoplasmic reticulum calcium ATPase 
(SERCA2a) are two of the key players that may drive excessive store-operated calcium 
release in dystrophic cardiomyocytes. In addition to some studies documenting altered 
channel expression, RyR2 has also been shown to undergo altered phosphorylation and 
S-nitrosylation in dystrophic hearts, resulting in disrupted channel regulation by calstabin 
and enhanced release of Ca2+ from the SR [58–60]. Accordingly, treatments interfering 
with RyR phosphorylation or reinforcing its association with calstabin were shown to 
normalize cytosolic calcium levels, reduce arrhythmogenicity, and improve cardiac 
pathology in mdx hearts [59–62].In a similar vein, some studies have demonstrated 
SERCA2a activity to be reduced in dystrophic hearts, possibly due to some combination 
of lower SECRA2a expression and alterations in its regulation by the inhibitory proteins 
phospholamban and sarcolipin [50,63,64]. Together, the failure of these mechanisms to 
adequately sequester SR calcium to maintain low diastolic calcium levels may 
compound upon the problem of high calcium leak across the sarcolemma, resulting in 
significant myocyte pathology. 
Elevated intracellular calcium not only interferes with proper contractile and 
electrical activity in a myocyte, but also stimulates increased proteolysis, mitochondrial 
dysfunction, and signaling cascades that promote cell death [65]. Calpains are a family 
of proteases activated by calcium that have an abundance of cellular targets, including 
cytoskeletal proteins, receptors, ion channels, and proteins that participate in excitation-
contraction coupling [66]. It has been suggested that robust activation of calpain activity 
could also lead to degradation of non-target proteins, and may even participate in 
activation of the ubiquitin-proteasome system to drive further proteolysis [67,68]. 
Recently it was demonstrated that even in healthy mouse hearts, cardiomyocyte injury 
resulting in endogenous IgG entry into the cell coincides with loss of dystrophin and 
destruction of the orderly sarcomeric organization of α-actinin within 8 hours after the 
injury [31]. These outcomes likely reflect the mass action of proteases activated by the 
calcium influx following major membrane disruption, but similar processes may be 
underway in dystrophic myocytes that have constant low-grade calcium elevations. 
In addition to triggering proteolysis, cytosolic calcium moves through voltage-
dependent anion channels and the mitochondrial calcium uniporter complex into the 
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mitochondria, where it may induce mitochondrial dysfunction that can precipitate cell 
death [69]. Mitochondrial oxidative metabolism depends upon the maintenance of a 
negative mitochondrial inner membrane potential that is essential for ATP synthesis. 
This process that is further stimulated by temporary elevations in mitochondrial matrix 
calcium that occur during increased workloads in healthy mitochondria [70]. However, 
excessive calcium loading into the mitochondria may trigger opening of the mitochondrial 
permeability transition pore (mPTP), depolarizing the mitochondria and interrupting ATP 
synthesis unless the mitochondrial membrane potential can be restored [71]. Opening of 
the mPTP leads to mitochondrial swelling, potentially resulting in destruction of the 
organelle, and can ultimately trigger cell death by depleting cellular ATP content and 
releasing reactive oxygen species and pro-apoptotic factors from mitochondria into the 
cytosol [71]. Indeed, mdx cardiomyocytes have been shown to have elevated 
mitochondrial calcium content and mitochondrial swelling, inspiring ongoing efforts to 
impede mPTP opening or mitochondrial calcium uptake to improve pathology in 
preclinical dystrophic animal models [56,72,73].     
 
4.3. Reactive Oxygen Species Dysregulation 
Dystrophin loss is associated with increased generation of reactive oxygen 
species (ROS) that contribute to the pathogenesis of DMD. A significant source of ROS 
production is NADPH oxidase 2 (NOX2), the primary muscle isoform of this membrane-
bound superoxide-generating enzyme. Mdx mice have been consistently shown to 
harbor increased NOX2 expression and activity, and NOX2 appears to be responsible 
for exaggerated stretch-induced ROS production in both skeletal and cardiac myocytes 
from mdx mice [74,75]. This exaggerated increase in NOX2 dependent superoxide 
production appears to underlie the disorganization of microtubules in skeletal muscle, 
likely also contributing to the disorganized microtubule array in dystrophic cardimyocytes 
[76–78]. Upon activation, NOX2 produces extracellular superoxide, which is converted 
by extracellular superoxide dismutase to the membrane-permeant H2O2 [79]. Once 
inside the myocyte, excess H2O2 can cause oxidation of proteins, lipids, carbohydrates, 
and nucleic acids, precipitating a variety of pathological effects that include deficits in 
calcium handling, contractility, and cell survival [80,81]. In fact, evidence suggests that 
NOX2-generated ROS may contribute to SR calcium leak and mitochondrial dysfunction 
in mdx myocytes [51,74–76,81,82]. 
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Accordingly, many studies have demonstrated a protective effect of 
pharmacological or genetic NOX2 inhibition in mdx heart and skeletal muscle, with 
decreased ROS generation, improved calcium handling, increased myocyte survival, 
and greater force production among the associated benefits [33,62,74,75,81,82]. NOX2 
is also a likely downstream effector of angiotensin II type 1 receptor (AT1R), which may 
be activated by the binding of angiotensin II or by stretch to stimulate ROS production 
via NOX2 [80,83,84]. This relationship could account for some of the reported benefits of 
angiotensin receptor blockers (ARBs) in dystrophic models, including recent work 
showing acute protection of mdx myocardium when treated with losartan only 1 hour 
before inducing cardiac injury with isoproterenol [31,85,86]. 
 
4.4. Nitric Oxide Dysregulation 
In skeletal muscle, there is clear evidence that dystrophin is critical for the 
localization of neuronal nitric oxide synthase (nNOS) at the membrane of the muscle 
fiber [81,87]. From this sub-membrane compartment, NO readily diffuses out of the cell, 
where it signals to neighboring vascular cells to dilate the vasculature, increasing blood 
flow to actively contracting muscle [88,89]. The presence of this molecular arrangement 
in the heart is not clearly understood. While dystrophin and nNOS are both expressed in 
the myocardium, co-immunoprecipitation studies have demonstrated that they do not 
interact to the same degree as in skeletal muscle [90]. Further, there are many 
concurrent mechanisms controlling coronary blood flow that may render this nNOS 
localization less necessary. 
Complicating the understanding of cardiac nitric oxide signaling is the fact that all 
three isoforms of NOS – nNOS, endothelial NOS (eNOS), and inducible NOS (iNOS) – 
are expressed in the heart. Evidence of NO-related alterations from preclinical studies 
include declines in nNOS activity and expression, significant increases in iNOS activity 
and expression, and no reported change in eNOS activity and expression [59,74,91–93]. 
iNOS is of particular interest in dystrophic hearts and muscle, as its expression is 
typically high in immune cells, and it is further increased with inflammation, potentially 
resulting in large contribution of iNOS to NO production in regions of ongoing tissue 
injury and degeneration [81,94,95]. Furthermore, despite the lack of evidence supporting 
the interaction of nNOS with dystrophin in the heart, there are indications that 
mitochondria from dystrophic hearts are associated with nNOS activity that is not 
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present in wild type hearts [96]. This suggests that nNOS localization is abnormal in 
dystrophic cardiomyocytes, which, together with the increase in iNOS activity, results in 
complex effects that alter the NO-dependent physiology of the dystrophic heart. Finally, 
both skeletal muscle and the heart harbor eNOS, and the regulation of its activity is 
multifactorial and complex, creating major obstacles to understanding this isoform’s 
contribution to the NO metabolism of dystrophic myocytes [97]. 
The signaling of nitric oxide is complex, but it can be broadly divided into roughly 
two branches: one mediated by cyclic guanylyl monophosphate (cGMP), and another via 
direct covalent modifications. Initially, preclinical work suggested that the cGMP branch 
of NO signaling may provide significant benefit, as both genetic and pharmacological 
manipulations of this pathway appeared to partially improve dystrophic cardiac function 
in mice [98,99]. Based on the promise of these results in the heart and other benefits in 
skeletal muscle [88,89,100], a clinical trial was initiated to test the effects of 
inhibiting phosphodiesterase 5 (PDE5), the enzyme partially responsible for the 
degradation of cGMP, with sildenafil. Surprisingly, this sildenafil trial was terminated due 
to several DMD patients receiving sildenafil displaying worsening cardiac function [101]. 
It is not clear if the sildenafil treatment accelerated the dystrophic disease process or 
simply failed to show a beneficial effect. Importantly, PDE5 inhibition only prolongs the 
duration of existing NO signaling, thus it is possible that NO synthesis may be too low or 
mislocalized for sufficient cGMP to be produced in dystrophic cardiomyocytes.  
Evidence shows that the dystrophic heart has increased levels of direct covalent 
modification of cysteine residues in the form of S-nitrosylation (SNO). Proteomics-based 
approaches demonstrate that mdx hearts have globally elevated levels of S-nitrosylation, 
with modifications of the electron transport chain being particularly prominent [102]. 
Increased S-nitrosylation of the cardiac ryanodine receptor has been shown to increase 
its Ca2+ leak, thus potentially contributing to increases in cytosolic Ca2+ and cardiac 
arrhythmias [59,60]. Furthermore, overexpression of nNOS has been shown to limit 
fibrosis and improve electrical and contractile properties of the dystrophic heart [103–
105]. Together these data describe a very complex role for NO signaling in the 
dystrophic heart, where it alternates between providing benefit and detriment depending 
on the particular target or the nature of the study. This complex physiology greatly 
confounds the use of NO signaling as a therapeutic approach in the dystrophic heart.  
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4.5. Fibrosis 
Fibrosis is one of the earliest clinical features of dystrophic cardiac pathology, 
making its first appearance in DMD patient hearts before 10 years of age [18,106]. 
Multiple cell types contribute to the development of fibrosis in the heart, including 
cardiomyocytes, fibroblasts, endothelial cells, and immune cells. All of these cells can 
secrete profibrotic cytokines and chemokines in response to stimuli like inflammation, 
mechanical signals, and signals from neighboring cells. Fibroblasts and cardiomyocytes 
are also capable of depositing the extracellular matrix components that comprise fibrotic 
scars. Fibroblasts are an abundant and reactive cell type in the heart, readily 
transforming into myofibroblasts and increasing their secretion of ECM and cytokines in 
response to a large number of endocrine, paracrine, and mechanical signals that include 
transforming growth factor β (TGFβ), ROS, angiotensin, aldosterone, ECM changes, and 
many others [107,108]. Cardiomyocytes may help drive the fibrotic process not only by 
dying and leaving a vacancy that must be filled in with ECM, but also by secreting their 
own signaling molecules and collagen to contribute to the process [109]. Cellular stress 
and necrotic death among cardiomyocytes likely kick off fibrosis in the dystrophic heart 
by polluting the surrounding tissue with cytokines, chemokines, and debris that attract 
neutrophils and macrophages. These cells are phenotypically-diverse, and various 
contextual factors may contribute to their polarization to promote tissue inflammation or 
repair through specific paracrine signaling profiles [110]. Furthermore, infiltrating myeloid 
cells have been shown to harbor aldosterone synthase, thus potentially representing a 
source of localized aldosterone production and promoting pro-fibrotic gene transcription 
in mineralocorticoid receptor-expressing fibroblasts and cardiomyocytes [111]. The 
nature of cardiac fibrosis in DMD is not unique or specific to the dystrophic process, but 
its start early in the disease course and implications for the rest of the heart make 
reducing fibrosis a major goal of cardiac-directed therapies for DMD. 
The removal of damaged tissue eventually ends with the deposition of a new 
fibrotic patch, and these lesions appear on CMR with LGE as areas of bright signal that 
are often distributed in a sub-epicardial pattern on the left-ventricular free wall 
[18,20,112]. The high consistency of lesion distribution in a mechanically-demanding 
setting like the heart may indicate that the forces experienced by cardiac cells in this 
particular region of the heart may be especially injurious, perhaps because of greater 
cellular dynamics in the epicardium [113]. Aside from the obvious issue of failing to 
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contribute to the pumping action of the heart, accumulation of fibrosis may present 
additional challenges. First, it likely accelerates further losses of functional myocardium 
by shifting the workload demand on the neighboring cardiomyocytes, which will now 
have to carry out excessive contractile work in a stiff, mechanically burdensome 
environment. Secondly, the scar may interrupt the tracts of electrical conduction through 
the heart, potentially giving rise to a variety of arrhythmias. Because the consequences 
of unmitigated fibrosis can be so dire, a major focus of established cardiac-directed 
therapies is the amelioration of these processes.  
 
5. Small Molecule Therapies for the Heart 
Because of a lack of any potentially curative therapies for dystrophic 
cardiomyopathy until very recently, these established small molecule-based therapies 
are aimed at reducing the symptoms and hindering the mechanisms of disease 
progression in the heart. The four groups of cardiac small molecule approaches listed 
here are all currently in use in DMD clinical management.  
 
5.1. Angiotensin-Inhibiting Therapies 
Inhibition of the renin-angiotensin system has become a cornerstone of cardiac-
directed therapeutic efforts in DMD patients, with the goal of ameliorating the adverse 
remodeling that follows cardiomyocyte loss. Angiotensin II (AngII) and the AngII type 1 
receptor (AT1R) exert many detrimental effects on the heart, including promoting fibrosis, 
remodeling, ROS production, and cardiomyocyte death [80,83,114–116]. Angiotensin 
receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) are the 
two main drug classes used to suppress the deleterious effects of angiotensin in heart 
failure patients in general and in DMD patients specifically. Current guidelines 
recommend that DMD patients be placed on either one of these two drugs by age 10 or 
earlier, influenced by the growing body of work reporting the first signs of ongoing 
cardiac disease processes around 6-10 years of age [18,19,21,22,106]. ACEIs are an 
older drug class that is often used as the first line of therapy for general heart failure, and 
was the first to be used in trials to demonstrate improved cardiac function and survival 
among DMD patients [117,118]. For these reasons, they have often been named first in 
guidelines and recommendations regarding management of DMD cardiomyopathy and 
are more frequently prescribed [5,6,119,120]. ARBs are listed as a secondary option or 
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an alternative in cases of poor ACEI tolerance, despite the fact that ARBs are not only 
equally effective when compared directly to ACEIs, they are better tolerated by patients, 
promoting improved compliance [121–123]. 
Importantly, recent preclinical work has shown that ARBs may have a unique 
ability to prevent cardiomyocyte damage during acute bouts of increased workload in the 
heart. Dystrophic mdx mouse hearts displayed 3-fold higher myocardial injury area than 
wild type hearts after a bolus of the β-adrenergic agonist isoproterenol, but this 
difference was eliminated by treatment with the ARB losartan [31]. Losartan reduced 
cardiac damage 2.8-fold in mdx hearts without any significant effect on injury in wild type 
hearts. Surprisingly, neither acute nor chronic ACEI treatment had any effect on the 
extent of damage in the mouse heart, suggesting that direct blockade of AT1R may be 
necessary to achieve the full benefit of anti-angiotensin therapy in the dystrophic heart 
[120]. One potential explanation could be rooted in the fact that ACE is not strictly 
necessary for the production of AngII and activation of AT1R. AngII can be produced 
through the actions of other peptidases, most notably chymase, thus the inhibition of 
ACE does not eliminate AngII production [124–126]. Furthermore, AT1R displays basal 
activity and can be readily activated further by stretch independently of any ligand, thus 
potentially giving rise to AngII-independent pathogenic signaling [127,128]. Another 
compelling explanation for the disparity in benefits of ARBs and ACEIs is the indirect 
augmentation of cardioprotective AngII type 2 receptor (AT2R) signaling as a 
consequence of AT1R blockade [114,129]. AngII is the main endogenous ligand for both 
receptors, and the blockade of AT1R feeds back to increase AngII production, resulting 
in the redirection of a very robust AngII pool for AT2R activation [126,129,130]. 
Further clinical trials with younger patients (<10 years old) will be needed to 
determine if ARBs have the same unique capacity to preserve cardiomyocytes in the 
face of ongoing physiological stresses in human dystrophic hearts. Until this work can be 
carried out, DMD patients should continue to be prescribed either one of these anti-
angiotensin drugs at the earliest age that the families and physicians can agree upon in 
order to protect these vulnerable hearts from the permanent loss of myocardial tissue.  
 
5.2. Beta-Adrenergic Receptor Blockers 
Tachycardia is a common characteristic of DMD, reflecting autonomic 
dysfunction in the dystrophic heart that predisposes it to arrhythmias. Holter monitoring 
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in DMD patients routinely reveals average heart rates >100 beats per minute, reflecting 
increased activation of the sympathetic nervous system and increased adrenergic 
signaling in the heart [6,20,131]. The heart expresses an abundance of β-adrenergic 
receptors (β-ΑR) in the pacemaker cells, conduction system, and the rest of the 
myocardium. Activation of cardiac β-AR drives heart rate elevations and increased 
contractility by augmenting and accelerating calcium transients in the myocyte, which 
contributes to arrhythmogenesis [132]. Beta-blockers are regularly used for the 
treatment of acquired heart failure, where they are often combined with ACEIs and 
diuretics to improve survival and reduce hospitalization rates [133]. Accordingly, beta-
blockers have been considered a candidate for cardiac-directed therapy in DMD with the 
goal of limiting β-AR effects, although it remains unclear whether these drugs deliver a 
significant benefit that cannot be achieved without them.  
Investigations using beta-blockers in DMD cardiomyopathy have turned up mixed 
results, with some studies demonstrating a clear benefit while others show little effect of 
β-AR blockade on outcomes [131,134,135]. Although some DMD patient studies indicate 
that beta-blockers preserve cardiac function and survival beyond the effects of ACEIs 
alone, a recent trial revealed no difference between treatment groups receiving ACEIs 
alone versus ACEIs with beta-blockers when the ACEI dose was adjusted according to 
the severity of cardiac dysfunction [131,134,135]. These inconclusive results have 
contributed to variable and often delayed initiation of beta-blocker use in DMD. 
Because beta-blockers are a second-line therapy in DMD, a major obstacle to 
successfully determining their capacity for benefitting the dystrophic heart may lie in the 
delayed initiation of therapy and combined use of beta-blockers with other drugs. 
Indeed, it seems most common in clinical practice to start beta-blockers once 
tachycardia or other arrhythmias become detectable, which may be well after the onset 
of early cardiac disease processes [6]. Because ACEIs and ARBs continue to be the first 
line of therapy, it is unlikely that studies investigating the effects of beta-blockers alone 
on the natural course of the disease will be possible [5]. However, sustained efforts 
should be made to evaluate outcomes in patients receiving early intervention with beta-
blockers compared to those receiving similarly early therapy without beta-blockers in 
order to identify any significant benefits specific to beta-blocker use. 
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5.3. Mineralocorticoid Receptor Antagonists 
Mineralocorticoid receptor (MR) activation by aldosterone can contribute to 
cardiac pathology by promoting cardiomyocyte death, hypertrophy, and fibrosis in DMD 
cardiomyopathy and other types of heart failure [136]. For this reason, MR antagonists 
like eplerenone and spironolactone are a part of the standard approach for managing 
heart failure with low EF, and are occasionally incorporated into treatment for DMD 
cardiomyopathy [7]. The potential importance of aldosterone signaling is underscored by 
reports that myeloid cells infiltrating the site of heart and muscle injury in dystrophic mice 
express aldosterone synthase, serving as a local source of paracrine aldosterone 
signaling that may exacerbate the injury and the adverse remodeling that follows it [111]. 
MR signaling may also play a larger role in DMD due to the ability of corticosteroids like 
prednisolone, which are used to preserve muscle function in DMD patients, to activate 
MR in addition to their target receptor [137]. It is worth noting that spironolactone is 
slightly more potent, but has lower selectivity for MR over androgen receptor, resulting in 
higher potential for side effects associated with androgen imbalance, whereas 
eplerenone is less likely to interfere with androgen receptor. 
Preclinical work using mouse models of DMD cardiomyopathy has shown a 
protective effect of the combination of spironolactone and ACEI in dystrophic muscles 
and hearts that was attenuated in the group treated later in life, again reinforcing the 
importance of proactive initiation of therapy [112,138]. Clinical trials went on to 
demonstrate that patients with DMD and preserved ejection fraction already receiving 
treatment with an ACEI or ARB showed modest but significant improvements in 
myocardial strain, ejection fraction, and chamber dilation with eplerenone treatment, 
compared to those without eplerenone [136]. The open label extension in patients using 
eplerenone with ACEI or ARB showed that myocardial circumferential strain was 
preserved over a period of 36 months [139]. The recent discovery of vamorolone, an MR 
antagonist that is equally potent to eplerenone and also mirrors the anti-inflammatory 
benefits of corticosteroids, may represent a critical step toward the inclusion of this MR 
antagonist as a standard and proactive therapy for DMD cardiomyopathy [137]. 
 
5.4. Corticosteroids 
Currently, a daily regimen with a corticosteroid like prednisone or deflazacort is 
the earliest and most widely used DMD therapy, based on the ability of steroids to 
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reduce inflammation and prolong strength and ambulation in DMD patients with 
[7,51,140]. Because steroids are unequivocally beneficial in ameliorating the natural 
course of DMD in skeletal muscle, therapy is often initiated fairly proactively around 2-5 
years of age, making corticosteroids the earliest pharmacological influence on the 
dystrophic heart [9]. The use of these drugs is not without controversy, with the primary 
obstacle rooted in challenging systemic side effects, which arise from the classic 
transcriptional effects of glucocorticoid receptor and include reduced bone density, 
increased adiposity, and increased muscle catabolism [141]. However, some additional 
concerns stem from preclinical studies providing evidence that steroids may worsen the 
progression of DMD in the mouse heart [138,142]. Nevertheless, DMD patient studies 
are largely in agreement that steroids are likely to be protective in the dystrophic heart, 
with possible benefits including improved survival, preserved ventricular function, and 
even reductions in fibrosis [143–148]. Perhaps the most telling is the observation that 
increased survival among the steroid-treated cohort of one study was largely reflective of 
a striking reduction in heart failure deaths [143].  
Vamorolone, the novel drug that recapitulates the anti-inflammatory actions of 
glucocorticoids and the anti-remodeling effects of MR antagonists, may deliver the same 
benefits derived from corticosteroid use with minimized side effects [137,149]. It 
represents a new class of steroids called dissociative steroids, which serve the function 
of activating glucocorticoid receptor for signaling transduction, but do not result in its 
binding to glucocorticoid response elements (GRE) and activation of GRE-dependent 
transcription [141]. It remains to be seen if Vamorolone may replace glucocorticoids 
and/or MR antagonists in the clinic, but it has already demonstrated efficacy in 
preclinical studies using dystrophic mice, and is currently being tested in DMD patient 
trials [137,149,150]. 
 
6. Gene-Targeted Therapies 
In recent years, potentially curative approaches for DMD have begun to take 
shape. Unlike the small molecule treatments, these gene-targeted therapies are 
designed with the goal to induce expression of a functional gene product that will 
reestablish normal myocyte physiology. Since these therapies aim to repair the original 
defect in the cell by restoring functional dystrophin expression, their success is less 
dependent upon making the correct assumptions regarding the exact mechanisms 
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driving the cellular dysfunction in the absence of dystrophin. However, the high 
complexity of these gene-targeted systems results in great challenges to achieving 
efficient and lasting correction. Because of the large variety of mutations that cause 
DMD, many of these approaches need to be tailored to suit subgroups of patients based 
on the location of their disease-causing mutation.  
An additional challenge lies in the difficulty of assessing the cardiac effects of 
these approaches, because their efficacy will depend absolutely upon the whole-body 
efficiency of transduction and dystrophin restoration. Ideally, corrective therapies should 
be initiated as early in life as possible, both to achieve maximal preservation of healthy 
muscle tissue and to facilitate dosing. Since the heart cannot be routinely biopsied to 
check the efficiency of dystrophin re-expression, clinicians will depend on more sensitive 
measures like myocardial strain to evaluate patient hearts at early time points in the 
natural course of the disease. Achieving sufficient therapeutic efficacy in the heart will be 
of the utmost importance, because correcting skeletal muscle without effectively 
addressing the cardiomyopathy may result in increased demand on the fragile 
myocardium, accelerating the progression of heart failure. Even if high efficiency of 
these therapies is achieved in skeletal muscle, the phenotypic outcome in DMD patients 
may resemble the disease characteristics of Becker muscular dystrophy or X-linked 
dilated cardiomyopathy (XLCM) due to the reduced expression and/or truncation of 
dystrophin. Patients with BMD and XLCM often have sufficient dystrophin expression to 
display mild skeletal muscle pathology, but BMD has a high risk of heart failure, and 
XLCM patients succumb to heart failure between 10-20 years of age [7,151–154]. To 
minimize the risk of this outcome, careful ongoing cardiac monitoring and therapy will be 
necessary to characterize the cardiac effects of these therapies and successfully 
manage all aspects of DMD patient health in the context of partial dystrophin 
replacement. Thus, even DMD patients who undergo treatments with good efficacy in 
the heart will likely continue to require careful cardiac monitoring and be good 
candidates for small molecule-based cardiac therapies to limit the effects of improved 
skeletal muscle function on the dystrophic heart.   
 
6.1. Stop Codon Readthrough 
Roughly 10% of DMD patients have a nonsense mutation that replaces a regular 
amino acid triplet with a premature stop codon and causes the ribosome to terminate 
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translation, failing to synthesize the remainder of the protein [8]. The principle of stop 
codon read-through, also referred to as nonsense suppression, is simply to induce the 
ribosome to continue translating the mRNA through the premature stop codon and the 
rest of the transcript. This concept was initially demonstrated using the aminoglycoside 
antibiotic gentamicin, but due to the toxicity of gentamicin, ataluren (Translarna) was 
developed as a safer alternative serving the same purpose. The drug works by binding 
to the ribosome itself and mildly disrupting its ability to recognize the premature stop 
codon, enabling the occasional addition of an amino acid in its place, followed by the 
synthesis of the remainder of the gene [155]. This mechanism appears to be fairly 
specific to premature stop codons, without enabling readthrough of regular stop codons, 
and effectively enables partial dystrophin expression in skeletal muscle [155,156].  
Based on preclinical efficacy, ataluren advanced to clinical trials and was 
approved for the treatment of DMD in Europe, although it is still under investigation for 
efficacy in the US. Unfortunately, very little evidence exists to inform the question 
whether ataluren displays any degree of efficiency or delivers a benefit in the heart. 
Preclinical work suggests that ataluren can induce a modest increase in diffuse 
dystrophin expression in the mdx mouse heart [156]. Results in human patients are 
more ambiguous, showing no measurable effect on cardiac function in a small cohort of 
non-ambulatory DMD patients, although the cardiac function remained stable during the 
treatment period of 20-24 months [157]. Additional work will need to be performed to 
better understand the effects of ataluren in the heart and the clinical relevance of these 
observations. 
 
6.2. Antisense-Mediated Exon Skipping 
Deletions are the most common type of DMD mutation, with many of them 
causing dystrophin loss due to the disruption of the open reading frame. When the open 
reading frame is shifted, it often results in a downstream premature stop codon that 
terminates translation, so the premise of exon skipping is to sacrifice one exon to restore 
the open reading frame of the rest of the gene. To accomplish this, antisense 
oligonucleotides (AON) are designed to bind to the premature mRNA at the splice 
acceptor site of the mutated exon to obscure the splice site. This causes the 
spliceosome to move on to the next available splice acceptor site, resulting in the 
omission of the mutated exon from the final mRNA transcript. Multiple AONs can be 
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used to skip adjacent exons in cases where the removal of multiple exons is required to 
restore the reading frame. The ultimate goal of this approach is the synthesis of a 
truncated dystrophin protein that harbors a deletion but retains most of its functionality. 
Over half of all DMD mutations and up to 80% of deletions are amenable to exon 
skipping therapy, but since each therapy must be tailored to the mutation region, each 
successfully-developed AON will only rescue a fraction of those mutations [8]. 
Preclinical studies demonstrated the strong potential of AON to reestablish dystrophin 
expression in skeletal muscles, but raised concerns about efficacy in the heart based on 
work showing negligible effects in cardiac muscle [158,159]. Upon probing the 
underlying cause of this discrepancy, it was found that these AON therapies, often 
delivered in the form of a phosphorodiamidate morpholino oligomer (PMO), were more 
likely to be trapped in endosomes in cardiomyocytes than skeletal muscle [160]. 
Subsequent preclinical work demonstrated that optimizing the dose and modifying the 
delivery system could solve this problem in the heart, showing improved cardiac muscle 
dystrophin restoration with these approaches in dystrophic mice and dogs [161,162]. 
Currently, conjugation of PMOs to peptides that enhances cell permeability is an active 
area of development, with preclinical studies demonstrating considerable expression of 
dystrophin in the hearts of mdx mice and dystrophic dogs treated with high doses of 
these peptide-conjugated PMO (PPMO) therapies [162–164]. 
At this time, one exon-skipping therapeutic is FDA approved, and several more 
are in development to target the exons that represent the highest proportions of 
deletions amenable to exon-skipping. Eteplirsen is a PMO from Sarepta Therapeutics 
that induces the skipping of DMD exon 51, which may target up to 14% of all mutations. 
It received FDA approval in 2016 amid controversy, with modest but positive results 
based on clinical trials and patient experiences despite surprisingly modest effects on 
dystrophin re-expression in patient biopsies [165,166]. However, tissue penetration and 
longevity of PMOs has remained an ongoing concern, and no evidence exists of 
significant eteplirsen uptake or benefits in the heart [51,167]. To address these 
shortcomings, other delivery systems for AON are currently being investigated to identify 
the modifications that can optimize cellular penetration and systemic safety, with a big 
focus on PPMOs [160]. Additionally, multiple other exon-skipping AONs are being 
actively developed, with PMOs targeting exons 45 and 53 already in clinical trials. 
Because these agents only work at the level of premature RNA and have limited 
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longevity in the cell, it will be important to set appropriate guidelines for dosing frequency 
to reflect sufficient efficacy in the heart in order to minimize the risk of XLCM-like heart 
failure. 
 
6.3. Micro-dystrophin Viral Gene Therapy 
Viral gene therapy has long been considered the potential key to curing genetic 
diseases, based on its theoretical capability to completely replace the missing gene 
product. For this reason, viral gene replacement therapy is the only approach currently in 
development for clinical use that offers hope for all DMD patients regardless of the 
underlying dystrophin mutation, and is the only available therapy for patients with 
mutations that span critically important regions of dystrophin. There is a long history of 
evidence from animal and human studies identifying both the great promise and the 
significant challenges of viral gene therapy, but the field has made major strides toward 
clinical applications in recent years. The broad lessons learned from this vast body of 
work are: 1) viral gene therapy is feasible and can even be efficiently systemically 
delivered; 2) only adeno-associated virus (AAV) is currently safe enough to use as a 
gene therapy vehicle in human patients; and 3) the safety and efficiency of viral gene 
therapy depend upon many factors that are unique to particular species and also the 
individual biology of the patient. 
In addition to the general limitations of viral gene delivery, the pursuit of a DMD 
gene therapy faces the additional obstacles of gene size, as the full coding DMD gene 
sequence exceeds the packaging capacity of AAV by over 2-fold. Because the 11 kb 
cDNA cannot be delivered by an AAV with a 4-5 kb capacity, great effort has been 
directed at optimally miniaturizing the DMD gene by reducing it to its most vital 
components, producing the candidate micro-dystrophin constructs currently under 
investigation [168]. Preclinical pursuit of over 30 of these micro-genes largely followed 
the lessons learned from mildly-affected BMD patients with extensive DMD sequence 
deletions, preserving the actin-binding N-terminus and the DGC-binding cysteine-rich 
domain, but sacrificing large sections of the central rod domain that spans between them 
[169]. While most of the preclinical work with AAV-delivered micro-dystrophins has 
focused on skeletal muscle, strong evidence of the cardiac benefits of systemic 
treatment includes marked reductions in histopathology and improvements in function, 
supporting their advancement into clinical trials [29,170,171].  
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Three different micro-dystrophins are currently under investigation in human 
DMD patient trials of AAV-mediated micro-dystrophin therapy. The composition of the 
micro-dystrophin constructs in these trials is relatively similar, however the micro-
dystrophin vector from Pfizer uses a skeletal muscle promoter that does not drive any 
expression in the heart [172]. The other two micro-dystrophin AAV trials, spearheaded 
by Sarepta Therapeutics and Solid Biosciences, are using vectors driven by different 
promoters that induce expression in both skeletal and cardiac muscle, delivered by a 
different AAV serotype, and injected at different doses, significantly complicating any 
comparison between these two trials [169]. Nonetheless, both the MHCK7 promoter in 
Sarepta’s AAV construct and the CK8 promoter in Solid’s AAV construct have been 
shown to drive robust cardiac expression of micro-dystrophins used in preclinical studies 
[173,174].  
It is still too soon to know if human cardiac function will be preserved by these 
micro-dystrophin treatments, but it is possible that these initial trials may reveal the need 
for higher doses to effectively transduce the majority of the post-mitotic myocardium, and 
these higher doses may be accompanied by significant side-effects [169]. While some 
preclinical literature supports the notion that transduction of half of the heart may be 
sufficient to reap the full benefits, it is difficult to extrapolate confidently from mice to 
human patients in light of the vastly different body sizes, lifespans, and phenotype 
severity [32]. Furthermore, AAV-delivered plasmids are not expected to last forever, so 
repeated dosing (along with immunosuppressive measures like plasmapheresis) may be 
needed if reductions in the therapeutic effect are detected [175,176]. Finally, even if it 
becomes possible to achieve complete cardiac transduction and lasting expression of 
these DMD micro-genes, the treated patient population will still be at a similar risk for 
developing cardiomyopathy as BMD and XLCM patients due to the extensive truncation 
of the gene. These limitations on the maximal theoretical efficacy of AAV gene therapy 
for DMD may result in the continued need for additional small molecule-based 
management of cardiomyopathy in the setting of an otherwise BMD-like phenotype. 
 
6.4. CRISPR-Cas9 Gene Editing 
CRISPR-Cas9 is a highly versatile genome-editing approach that was found at 
the root of a bacterial self-defense system against viral infection and gave rise to a 
promising new strategy for correcting genetic diseases. This system is based simply 
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upon a single guide RNA (sgRNA) molecule that recognizes a genomic sequence and 
flags down an endonuclease to create a double-stranded break in the DNA at specific 
recognition sites. In bacteria, both the Cas9 endonuclease and the guide RNAs are 
encoded by genomic sequences, the latter of which is made up of clustered regularly-
interspaced short palindromic repeats (CRISPR), but in eukaryotic applications, the 
sgRNA and Cas9 gene must be delivered exogenously. In non-proliferating cells like 
skeletal muscle fibers and cardiomyocytes, CRISPR-Cas9 editing can be used to excise 
a duplication or out-of-frame exon, disrupt a splice site to induce exon skipping, edit a 
nucleotide in a nonsense mutation, or reframe an exon with a base insertion or deletion 
that accompanies non-homologous end-joining repair [177,178]. Because the editing 
occurs at the genomic level and myocyte nuclei will not divide further, this approach 
represents the potential to treat DMD by reinstating dystrophin expression through a 
single administration of the therapeutic agent. 
Since the CRISPR-Cas9 treatment strategy depends upon the systemic delivery 
and expression of foreign genes, this therapeutic approach has often made use of AAV-
mediated gene delivery in preclinical work to achieve sufficient transduction in vivo, with 
promising outcomes from a large number of separate studies [178]. Using either a single 
vector or two separate vectors to encode the sgRNA and the Cas9 sequences with a 
cardiac-expressing promoter, several studies have demonstrated significant restoration 
of cardiac dystrophin expression and improvement in cardiac pathology in different 
mouse and dog models of DMD [179–182]. Importantly, the correction was shown to 
persist long-term in mice, supporting the notion of permanent gene repair with this 
genomic editing strategy [183–185]. 
Despite significant promise, this approach is not without its own setbacks. AAV-
mediated gene delivery will always face the challenge of possible immunogenicity, and 
the delivery of a foreign gene exacerbates the issue with the potential of eliciting an 
immune response to the bacterial protein. Careful screening and immunosuppressive 
measures will be required to ensure patient safety and effective transduction, although 
long term studies in preclinical models suggest immune response against Cas9 does not 
limit the therapeutic efficacy [179,186]. Furthermore, the possibility of off-target 
mutagenesis with CRISPR-Cas9 is a cause for concern that has previously been 
substantiated in human cells, and recent studies have identified dozens of off-target 
mutations throughout the mouse genome following 8 weeks of CRISPR-Cas9 
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expression [185,187]. While most of these off-target mutations are found in introns, 
many are in exons, indicating a need for additional preclinical work to investigate the rate 
of accumulation and the physiological significance of these mutations. The risk of off-
target editing can be managed by optimizing both the guide RNAs and the Cas9 
endonucleases to minimize non-specific activity and improve fidelity [178,188]. Finally, 
as with AON-mediated exon skipping, some of the patients undergoing CRISPR-Cas9-
mediated exon skipping therapy may still find themselves with a BMD-like risk of 
cardiomyopathy. Additional preclinical studies with longer post-treatment monitoring in 
dog and/or non-human primate DMD models will be required to confirm the safety and 
efficacy of this genome-editing therapy, but current results inspire optimism about the 
possibility of CRISPR-Cas9 treatment reaching clinical trials. 
 
7. Conclusions 
Just over 30 years since the discovery of the protein dystrophin, and nearly two 
centuries after the first descriptions of the devastating disease precipitated by its loss, 
efforts to understand and correct the underlying pathology of DMD are advancing by 
leaps and bounds. The preceding decades have been marked by careful mechanistic 
studies aiming to tease part the molecular processes derailed by dystrophin loss, 
providing extensive insights into the cellular dysfunction driving the progressive 
deterioration and premature death seen in patients. These insights helped to form the 
foundation for devising symptomatic interventions and small molecule treatment 
strategies to prolong and improve the lives of DMD patients. Now, the tireless and 
innovative efforts of the neuromuscular disease research community have started to 
open the door for potentially curative approaches that may allow individuals with DMD-
causing mutations to live out their adult lives with manageable health.  
 This turning point in the development of DMD therapies marks the beginning of a 
new mission to map the shifting landscape of cardiac health and disease in patients that 
undergo these cutting-edge treatments. This will require continued improvements in 
cardiac diagnostic and treatment strategies used in the clinics and in preclinical studies 
that will build upon recent breakthroughs. Deletions are the most common mutation type 
underlying DMD, but even at their highest theoretical efficiency, these corrective 
approaches cannot restore missing portions of the DMD gene sequence. For this 
reason, even patients that are successfully treated with the next generation of gene-
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targeted therapies will likely continue to benefit from regular monitoring or treatment by a 
cardiologist. Ensuring that the vulnerable hearts of DMD patients receive careful 
consideration should remain a major priority in the management of this deadly disease 
as new questions and possibilities continue to arise from current and future discoveries. 
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Summary 
Duchenne muscular dystrophy (DMD) is an X-linked disease characterized by 
skeletal muscle degeneration and a significant cardiomyopathy secondary to 
cardiomyocyte damage and myocardial loss. The molecular basis of DMD lies in the 
absence of the protein dystrophin, which plays critical roles in mechanical membrane 
integrity and protein localization at the sarcolemma. A popular mouse model of DMD is 
the mdx mouse, which lacks dystrophin and displays mild cardiac and skeletal pathology 
that can be exacerbated to advance the disease state. In clinical and pre-clinical studies 
of DMD, angiotensin signaling pathways have emerged as therapeutic targets due to 
their adverse influence on muscle remodeling and oxidative stress. Here we aim to 
establish a physiologically relevant cardiac injury model in the mdx mouse, and 
determine whether acute blockade of the angiotensin II type 1 receptor (AT1R) may be 
utilized for prevention of dystrophic injury.  
In the present study, a single IP injection of isoproterenol (Iso, 10 mg/kg) was 
used to induce cardiac stress and injury in mdx and wild type (C57Bl/10) mice. Mice 
were euthanized 8 hours, 30 hours, 1 week, or 1 month following the injection, and 
hearts were harvested for injury evaluation. At 8 and 30 hours post-injury, mdx hearts 
showed 2.2-fold greater serum cTnI content and 3-fold more extensive injury than wild 
type hearts. Analysis of hearts 1 week and 1 month after injury revealed significantly 
higher fibrosis in mdx hearts, with a more robust and longer-lasting immune response 
compared to wild type hearts. In the 30-hour group, losartan treatment initiated 1 hour 
before Iso injection protected dystrophic hearts from cardiac damage, reducing mdx 
acute injury area by 2.8-fold, without any significant effect on injury in wild type hearts. 
However, both wild type and dystrophic hearts showed a 2-fold reduction in the 
magnitude of the macrophage response to injury 30 hours after Iso with losartan.  
This work demonstrates that acute blockade of AT1R has the potential for robust 
injury prevention in a model of Iso-induced dystrophic heart injury. In addition to 
selectively limiting dystrophic cardiac damage, blocking AT1R may serve to limit the 
inflammatory nature of the immune response injury in all hearts. Our findings strongly 
suggest that earlier adoption of angiotensin receptor blockers in DMD patients could limit 
myocardial damage and subsequent cardiomyopathy.  
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1. Introduction 
Muscular dystrophies are a genetically diverse group of rare muscle wasting 
diseases that often involve the heart, resulting in clinically significant cardiomyopathy 
[3,5,6,148,189]. Duchenne muscular dystrophy (DMD) is the most common form, having 
an X-linked inheritance pattern with an incidence of roughly 1 in every 3,500-5,000 boys 
[5,11]. The molecular basis of DMD lies in the loss of the protein dystrophin, which 
normally plays a critical role in maintaining the membrane integrity of muscle cells by 
serving as a molecular link between the cytoskeleton and the extracellular matrix and a 
signaling scaffold at the sarcolemma [52,190–193]. Dystrophin loss results in myocyte 
necrosis, replacement of myocytes with extensive fibrosis, and eventual loss of muscle 
mass [194,195]. Clinically, DMD is characterized by rapidly progressing skeletal muscle 
wasting, loss of ambulation and other motor functions, respiratory insufficiency, and 
pronounced heart disease [5,6,196]. As improvements in symptomatic respiratory 
therapies have prolonged patient life spans, heart failure is becoming a more common 
cause of premature death in patients with muscular dystrophy [1–3]. 
The mdx mouse is a commonly-used preclinical model of DMD, having a 
spontaneous mutation in the DMD locus that results in the absence of dystrophin 
[190,197,198]. In young adulthood, its disease is mild, but investigators have 
successfully used aged mice, exogenous stressors, or additional genetic manipulations 
to advance the disease state [5,29,32,112,199–203]. Multiple studies aimed at 
modulating the mdx phenotype have pointed to angiotensin-related signaling pathways 
and oxidative stress as important factors in both the skeletal and cardiac phenotype of 
dystrophic mice [111,203–207]. Importantly, drugs including ACE inhibitors (ACEi), 
angiotensin receptor blockers (ARBs), and antioxidants have shown a significant benefit 
for dystrophic mice and human patients [86,112,123,131,208–211]. Current 
recommendations guide clinicians to consider initiating ACEi or ARB therapy at the age 
of 10 in Duchenne patients even without cardiac symptoms. This recommendation is 
grounded in the thought that these drugs help primarily by minimizing adverse 
remodeling following cardiomyocyte loss [5,6]. However, if these drugs are able to limit 
cardiomyocyte loss, initiation at the age of 10 may be too late, as patients may already 
be losing myocardium well before this point [3,212–214].  
Our group and others have used adrenergic agonists like isoproterenol (Iso) and 
dobutamine to stress mdx hearts to better recapitulate the severity of the human cardiac 
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pathology [29,32,45,77]. Iso is a selective agonist of all β-adrenergic receptor isoforms 
that drives a sharp increase in heart rate and cardiac contractility [215], producing a 
sufficiently high workload to damage membranes of susceptible cardiomyocytes. This 
model has advantages over further genetic manipulation or aging by reducing 
confounding factors and allowing for more direct comparisons to other literature featuring 
adult mdx mice. Additionally, this adrenergic stress model may be particularly relevant to 
the perioperative stresses faced by Duchenne patients, whose treatment course may 
include procedures requiring anesthesia, such as scoliosis correction or fracture repair, 
that may result in bouts of elevated cardiac stress [6,216]. 
  In the present study, we evaluate the cardiac consequences of a single bolus of 
Iso in the mdx mouse, and combine this Iso-mediated cardiac insult with acute losartan 
treatment to evaluate the potential benefits of ARB therapy for cardiomyocyte survival. 
These data reveal an interaction between workload-induced cardiac injury and 
exacerbation of this injury downstream of angiotensin II type 1 receptor (AT1R) in 
dystrophic hearts, showing a significant reduction in acute myocardial damage with ARB 
treatment at the time of Iso-induced cardiac stress. The potential cardiac protection and 
good overall tolerability suggest that early initiation of ARB therapy may provide a readily 
available means to slow the onset of dystrophic cardiomyopathy. 
 
2. Methods 
2.1. Animals 
The wild type control strain C57BL/10SnJ (C10) and the dystrophic strain 
C57BL/10ScSn-Dmdmdx/J  (mdx) were bred and maintained at the University of 
Minnesota from breed stock obtained from Jackson Laboratories. To limit genetic drift in 
this colony, breed stock were purchased from Jackson Laboratories every 5-6 
generations. All mice were 4-6 months of age at the time of experiments and were 
housed in static (non-ventilated) cages with a 12-hour light-dark cycle. As DMD is a 
disease predominantly affecting males, only male mice were used in these studies. All 
animal procedures were approved by the University of Minnesota Institutional Animal 
Care and Use Committee and performed in compliance with all relevant laws and 
regulations. 
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2.2. Isoproterenol studies 
(-)-Isoproterenol hydrochloride (Iso; Sigma #I6504) was dissolved in saline and 
sterile filtered into a foil-wrapped red-top glass vial prior to injection. The sterile Iso 
solution was stored at 4˚C for no more than 3 days, and any solution developing 
discoloration indicative of degradation was discarded. Mice received a single IP bolus 
injection of 10 mg/kg Iso in volumes of 40-70 µl adjusted for body weight. Hearts were 
harvested at timepoints of 8 hours, 30 hours, 1 week, and 1 month after the injection 
(Fig. 2.1A). 
  
2.3. Serum cTnI measurements 
For a subset of mice, blood was collected from the facial vein of isoflurane-
anesthetized mice 1 week prior to the Iso injection for the baseline serum cTnI 
measurement, and again 8 hours following the Iso injection. The collected blood was 
allowed to clot on ice, then spun to separate the serum, which was then stored at -80˚C 
until analysis. Serum cardiac troponin I content (cTnI) was measured via a cTnI test kit 
on the Stratus CS Stat fluorometric analyzer (Siemens Healthcare). 
  
2.4. Losartan studies 
An additional subset of mice was assigned to receive losartan 1 hour prior to and 
alongside Iso, terminating at the 30-hour timepoint. Losartan solution was made on the 
day prior to Iso injections from a crushed generic losartan tablet (100mg) dissolved in 
saline to a final concentration of 6 mg/ml, and sterile filtered. Doses were calculated 
based on mouse body weights, the injection schedule, and the pharmacokinetics of 
losartan as well as its primary active metabolite EXP3174 [217,218]. At the start of the 
light cycle on the day of the study (7am), the mice received a loading dose in the form of 
a 60 mg/kg losartan bolus injection, followed a single 10mg/kg Iso injection 1 hour later 
(8am), and a 20 mg/kg losartan booster 6 hours after the first bolus (1pm). At the end of 
the light cycle, the mice received another bolus of 60 mg/kg losartan to span the dark 
cycle (7pm). At the end of the dark cycle, they received a final booster of 20 mg/kg 
losartan (7am), and hearts were harvested 7 hours later (30 hours from the Iso bolus). 
This dosing regimen was based on the half-lives of losartan and its major active 
metabolite, and intended to minimize the troughs in drug serum levels after the loading 
dose without disruptions to the dark cycle.  
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2.5. Histopathology 
Fresh excised hearts were rinsed in PBS and cut in half along the transverse 
plane. The apical half was placed into OCT medium inside a block mold, and the OCT 
block was frozen in liquid nitrogen-cooled isopentane. Heart block sections were cut to 7 
microns and placed on plus slides to be stained. Slides used for dystrophin and actinin 
staining were fixed in cold acetone for 10 minutes before rehydration and staining, while 
all other immunofluorescent staining was performed on unfixed slides. The following 
antibodies and reagents were used for IF staining: goat serum for blocking (Jackson 
ImmunoResearch # 005-000-121, 10%), rabbit actinin polyclonal antibody (Novus 
#NBP1-32462, 1:150), rabbit dystrophin polyclonal antibody (Abcam #ab15277, 1:150), 
rat AlexaFluor 488 anti-mouse CD68 antibody – clone FA-11 (Biolegend, 1:150), rat 
AlexaFluor 647 anti-mouse CD45 antibody – clone 30-F11 (Biolegend, 1:100), goat anti-
mouse IgG (H+L) secondary antibody (Invitrogen #R37121, 1:200), goat anti-rabbit IgG 
(H+L) secondary antibody (Invitrogen #A-11008, 1:200), WGA AlexaFluor conjugate 
(ThermoFisher, 5µg/ml), and ProLong Gold Antifade Mountant with DAPI 
(ThermoFisher). All immunofluorescence incubation steps were carried out at room 
temperature for 1 hour, separated by three 5-minute washes in fresh PBS.  
The following reagents were used for Sirius Red Fast Green (SRFG) staining: 
1.2% picric acid solution (Ricca #R5860000), Direct Red 80 (Sigma #365548), Fast 
Green FCF (Sigma #F7252), Formula 83 clearing solvent (CBG Biotech F83), and 
organic mounting medium (CBG Biotech MM83). Prior to SRFG staining via a modified 
protocol based on previously described methods [200], slides were fixed for 3 hours in 
cold acetone, then rehydrated in 70% ethanol followed by tap water. The tissue was then 
stained for 25 minutes in SRFG dye solution of picric acid, 0.1% Direct Red 80, and 
0.1% Fast Green FCF, followed by washes in tap water and dehydration in 70% ethanol, 
100% ethanol, and Formula 83. 
  
2.6. Microscopy 
All imaging was performed in NIS Elements software on a Nikon Eclipse Ni-E 
upright epifluorescent microscope with motorized stage and filter wheel. For cell 
infiltration and acute lesion studies, whole heart montages were collected as a stack of 
three to four fluorescent channels at a resolution of 0.92 µm/pixel. For fibrosis studies, 
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SRFG-stained sections were collected as brightfield montages at a resolution of 0.85 
µm/pixel. For assessment of birefringence, images with a resolution of 0.17 µm/pixel 
were collected using orthogonally oriented polarized filters flanking the slide. Dystrophin 
and actinin IF close-up images were collected at a resolution of 0.23 µm/pixel, and 
deconvolved via the automatic 2D deconvolution package in NIS Elements. 
  
2.7. Image analysis 
All images were analyzed under deidentified names in a blinded fashion in Fiji 
using custom macros and scripts [219]. IgG analysis was carried out using 1180×944 
µm (1280×1024 pixels) non-overlapping frames taken from whole montages to minimize 
complications arising from variations in brightness across the whole heart section. IgG 
lesion area was determined by thresholding the IgG image for total lesion area (indicated 
by bright IgG-positive signal) and dividing that by total heart section area (provided by 
tissue autofluorescence). 
Fibrosis analysis of SRFG-stained sections was carried out on entire heart 
montages using the color threshold function in Fiji. Areas containing collagen, which 
takes up Sirius Red dye, were identified by measuring the pixel area corresponding to a 
red hue. The fibrotic area was then divided by total heart pixel area, corresponding to 
any hue and saturation that exceeds the neutral background. 
Birefringence analysis was carried out using 2360×1770 µm (2560×1920 pixels) 
frames imaged using brightfield, and matching frames imaged with orthogonally oriented 
polarized filters flanking the slide. Total birefringent area was calculated as the number 
of pixels corresponding to a signal that exceeds the brightness of the surrounding 
myocardium. The birefringent area was divided by the total red area from the matched 
brightfield image to calculate the percent birefringence of each fibrotic lesion. 
Cell infiltration analysis workflow began with a blinded scrubbing of IF montage 
images in which artifacts were removed, including blood within the ventricles or large 
vessels, non-specific aggregates of dye, and areas in which the tissue was folded. 
Lesion-positive regions and total muscle area were determined by thresholding the 
entire montage, followed by a manual removal or addition of misidentified areas. Cell-
specific thresholds were set to identify cell-positive regions, which were then compared 
to the lesion areas. Any cell-positive region containing a shared pixel with a lesion was 
considered a lesion-positive cell region. Results represent the percentage of cell-positive 
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pixels relative to the total number of heart pixels. All data analysis scripts were 
performed in Fiji and R. 
  
2.8. Statistics 
Statistical analyses were performed using Prism 7 (GraphPad Software) and R [220]. 
Statistical comparisons were made using one-way ANOVA or two-way ANOVA where 
appropriate, with Sidak multiple comparison post-hoc test to identify specific differences 
between relevant groups. All column and line graphs display the mean ± standard error. 
 
3. Results 
3.1. A single dose of isoproterenol causes acute myocardial injury that is significantly 
exacerbated in dystrophic hearts. 
Within hours of injection of a single dose of isoproterenol (Iso), areas of acute 
myocardial injury could be identified by staining for myocyte infiltration of endogenous 
IgG. The accumulation of intracellular IgG is only expected to occur in myocytes whose 
membranes have been sufficiently disrupted to become permeable to large molecules 
like serum proteins. Quantification of acute myocardial damage revealed that injured 
myocyte area is already prominent as early 8 hours, with a peak at 30 hours after Iso 
administration. This acute injury is completely removed 1 week after the Iso injection 
(Fig. 2.1B).  A significant difference was found between healthy and dystrophic hearts at 
the 30-hour timepoint, with mdx hearts showing 3-fold greater injury than that seen in 
wild type hearts (18.9±2.8% versus 6.3±1.7%, respectively).  
Examination of entire heart montages revealed that in dystrophic hearts, these 
acute lesions were large and scattered throughout the whole heart section. In contrast, 
acute injury in wild type hearts manifested as smaller lesions that were concentrated in 
the endocardium (Fig. 2.1C). This hints that the Iso-induced injury in C10 hearts may 
result from perfusion-demand mismatching, with relative hypoperfusion of the 
endocardium during Iso-induced increases if cardiac workload resulting in myocardial 
injury. This mechanism is likely also active in the dystrophic heart, but large swaths of 
injured myocardium are also found throughout the rest of the heart, suggesting an 
additional mechanism of injury is at play. Mice with genetic ablation of all β-adrenergic 
receptors showed no functional or histological response to the dose of Iso used in these 
studies (data not shown), confirming the β-adrenergic receptor specificity of Iso action.  
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3.2. Isoproterenol-induced sarcolemmal injury triggers cardiomyocyte destruction.  
Closer inspection of the regions of acute injury revealed multiple signs of 
myocyte degeneration at 8 hours after Iso injection. In intact myocytes, sarcomeric α-
actinin was localized in a pattern of orderly striations, but within IgG+ myocytes it 
displayed a marked disruption of this striated pattern (Fig. 2.2A). Signs of myocyte 
breakdown are not limited to the degradation of the contractile apparatus, as dystrophin 
staining at the membrane was also largely lost in injured wild type myocytes (Fig. 2.2B). 
The loss of normal sarcomeric patterning and sub-membrane protein localization 
suggests that these damaged myocytes are undergoing widespread proteolysis. No 
qualitative differences in the myocyte degradation process were found between injured 
areas in wild type and dystrophic hearts at 8 or 30 hours after Iso administration. 
Serum cardiac troponin (cTn) content is an index of cardiomyocyte integrity, and 
elevated cTnI and cTnT levels have been documented in boys with DMD [21–23,30]. 
Untreated adult dystrophic mice showed no detectable ongoing basal cardiac injury, as 
indicated by little to no IgG+ cardiac myocytes and negligible levels of serum cTnI that 
are not different from those observed in wild type mice. Corroborating the histological 
evidence of cardiomyocyte breakdown, serum levels of cTnI were found to be 
dramatically increased 8 hours after Iso administration in both mdx and C10 hearts. 
Serum collected from mdx mice 8 hours after the induction of Iso-induced injury showed 
2.2-fold greater cTnI concentration than wild type mouse serum (Fig. 2.2C), consistent 
with the greater acute myocardial injury present in dystrophic hearts (Fig. 2.1B).  
 
3.3. Fibrotic replacement of Iso-induced cardiac injury is dynamic. 
Many, if not all, of the acutely damaged cardiomyocytes were removed following 
injury, resulting in their replacement with fibrotic lesions by 1 week after Iso 
administration. At timepoints of 1 week and 1 month following Iso-induced injury, 
dystrophic hearts displayed over 2-fold larger fibrosis area relative to wild type hearts 
(Fig. 2.3A), consistent with the elevated acute injury observed in mdx hearts at earlier 
timepoints. Replacement fibrosis area was highest 1 week following Iso administration in 
hearts from both strains, and closely reflected the peak acute injury area measured at 30 
hours (Fig. 2.1B). Interestingly, 1 month after Iso-induced injury, total fibrotic lesion area 
was lower relative to its peak at 1 week after injury (Fig. 2.3A). 
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This curious observation of fibrotic area reduction between 1 week and 1 month 
following Iso administration could be explained by lesion contraction over this time 
period rather than by removal of deposited matrix. Collagen bundles display 
birefringence, the optical property that causes transmitted light to become polarized 
[221]. Collagen’s orderly triple-helical structure underlies its inherent birefringence, which 
becomes more pronounced as the density of collagen fibers increases. Sirius Red 
staining further enhances this property due to the alignment of the dye molecule along 
the collagen strands [221–223]. Birefringence can be assessed microscopically by using 
two orthogonally-oriented polarized filters, referred to as the polarizer and the analyzer, 
flanking the sample [200]. Polarized light passing through the first filter (polarizer) and 
non-birefringent material will be blocked by the second filter (analyzer). However, a 
birefringent material will polarize the light further as it traverses, allowing some of it to 
pass through the analyzer and be detected by the camera. The wavelength and intensity 
of the light passing through the analyzer can provide information about the relative 
amount and organization of the birefringent material in the sample. For example, a 
diffuse patch of collagen fibers that are oriented in many directions results in a small 
amount of green or yellow polarized light. In contrast, a patch of densely-bundled and 
organized collagen strands would result in bright orange or red light, with structural 
collagen (e.g. tendons) serving as an excellent example of the latter [222–225]. Upon 
measuring the polarized light passing through prominent lesions of 1-week and 1-month 
mdx hearts, the older lesions were found to display a significantly greater birefringent 
area relative to the total area stained by Sirius Red (Fig. 2.3C). Accordingly, 
representative images show that the polarized light exiting 1-month-old lesions appears 
noticeably brighter with prominent areas of red and orange color (Fig. 2.3D), supporting 
the notion that tighter bundling of collagen over time is likely responsible for the modestly 
reduced area seen in older lesions. 
 
3.4. Iso-induced injury triggers extensive immune cell infiltration in dystrophic hearts.  
Infiltrating immune cells were labeled by antibody staining for CD45, a cell 
marker expressed by all leukocytes [226,227], and CD68, a phagocytic marker that is 
generally utilized as a differentiated macrophage marker [207,228–230]. Both of these 
immune cell markers showed a robust response to Iso-induced damage in mdx hearts, 
but this response was significantly attenuated and truncated in C10 hearts (Fig. 2.4 A 
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and D). Immune cell infiltration appeared to be delayed relative to the appearance of 
cardiac injury, with no response evident at 8 hours after Iso administration. In dystrophic 
hearts, an upsurge in immune infiltration could first be noted at 30 hours, with similarly 
robust immune cell presence lingering for at least 1 week following injury. In wild type 
hearts, a smaller increase in immune cells was apparent at 30 hours, and began to 
regress toward baseline levels 1 week post-injury. The prevalence of these immune cell 
markers dropped off to near-baseline levels 1 month post-injury in hearts from both 
strains. 
In addition to different amplitudes of the peak response, immune infiltration also 
displayed different distribution in mdx and wild type hearts. CD45+ leukocytes and CD68+ 
macrophages were diffusely scattered throughout all of the hearts at baseline, and 
remained so up to 8 hours after injury. In dystrophic hearts, 30 hours and 1 week after 
injury both immune cell markers displayed robust expansion predominantly in regions of 
damage, evidenced by the majority of the cells clustering in lesion areas (Fig. 2.4 B and 
E). Although wild type hearts showed significant immune expansion in lesion areas at 
the 30-hour timepoint, some augmentation of non-lesion immune cells was also 
observed. At least 50% or more of the immune cells continued to occupy non-lesion 
areas of wild type hearts at all timepoints, possibly due to the more diffuse nature of C10 
cardiac injury.  
 
3.5. Acute AT1R blockade dramatically reduces dystrophic Iso-induced injury and 
modulates the immune response in the heart. 
Angiotensin II (AngII) type 1 receptor (AT1R) is expressed in many cell types, 
serving as a major mediator of AngII effects, including pro-fibrotic gene program 
activation and increased ROS production [80,83,84,231,232] (Fig. 2.5A). These 
outcomes can be attenuated by blocking activation of AT1R with an angiotensin receptor 
blocker (ARB) like losartan. The anti-remodeling effects of ARBs are well-documented in 
long-term studies [194,233,234], but much less is known about the potential acute 
benefits of AT1R blockade for the dystrophic heart. To shed more light on this question, 
mdx and wild type mice were treated with a brief course of intraperitoneal injections of 
losartan starting 1 hour before the bolus of Iso and spanning the period of 30 hours after 
Iso (Fig. 2.5A). Acute losartan treatment dramatically protected dystrophic hearts from 
cardiac damage following Iso injection, cutting mdx IgG+ injury area by 2.8-fold (Fig. 
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2.5B). Conversely, AT1R blockade showed no significant effect on wild type cardiac 
damage, resulting in comparable Iso-induced injury area in wild type and dystrophic 
hearts with acute losartan treatment. Interestingly, losartan did not change the 
distribution of lesions in dystrophic hearts, with mdx lesions remaining larger and 
localized more epicardially than C10 lesions (Fig. 2.5C). 
The CD45+ leukocyte response in 30-hour post-Iso hearts reflected the same 
trends as acute injury area. While C10 hearts showed no significant reduction in CD45+ 
area with losartan, mdx hearts showed a 38% reduction in the prevalence of CD45 after 
losartan treatment, resulting in CD45 levels that are not different from those observed in 
wild type hearts (Fig. 2.5D). Interestingly, CD68+ macrophages showed a different trend, 
with a significant 53% reduction in total CD68+ area in C10 hearts treated with losartan, 
despite no change in total injury area or total leukocyte infiltration (Fig. 2.5E). Dystrophic 
hearts also showed a trend toward a proportionately larger CD68 decline with losartan, 
with 56% lower CD68 compared to only 38% reduction in CD45. These declines in 
CD68+ area appeared to manifest in both lesion and non-lesion areas in hearts of both 
strains, suggesting that the overall immune profile of these mice may have shifted as a 
consequence of AT1R blockade (Fig. 2.5E). Representative images, highlighting lesion-
positive areas in hearts of both strains, demonstrate the visibly reduced prominence of 
CD68+ cellular infiltrates in losartan-treated groups (Fig. 2.5F).  
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Figure 2.1: Effects of a single dose of isoproterenol on healthy and dystrophic hearts. 
(A) After one bolus injection of 10 mg/kg isoproterenol (Iso), mice were sacrificed at 
timepoints of 8 hours, 30 hours, 1 week, or 1 month. (B) Left: Acute Iso-induced injury, 
measured by IgG incorporation, was prevalent as early as 8 hours, with a peak at 30 
hours. Evidence of acute injury was totally removed by 1 week. (*** indicates p<0.001 vs. 
baseline; interaction p=0.01; n = 6-17 mice per group). Right: Wild type (C10) hearts 
displayed a peak acute injury area of only 6±2%, while mdx peak injury was 3-fold higher 
at 19±3%. (*** indicates p<0.001). (C) Representative images of data shown in panel B. 
Whole hearts are shown with WGA (green) marking the total tissue area and IgG (red) 
indicating areas of acute myocyte injury. Scale bar = 1mm. 
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Figure 2.2: Sarcolemmal injury triggers cardiomyocyte destruction as early as 8 hrs after 
Iso. 
(A) In both wild type (C10) and dystrophic hearts, uptake of IgG into injured myocytes 
corresponds with profound disruption of sarcomere structure as early as 8 hours following 
a bolus of Iso, compared to uninjured cardiomyocyte sarcomeres (right). Sarcomeres were 
visualized by α-actinin staining (green), myocyte injury was marked by endogenous IgG 
uptake (red), and extracellular matrix was visualized by WGA staining (magenta). Scale 
bar = 20 µm. (B) In wild type mouse hearts, myocytes that had taken up IgG also lost 
dystrophin at the sarcolemma, evidenced by absence of dystrophin staining (green). As 
expected, mdx hearts did not exhibit dystrophin staining. Scale bar = 50 µm. (C) Cardiac 
troponin I (cTnI) concentration was measured in serum collected from wild type and mdx 
mice as an index of myocardial damage. Dystrophic mice showed significantly higher 
serum levels of cTnI 8 hours after Iso. (*** indicates p<0.001; n ≥ 8 mice per group).   
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Figure 2.3: Fibrotic replacement of Iso-induced cardiac injury is dynamic. 
(A) Left: In wild type and dystrophic hearts, the area of fibrosis was the highest 1 week 
after Iso-induced injury, and declined by 1 month (** indicates p=0.009 vs. baseline, *** 
indicates p<0.001 vs. baseline, ## indicates p=0.003 vs. 1 month; interaction p=0.02; n = 
8-15 mice per group). Right: One month after injury, mdx hearts displayed significantly 
larger fibrotic area (13±1%) than control hearts (6±1%) (*** indicates p<0.001). (B) 
Representative montages of data displayed in panel A. Whole hearts are shown with Fast 
Green-stained myocardium and Sirius Red-stained fibrosis. Scale bar = 1mm. (C) One 
month after Iso-induced injury, fibrotic lesions in mdx hearts displayed dramatically 
increased birefringent area relative to 1-week lesions, suggesting that replacement fibrosis 
contracts during maturation. (*** indicates p<0.001, n = 76-86 lesions from 14 mice per 
group). (D) Representative images of data displayed in panel C. Matched brightfield, 
cross-polarized, and overlay images of mdx hearts show the change in the birefringence 
of 1-week and 1-month-old lesions; areas of birefringence are denoted in yellow on overlay 
images. Scale bar = 100 µm. 
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Figure 2.4: Iso-induced injury triggered a significantly greater immune cell response in 
dystrophic hearts. 
(A) CD45+ cell area was dramatically increased in mdx hearts 30 hours and 1 week after 
Iso administration, with a return toward baseline at 1 month after injury. Wild type (C10) 
hearts followed a similar pattern, with lower overall levels of infiltration and a faster return 
toward baseline levels (*** indicates p<0.001, ** indicates p=0.008 vs. baseline; ### 
indicates p<0.001, ## indicates p=0.004 difference between strains at the same timepoint; 
interaction p=0.02; n = 5-11 mice per group). (B) The expansion of the CD45+ cell 
population occurred primarily in lesioned areas of the heart, where the CD45+ area 
significantly increased compared to baseline in dystrophic hearts (*** indicates p<0.001, 
** indicates p=0.008, * indicates p<0.05 vs. baseline). (C) Representative images for data 
shown in panels A and B. Cardiac lesions are represented by endogenous IgG uptake 
(red, baseline and 30 hours) and WGA accumulation (red, 1 week and 1 month). CD45+ 
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cells are shown in green. Each panel is 1 mm2. (D) CD68+ immune infiltrates were 
significantly increased in dystrophic hearts 30 hours and 1 week after Iso administration, 
with a return toward baseline by 1 month post-injury. Wild type hearts displayed a smaller 
and shorter-lived surge in cardiac CD68+ cells, with a significant increase observed only 
at 30 hours after Iso injection (*** indicates p<0.001, * indicates p=0.02 vs. baseline; ### 
indicates p<0.001, # indicates p=0.01 difference between strains at the same timepoint; 
interaction p=0.02; n = 4-12 mice per group). (E) CD68+ cell expansion occurs primarily in 
lesioned areas of the heart, where their numbers are significantly greater compared to 
baseline. Only wild type hearts showed any expansion of non-lesion CD68+ cell numbers 
at 30 hours after Iso injection (*** indicates p<0.001 vs. baseline, * indicates p=0.02 vs. 
baseline). (F) Representative images for data shown in panels D and E, with CD68+ cells 
shown in cyan. Each panel is 1 mm2. 
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Figure 2.5: Acute losartan administration dramatically reduces Iso-induced injury in 
dystrophic hearts. 
(A) Angiotensin II type 1 receptors (AT1R) are G protein-coupled receptors that can be 
activated by angiotensin II (Ang II) and blocked by losartan. Top: Mice were treated with 
bolus injections of losartan (blue) 1 hour prior to Iso administration (orange), and at regular 
intervals over 30 hours following Iso injection. (B) 30 hours after Iso, losartan treatment 
caused no significant change in wild type (C10) cardiac injury, resulting in similarly low 
levels of acute Iso-induced injury in wild type and dystrophic hearts with losartan 
treatment. Untreated C10 and mdx data originally presented in Fig. 1B, shown here for 
comparison. (*** indicates p<0.001; interaction p=0.02; n = 10-17 mice per group). (C) 
Representative images of data shown in panel B. Whole hearts are shown with WGA 
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(green) marking the total tissue area and IgG (red) indicating areas of acute myocyte 
injury. Scale bar = 1mm. (D and E) CD45+ and CD68+ areas with and without losartan in 
wild type and mdx hearts, in both lesion and non-lesion areas. (*** indicates p<0.001, ** 
indicates p<0.01, * indicates p=0.03 vs. same domain without losartan; ### indicates 
p<0.001, ## indicates p<0.01 difference in total immune area; n = 9-13 mice per group). 
(F) Representative images for data shown in panels D and E, with CD45+ cells shown in 
green and CD68+ cells shown in cyan. Cardiac lesions are indicated by endogenous IgG 
uptake (red). Each panel is 0.25 mm2.  
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4. Discussion 
Dystrophic cardiomyopathy is a progressive disorder in which the accumulation 
of lesions results in extensive fibrosis and global cardiac dysfunction. One major goal of 
the present study is to characterize myocardial injury in the dystrophic heart and the 
response to this injury over time. The cardiac injury protocol detailed here, resulting in a 
scattered distribution of myocardial lesions sustained secondary to increased workload 
on the heart, represents a physiologically relevant approach for modeling the injury that 
a dystrophic patient’s heart might sustain during surgical procedures or other severely 
stressful events. This applicability is underscored by reports of elevated cardiac troponin 
I in DMD and Becker muscular dystrophy (BMD) patient serum [21,30], aligning with our 
observation of elevated cTnI in the serum of mdx mice following Iso-induced cardiac 
damage. Isoproterenol’s well-characterized actions, ease of handling, and specificity for 
β-adrenergic receptors result in a simple and reproducible adrenergic stress model that 
can provide a reliable basis for evaluation of cardiac therapies. In addition to its utility in 
evaluating acute injury prevention as demonstrated here, this Iso-based injury model 
also provides quantifiable readouts for therapies that may target fibrosis or immune 
infiltration, broadening its applicability.  
Another major goal of this work is to investigate whether intervention with 
angiotensin receptor blockers (ARBs) at the time of injury may help limit myocardial 
damage during the early necrotic phase, rather than only mitigating the cardiac 
remodeling during the later fibrotic period. ARBs may exert their action through multiple 
mechanisms downstream of angiotensin II type 1 receptor (AT1R), a G-protein coupled 
receptor (GPCR) found widely expressed in many tissues, including cardiomyocytes and 
non-myocyte cardiac cells [114]. One pathway classically linked to AT1R activation in the 
heart is the upregulation of genes associated with adverse remodeling, most notably 
TGF-β [108,232,235], a cytokine known to worsen dystrophic processes [236,237]. The 
inhibition of this pro-fibrotic and pro-hypertrophic gene program is often discussed as the 
main benefit of ARBs as a cardiac therapy. However, mounting evidence suggests that 
more acute effects of AT1R activation include increased production of reactive oxygen 
species (ROS) by NADPH oxidase, a key mediator of angiotensin II’s effects in many 
tissues [80,83]. Current literature features multiple reports of excessive NADPH oxidase-
mediated superoxide production contributing to cardiac and skeletal muscle injury in mdx 
mice [33,74,81,207,238], indicating that early treatment with ARBs is a promising 
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approach for limiting dystrophic injury. Here we show that Iso-induced cardiac injury can 
be reduced 3-fold in dystrophic hearts by acute losartan treatment initiated 1 hour prior 
to adrenergic stress and maintained during the 30-hour period that followed it. This rapid 
protective effect strongly implicates an immediate signaling-based mechanism of action 
rather than transcriptional effects. Importantly, Iso-induced cardiac injury in wild type 
mice did not reflect any losartan benefit, suggesting that the mechanism of myocardial 
injury targeted by losartan’s actions is uniquely exaggerated in dystrophic hearts. This 
notion is further supported by the different distributions of cardiac lesions in dystrophic 
and wild type hearts, even in the context of a strong reduction in dystrophic injury area. 
Wild type hearts display a peppering of small lesions clustered in endocardial regions, 
while mdx hearts show larger patches of damaged myocardium, which seem distributed 
at random throughout the walls of the heart. These mdx lesions become smaller and 
less frequent in losartan-treated hearts, but the distribution remains constant.  
Our results, along with existing literature, support a model wherein ROS-
mediated exacerbation of initial myocyte injury is a key driver of the accumulation of 
dystrophic heart damage. Oxidative stress induces a wide variety of pathological 
processes in the cell, including sarcolemmal damage, and has been thoroughly 
implicated in worsening cell survival [81,239]. NADPH oxidase, an effector of AT1R 
signaling and an important source of reactive oxygen species within the heart, has been 
shown to have increased expression and activity in dystrophic muscle, and can be 
further activated in a stretch-dependent manner [75,82]. The approaches of specific 
inhibition of NADPH oxidase or general scavenging of ROS via N-acetylcysteine have 
been shown to improve both the skeletal muscle and cardiac phenotypes in dystrophic 
mice [33,74,81,207,240]. Together, these data suggest that AT1R inhibition may benefit 
DMD patients by limiting the amplification of myocardial injury secondary to excessive 
ROS production in the dystrophic heart.  
This work raises important questions regarding the mechanism of losartan action. 
The first question regards the significance of the altered immune response to cardiac 
injury, represented by the change in relative prevalence of macrophages. Wild type 
hearts showed a 53% reduction in CD68+ area with losartan treatment, despite showing 
no significant changes in acute injury area or total CD45+ leukocyte infiltration. A similar 
trend in relative proportions of immune cell markers can be observed in mdx hearts, 
where losartan treatment resulted in a 38% reduction in CD45+ leukocytes, but a larger 
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56% reduction in CD68+ cells. CD68 is a surface marker that is expressed to some 
degree by nearly all differentiated macrophages [229,230]. Similar reductions in CD68 
content have been demonstrated in models of atherosclerosis and diabetic nephropathy 
treated with losartan [241,242]. Furthermore, it has been shown that macrophage AT1R 
activation plays an important role in macrophage polarization toward the more pro-
inflammatory M1 form and increased ROS production via macrophage NADPH oxidase 
[239,243,244]. If the immune response to cardiac damage is modified by losartan to 
become less inflammatory, then it’s possible that both dystrophic and healthy hearts 
could derive delayed benefits from losartan in the form of more effective post-injury 
healing and less adverse remodeling. 
Another important question is the relative benefit of ARB therapy compared to 
the broadly acting ACE inhibitors, which are currently more often prescribed to treat 
DMD patients despite showing lower tolerability [209,233]. Despite targeting similar 
physiological pathways, these two approaches have divergent effects on endogenous 
angiotensin signaling. ACE is a critical step in the enzymatic process that convert 
angiotensin I (AngI) to a variety of biologically active angiotensin peptides, including 
angiotensin II (AngII) and angiotensin (1-7). AngII may bind to both AT1R and AT2R, 
while angiotensin (1-7) binds to Mas receptor (MasR), triggering physiologically distinct 
downstream responses [245–247]. Importantly, signaling through AT2R and MasR is 
considered to be protective, and is often characterized in terms of opposing the adverse 
pro-fibrotic and pro-inflammatory effects of AT1R. ACE inhibition results in a large pool of 
uncleaved AngI, which, through the actions of non-ACE peptidases, may partially spill 
over into greater production of angiotensin (1-7) and greater MasR activation [126]. On 
the other hand, AT1R blockade may leave large pools of both AngII and AngI [130], with 
much of the AngII presumably being displaced to signal more through AT2R when AT1R 
is inaccessible. Furthermore, ACE inhibition has been shown to alter the availability of 
bradykinin, another peptide associated with cardiac protection, by blocking its 
breakdown to inactive metabolites, whereas ARBs leave it unaffected [248,249]. Despite 
these differences, little work has been done to directly compare these two treatment 
approaches, and clinical trials in dystrophic patients have demonstrate that ARBs or 
ACEi have similar effects on the preservation of cardiac function when initiated after the 
onset of cardiac pathology [123]. 
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 Preclinical work has made only limited contributions to shedding light on this 
matter. Previous work using a 6-month or 2-year course of oral losartan demonstrated 
reductions in muscle fibrosis and cardiac remodeling, significantly preserved cardiac 
function, and markedly improved survival in losartan-treated mdx mice [85,250]. 
Comparable treatment courses with ACEi have not been documented in dystrophic 
mice. Studies using young, unstressed dystrophic mice with treatment periods of 2-4 
months show mixed results, with most studies demonstrating little to no cardiac benefit 
compared to the natural disease course [138,142,251]. The short duration, lack of 
challenge, and co-administration of other drugs complicate the interpretation of the 
benefit of ACEi in dystrophic mice. The robust prevention of cardiac injury by AT1R 
blockade presented here suggests that additional preclinical studies and patient trials 
should investigate the relative efficacy of ARB-based versus ACEi-based therapeutic 
approaches in limiting cardiac dysfunction when initiated prior to clinically evident 
cardiac disease.  
Current best practice recommendations suggest that anti-angiotensin therapy 
should be initiated in DMD patients by the age of 10 [5,6]. This recommendation is 
based on a trial of the ACEi perindopril, in which the group of patients that initiated 
therapy at 10.7 ± 1.2 years of age demonstrated better cardiac function 5 years later and 
higher 10-year survival than the group that started therapy at 13.6 ± 1.2 years of age 
[117,118]. This clinical trial underscores the importance of early initiation of therapy. 
However, the observation that global cardiac dysfunction can be detected in patients at 
the age of 10 indicates that the loss of myocardium likely begins much earlier [3,212]. A 
significant concern with early initiation of cardiac therapy in the pediatric patient 
population is that potential side effects may significantly impact quality of life. The issue 
of tolerability has been studied in over 250,000 heart failure patients, demonstrating that 
ACEi and ARBs are equally effective, but ARBs are significantly better tolerated 
[121,122]. The new discovery of a striking benefit for acute myocardial injury shown 
here, coupled with limited side effects, strongly supports inclusion of ARBs among the 
first interventions to limit cardiomyopathy in DMD patients, well before the onset of 
global cardiac dysfunction. The earliest age at which any cardiac damage can be 
identified remains unclear, but it is clear that once myocardial damage occurs, that 
myocardium is lost forever. 
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The studies presented here provide a new, readily reproducible model of 
inducing cardiac injury in a genetic model of DMD. This approach provides an excellent 
platform for the study of myocardial injury responses, and offers significant potential for 
the pre-clinical assessment of therapies directed at dystrophic cardiomyopathy. The 
nature of the progression of dystrophic cardiomyopathy is unclear, but recent evidence 
suggests that DMD patients experience periods of significant cardiac damage resulting 
in elevations in serum markers of cardiac injury [3,212–214]. These episodic periods of 
cardiac injury are closely mirrored by the Iso-induced injury model used in these studies. 
The heart disease associated with DMD is of growing clinical importance, however many 
of the new therapeutic approaches have limited efficacy in the heart. Using this new 
model system, we demonstrate the acute protective capability of losartan pre-treatment 
in limiting the extent of new cardiac injury. This raises the important possibility that AT1R 
blockade may not only result in favorable cardiac remodeling, but may limit the 
accumulation of injury in the first place. If true, early ARB therapy could significantly 
delay the onset of cardiac dysfunction in DMD patients, extending survival and improving 
their quality of life.  
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Summary 
Duchenne muscular dystrophy (DMD) is a devastating muscle disease that 
afflicts males due to the loss of the protein dystrophin, resulting in muscle deterioration 
and cardiomyopathy. Dystrophin’s absence causes increased membrane fragility, 
myocyte death, and tissue remodeling. Inhibition of angiotensin signaling with ACE 
inhibitors or angiotensin receptor blockers (ARBs) is a mainstay of DMD therapy, with 
clinical guidelines recommending starting one of these therapies by the age of 10 to 
address cardiomyopathy.  
Using the mdx mouse model of DMD, we previously showed that isoproterenol 
causes extensive damage in dystrophic hearts, and treatment with the ARB losartan 
starting only 1 hour before isoproterenol dramatically reduced this myocardial injury. In 
the present study, we probed whether ACE inhibitors, which are more frequently 
prescribed, can deliver similar protection. Surprisingly, lisinopril treatment initiated 1 hour 
before isoproterenol failed to demonstrate any effect on injury in mdx hearts. Further, 
with a 2-week pretreatment, only losartan significantly lowered mdx cardiac injury, 
without any benefit associated with lisinopril treatment. These results confirm the ability 
of ARBs, but not ACE inhibitors, to prevent acute injury in mouse hearts, and prompt the 
question whether ARBs should be more frequently used for DMD cardiomyopathy 
because of these potential protective actions.  
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1. Introduction 
Duchenne muscular dystrophy (DMD) is a devastating muscle wasting disease 
that results in the loss of skeletal muscle function and development of cardiomyopathy. 
This X-linked disease occurs almost exclusively in males at a rate of roughly 1:5000 live 
male births [10,11]. The absence of the protein dystrophin leads to increased 
sarcolemmal fragility and dysregulation of signaling processes associated with proper 
dystrophin localization, triggering myocyte necrosis and replacement with fibrosis. DMD 
is lethal in young adulthood, with death typically occurring from respiratory or heart 
failure. In recent decades, advancements in symptomatic respiratory therapies have 
resulted in prolonged patient lifespans, leading to higher rates of advanced heart 
disease among individuals with DMD [1].  
The cardiomyopathy of DMD is a progressive disorder, with the earliest signs of 
disease processes appearing before the age of 10, and extensive myocardial fibrosis 
and contractile deficits marking the end stage of the disease [11,18,22,106]. Attempts to 
slow the progression of heart disease in patients with DMD include the recommendation 
that chronic treatment with ACE inhibitors (ACEIs) or angiotensin receptors blockers 
(ARBs) be initiated by 10 years of age or earlier, with the goal of mitigating fibrosis and 
adverse remodeling that follows cardiomyocyte loss in the dystrophic heart [5,6]. Both 
drugs aim to limit the deleterious processes associated with angiotensin II (AngII) 
signaling in the heart and muscle, which include increased production of reactive oxygen 
species (ROS), profibrotic gene transcription, and myocyte death [80,83,84,231]. ACEIs 
interfere in these processes upstream of AngII, hindering its production by blocking the 
ability of angiotensin-converting enzyme (ACE) to cleave angiotensin I into AngII. 
Conversely, ARBs limit the effects of AngII after it is formed by blocking activation of 
angiotensin II type 1 receptor (AT1R), a key mediator of many of AngII’s harmful effects. 
Several early clinical trials demonstrated improved cardiac function in DMD patients 
using ACEIs, paving the way for ACEIs being viewed as the top candidate for heart 
failure therapy [117,118]. Additional trials went on to show that ARBs were just as 
effective as ACEIs when used in patients whose cardiac health has begun to decline, 
and that ARBs are better tolerated by patients, but ACEIs continue to be used more 
widely in clinical management of DMD [121,123,233]. 
Recently, our group used the mdx mouse model of DMD to demonstrate that a 
single bolus injection of the β-adrenergic receptor agonist isoproterenol (Iso) results in 
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acute damage to 18.9±0.3% of the mdx myocardium, relative to 6.3±2% injury in wild 
type mice [31]. This experimental model of increased cardiac workload aims to 
approximate the bouts of stress experienced by DMD patient hearts during surgical 
procedures [216], with the subsequent injury likely resulting from the exacerbation of the 
ongoing disease mechanisms of the dystrophic heart [30,252]. Importantly, we reported 
that dystrophic mdx mice acutely treated with the ARB losartan shortly before this 
injurious stimulus show a striking degree of protection from myocardial injury. High-dose 
losartan treatment initiated only 1 hour prior to the bolus of Iso resulted in a 2.8-fold 
reduction in mdx myocardial injury, seemingly preventing the accumulation of myocyte 
damage in the dystrophic heart [31]. Interestingly, acute losartan did not have a 
significant effect on Iso-induced damage in wild type hearts, resulting in similarly low 
injury area in mdx and healthy hearts (6.8±2% vs. 4.9±1%, respectively) [31]. This 
demonstrated that dystrophic hearts are uniquely vulnerable to AT1R-based 
exacerbation of myocardial injury via a mechanism that plays a negligible role in healthy 
hearts.  
This discovery of losartan’s ability to prevent dystrophic heart injury has 
prompted the question whether ACEIs would exert a similar effect. While it is well-
documented that both classes of drugs are effective at limiting the fibrosis and 
remodeling that follow injury, the preservation of functional dystrophic myocardium is of 
utmost importance in the management of cardiac disease in patients with DMD. To 
determine the effectiveness of ACEIs in preserving dystrophic myocardium, here we 
present our previously published Iso-induced injury protocol with the ACEI lisinopril. Our 
new findings demonstrate that neither acute nor chronic treatment with lisinopril shows 
the protective capacity to limit Iso-induced myocardial loss in dystrophic hearts that is 
present with ARB treatment.  
 
2. Methods 
2.1. Animals 
The wild type control strain C57BL/10SnJ (C10) and the dystrophic strain 
C57BL/10ScSn-Dmdmdx/J (mdx) were bred and maintained at the University of 
Minnesota from breeding stock obtained from Jackson Laboratories. All mice were 4-6 
months of age at the time of experiments. Since DMD almost exclusively affects males, 
male mice were used in these studies. All animal procedures were approved by the 
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University of Minnesota Institutional Animal Care and Use Committee, and were 
performed in compliance with all relevant laws and regulations. 
 
2.2. Isoproterenol studies 
(-)-Isoproterenol hydrochloride (Iso; Sigma #I6504) was dissolved in saline to a 
concentration of 6 mg/ml and sterile-filtered prior to injection. The sterile Iso solution was 
stored protected from light at 4˚C for up to 3 days, and discarded at the first sign 
discoloration indicative of degradation. Mice received a single intraperitoneal bolus 
injection of 10 mg/kg Iso in a volume of 40-70 µl, and hearts were harvested 30 hours 
after the Iso injection, as previously described [31].  
 
2.3. Acute lisinopril study 
A subset of mice received acute lisinopril treatment starting 1 hour prior to Iso 
and continuing after Iso, terminating at the 30-hour timepoint. Lisinopril powder (Cayman 
Chemical #16833) was dissolved in sterile saline on the evening prior to Iso injections to 
a concentration of 12 mg/ml, and stored protected from light at 4˚C. At the start of the 
light cycle (7 am) on the day of the study, the mice received a 20 mg/kg loading dose of 
lisinopril via IP injection in a volume of 40-70 µl, followed by a 10mg/kg Iso injection 1 
hour later. At the end of the light cycle (7 pm), the mice received another bolus of 20 
mg/kg lisinopril to span the dark cycle. At the end of the dark cycle, they received a final 
dose of 20 mg/kg lisinopril, and hearts were harvested 7 hours later (30 hours after the 
Iso bolus). This dosing regimen was based on the serum half-life of lisinopril, and 
designed to minimize troughs in drug serum levels. Littermate mdx and wild type mice 
were distributed evenly between the groups receiving Iso with lisinopril or Iso only. 
 
2.4. Lisinopril and losartan pretreatment studies 
To account for the possibility that additional protective effects may be revealed 
with pretreatment, an additional subset of mice was assigned to drink either lisinopril or 
losartan dissolved in water for 2 weeks prior to Iso-induced injury. Lisinopril was given at 
a concentration of 264 mg/L in 1% dextrose water with an average consumed dose of 40 
mg/kg daily [253]. Losartan was given at a concentration of 600 mg/L in 3% dextrose, 
with an average consumed dose of 80 mg/kg daily [138]. The 2-fold difference in doses 
of losartan and lisinopril is reflective of the similar 2- to 3-fold difference in doses of 
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these drugs in human clinical applications. Drug-containing water was replaced 3 times 
per week, and each mouse was weighed before and during the pretreatment at weekly 
intervals [253].  
The physical discomfort experienced by mice following Iso administration can 
disrupt their water and food intake for up to 24 hours, so the mode of drug delivery was 
switched from the drinking water to IP injections to ensure that therapeutic levels are 
maintained during that time. At the start of the light cycle on the 15th day after the start of 
pretreatment, mice received fresh tap water and a single a single 10mg/kg Iso IP 
injection. For the next 30 hours, the mice pretreated with lisinopril received the same 
booster injections of lisinopril as described in section 2.3 above, and mice pretreated 
with losartan received booster injections as described previously [31]. Mice were 
sacrificed and hearts were harvested 30 hours after the Iso injection.  
 
2.5. Histopathology 
Histopathology studies were carried out as previously described [31]. Briefly, 
fresh excised hearts were cut in half along the transverse plane and placed into OCT 
medium to be frozen in liquid nitrogen-cooled isopentane. Heart sections were cut to 7 
µm, and the slides were stored at -80˚C before staining. All staining was performed on 
unfixed tissue. The following reagents were used for IF staining: goat serum for blocking 
(Jackson ImmunoResearch # 005-000-121, 10%), goat anti-mouse IgG (H+L) secondary 
antibody (Invitrogen #R37121, 1:200), WGA AlexaFluor conjugate (ThermoFisher, 
5µg/ml), and ProLong Gold Antifade Mountant with DAPI (ThermoFisher). After blocking, 
staining was performed as a single step at room temperature for 1 hour, flanked by three 
5-minute washes in PBS.  
Only hearts from mice that survived the initial 24 hours were analyzed for injury 
area, due to the difficulty of quantifying the poorly-defined early IgG-positive injury 
present in hearts that succumb earlier in the time course. To ensure that this approach 
would not skew results, we confirmed that the mortality rates of 20-37% among mdx 
mice and 5-14% among wild type mice did not differ significantly between treatments.  
 
2.6. Microscopy and image analysis 
All imaging was performed in NIS Elements software on a Nikon Eclipse Ni-E 
upright epifluorescent microscope with motorized stage and filter wheel. Whole heart 
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montages were collected as a stack of three fluorescent channels at a resolution of 0.92 
µm/pixel. IgG-positive injury area was determined using Fiji by subtracting the WGA 
channel (staining extracellular matrix) from the IgG channel to better distinguish intra-
myocyte IgG signal [219]. This lesion area was then quantified by thresholding the 
resulting IgG image for total lesion area, and normalizing it to total heart section area. 
 
2.7. Patient anti-angiotensin drug information 
Electronic medical records from patients diagnosed with Duchenne muscular 
dystrophy at the University of Minnesota were surveyed for prescriptions of either ACEIs 
or ARBs. In total, we examined the records of 95 DMD patients seen from 2009-2019. 
The 30 patient records that did not specifically mention an ACE inhibitor or an ARB were 
excluded from the analysis. Several patients had received both ACEIs and ARBs, and in 
these cases they were classified by the most recent prescribed class of medication. No 
patients were receiving both drug classes at the same time. Collection and analysis of 
these data were performed in accordance with an IRB-approved protocol.  
 
2.8. Statistics 
Statistical tests were performed using Prism 7 (GraphPad Software). Preclinical 
study statistical comparisons were made using two-way ANOVA with Sidak post-hoc 
test. Ages from patient data were compared using the non-parametric Mann-Whitney 
test. All graphs display the mean ± standard error. 
 
3. Results 
3.1. Acute treatment with lisinopril has no effect on Iso-induced cardiac injury area. 
Acute ACE inhibition with lisinopril initiated 1 hour prior to the bolus of Iso failed 
to decrease IgG+ cardiac injury area in both mdx hearts and wild type hearts (Fig. 3.1). 
As previously shown, mdx hearts stressed with a 10 mg/kg bolus of Iso displayed very 
high injury compared to wild type hearts (20.2±2% vs. 5.3±2%), and this difference 
persisted with ACE inhibition (16.2±2% vs. 6.4±2%) (Fig. 3.1 B and C). This result 
stands in stark contrast to our earlier published findings demonstrating that acute 
losartan treatment has a robust capacity for myocardial injury reduction in dystrophic 
hearts [31].   
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3.2. Pretreatment with losartan, but not with lisinopril, significantly reduces Iso-induced 
injury in mdx hearts. 
To address the possibility that lisinopril may require a period of pretreatment to 
exert a protective effect, mdx and C10 mice were placed on a 2-week course with either 
lisinopril or losartan delivered in their drinking water before repeating the bolus injection 
protocol (Fig. 3.2A). In agreement with our earlier work, losartan pretreatment exerted a 
significant protective effect in dystrophic hearts, reducing mdx cardiac injury to 12.2±3% 
without any effect in C10 hearts (5.7±1% injury area) (Fig. 3.2 B and C). In contrast, 
pretreatment with lisinopril still did not reveal any protective effect on myocardial damage 
in mouse hearts. Mdx mice pretreated with lisinopril and injected with a bolus of Iso 
showed 20.9±2% IgG-positive cardiac injury, and C10 mice in the same treatment group 
showed 5.4±2% cardiac injury (Fig. 3.2 B and C). 
 
3.3. Patient records show that few patients with DMD receive ARB-based therapies.  
According to electronic records from patients with DMD seen in the years 
between 2009-2019 at the University of Minnesota, the majority of patients whose 
records mention an anti-angiotensin drug are receiving ACE inhibitors. Among the 
records that indicated the use of one of these drug classes, 72% of patients were on 
ACEIs while only 28% were taking ARB drugs (Fig. 3.3). The ACE inhibitor group 
included several patients that had begun the treatment before the age of 10, but all 
patients in the ARB treatment group were above the age of 10. Interestingly, only 38% 
(18/47) of patients in the ACEI-treated group but 72% (13/18) of the patients receiving 
ARBs were also being treated with beta blockers. This may be related to the fact that 
patients receiving ARBs were on average significantly older than those receiving ACEI, 
and thus more likely to be in more advanced stages of cardiac dysfunction (Fig. 3.3). Out 
of 95 patient records listing a diagnosis of DMD, 30 lacked any mention of ACE inhibitors 
or ARBs, and were thus excluded from the analysis.  
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Figure 3.1: Acute ACE inhibition is insufficient to protect the heart from Iso-induced 
injury. 
(A) The ACE inhibitor lisinopril was given as a 20 mg/kg IP injection 1 hour prior to a 10 
mg/kg bolus injection of isoproterenol (Iso). Booster injections of lisinopril were given 
twice at 12-hour increments to maintain drug serum levels. (B) Dystrophic (mdx) hearts 
displayed 3.8-fold higher myocardial injury than wild type (C10) hearts 30 hours post-Iso. 
Acute treatment with lisinopril (Lsp) did not significantly change Iso-induced injury area 
in either group (*** p<0.001, ** p= 0.003; C10 n=6 per group; mdx n=10-11 per group). 
(C) Representative images of data in panel B. Whole heart transverse sections are 
shown with WGA (green) marking the tissue area and IgG (red) indicating areas of 
myocardial injury. Scale bar = 1 mm. 
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Figure 3.2: Pretreatment with losartan, but not lisinopril, protects mdx hearts from acute 
myocyte injury.  
(A) To investigate and compare potential chronic benefits of lisinopril (Lsp) and losartan 
(Los), each drug was given as a pretreatment in drinking water for 2 weeks before 
resuming the injection-based 30-hour protocol. (B) Losartan pretreatment significantly 
lowered Iso-induced IgG+ injury in mdx hearts, but did not alter the injury outcome in 
C10 hearts. Lisinopril pretreatment failed to show an effect in either group. Red dashed 
line indicates injury level of Iso-only mdx hearts, and black dotted line indicates injury in 
Iso-only C10 hearts, as shown in Fig. 1. (*** p<0.001, ** p=0.004; C10 n=6-7 per group; 
mdx n=14-18 per group). (C) Representative images of data in panel B. Whole heart 
transverse sections are shown with WGA (green) marking the tissue area and IgG (red) 
indicating areas of myocardial injury. Scale bar = 1 mm. 
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Figure 3.3: Patient records show that fewer patients with DMD receive treatment with 
ARBs than ACE inhibitors. 
Left: Of 65 records belonging to patients diagnosed with DMD that mentioned an anti-
angiotensin drug, 72% (47/65) indicated the use of an ACEi, and 28% (18/65) indicated 
the use of an ARB. Right: The dotted line at 10 years of age corresponds to the 2015 
guideline to initiate treatment with an ACEi or ARB at or before 10 years of age. Only the 
ACEi group includes patients who are younger than 10 years of age, and the group of 
patients receiving ARBs is older on average than the group receiving ACEi (*p=0.02).  
 
 
  
Patient Record Data
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4. Discussion 
Cardiomyopathy is a major feature of DMD that afflicts essentially all patients 
over 18 years of age, becoming a leading cause of death in this era of life-prolonging 
symptomatic respiratory therapies [1,3,7]. The earliest signs of cardiac pathology appear 
in childhood, with transient elevations in serum levels of cardiac troponins and early 
cardiac fibrosis detected in patients as young as 6 years of age [18,19,21,22,106]. 
These observations indicate that the destruction of healthy myocardium is ongoing well 
before the onset of global cardiac dysfunction manifesting in reduced ejection fraction 
[19,106]. Therefore, clinical approaches that preserve the myocardium by preventing this 
early degeneration are critically important for the successful management of dystrophic 
cardiomyopathy. This evidence of early cardiac degeneration has resulted in the 
updating of earlier recommendations, that cardiac treatment be initiated in response to 
detectable deficits in function, with the current guidelines that all DMD patients without 
contraindications should start on ACE inhibitors or ARBs by 10 years of age or earlier 
[5,20]. Currently, most DMD patients receiving an anti-angiotensin therapy are on 
ACEIs, which are considered to be a first-line therapy for heart failure in general and are 
named first by the guidelines for managing dystrophic cardiomyopathy [5,6,254]. ARBs 
are often mentioned as an alternative to ACEIs or the next step for those who are poorly 
tolerant of ACEI side effects, although clinical trials have not shown any differences in 
efficacy between the two drugs in DMD [121,123].  
This study and our previous work demonstrated that losartan treatment 
significantly lowered myocardial injury following Iso-induced cardiac stress in the mdx 
mouse heart. This injury-preventing effect is only evident in the dystrophic hearts, 
without significant reduction in wild type cardiac damage after losartan treatment. This 
observation suggests that an angiotensin-related mechanism that is uniquely 
exaggerated in the dystrophic process is driving the accumulation of myocardial injury in 
the dystrophic heart. This finding raised many questions regarding the potential ability of 
ACE inhibitors to deliver similar protection, prompting the work presented here. 
Surprisingly, we found a lack of benefit associated with lisinopril treatment before the 
onset of Iso-induced myocardial injury, regardless of the treatment being initiated 1 hour 
or 2 weeks before injury. These results indicate that ARBs have a unique protective 
action in the dystrophic heart that is not recapitulated by ACEI treatment.  
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Since ACE inhibitors and ARBs exert their respective actions at different points 
within the renin-angiotensin system, it may be expected that these drug classes would 
have similar beneficial effects. Indisputably, both drugs do provide significant benefits in 
the dystrophic heart, as indicated by multiple clinicals trials supporting their efficacy. 
However, the path from angiotensin I to AngII and AT1R activation is complex and 
multifaceted, opening the door for some divergence in the effects and benefits of these 
two drug classes that could explain the differences reported here. One possibility is that 
some combination of ACE-independent production of AngII by other peptidases and 
stretch-dependent activation of AT1R by the mechanical forces induced by increased 
cardiac workload results in substantial AT1R signaling even in the presence of ACEIs 
[124–128]. If the maximum benefit of anti-angiotensin therapies to cardiomyocytes lies in 
blocking AT1R activation, then the indirect inhibition provided by ACEIs may be 
insufficient to protect cardiomyocytes from damage in light of these alternative activating 
mechanisms.  
Another possible explanation is that ARB and ACEI treatments trigger distinct 
homeostatic responses that result in different secondary effects on the production and 
metabolism of angiotensin peptides. One unique secondary effect that may contribute to 
the distinctive ability of ARBs to prevent cardiomyocyte injury may lie in enhanced 
activation of angiotensin II type 2 receptor (AT2R) as a compensatory consequence of 
AT1R antagonism. When AT1R is blocked, homeostatic mechanisms feed back to 
increase circulating levels of AngII, and all of this displaced AngII can serve as a ligand 
for AT2R activation, which has been shown to mediate cardioprotective effects of 
angiotensin peptides [126,129]. Conversely, the distinct secondary effects induced by 
ACEIs include increases in angiotensin (1-7) and bradykinin, both of which have 
documented cardioprotective actions that may play a role in the demonstrated clinical 
efficacy of ACEIs. Angiotensin (1-7) may be produced at higher rates by non-ACE 
peptidases secondary to the accumulation of angiotensin I that follows ACEI treatment, 
and may also be removed at a slower rate because its degradation is normally mediated 
by ACE, resulting in its accumulation with ACE inhibition [126,130]. Angiotensin (1-7) is 
the endogenous ligand for the Mas receptor, and like AT2R, Mas receptor activation 
causes a variety of protective effects that oppose the actions of AT1R, including reducing 
inflammation, reducing oxidative stress, and increasing vasodilation [245,255,256]. 
Bradykinin, the ligand for BK receptors, is another substrate for degradation by ACE that 
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accumulates during ACE inhibition and may bear protective effects. However, while 
bradykinin is indeed linked to beneficial effects on inflammation, NO signaling, and pain, 
it is also a major contributor to the poorer tolerance of ACEIs, triggering a cough that 
prompts many patients to discontinue ACEI use [248]. Together, the joint effects of these 
protective mechanisms may drive the documented ACEI benefits of preventing 
remodeling and preserving function in the surviving myocardium. However, the inability 
of ACEIs to prevent myocardial damage in the Iso-induced injury model used here 
suggests that its protective mechanisms may be insufficient to overcome the acute 
effects of ACE-independent AT1R activation.  
 The work presented here has some important limitations that should be 
addressed in future studies. First, the molecular effects of ACEI and ARB that are 
described above participate in overlapping physiological pathways, thus it is not possible 
to estimate the magnitude of their respective contributions to the overall protection 
derived from the use of these drugs in a whole animal model. Further work should make 
use of more selectively targeted agonists and antagonists to investigate the distinct 
mechanisms that contribute to ACEI and ARB cardiac effects, including AT1R 
modulation, AT2R activation, and Ang 1-7 signaling, to better understand the protective 
pathways in the dystrophic heart. Furthermore, the studies described here have used the 
mildly-affected mdx mouse, so additional work will be needed to determine if these 
protective actions of ARBs are present in more severe or earlier-onset disease models. 
It is possible that a different approach to evaluating cardiac or skeletal muscle 
vulnerability in a dystrophic animal model would reveal a different relationship between 
the benefits of ACEI and ARB treatments.  
Despite these limitations, the existence of the novel and specific protective 
influence of ARBs that we have described may carry major implications for clinical 
management of dystrophic cardiomyopathy. Not only does the injury-limiting capacity of 
ARBs support earlier initiation of anti-angiotensin therapies to precede the beginning of 
cardiac deterioration, but it also calls for a more thorough comparison of potential 
benefits between ARB and ACEI treatments. To date, clinical trials comparing ACEIs 
and ARBs have been performed in DMD patients old enough to have established 
cardiac injury, and records matching a DMD diagnosis from the University of Minnesota 
show a trend toward older patients in the ARB treatment group than the ACEi group. 
Based on these limitations, the lack of evidence supporting a significant benefit of ARBs 
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over ACEIs may reflect the possibility that the additional ARB benefits described here 
are less evident in hearts with significant pre-existing myocardial damage. Additional 
clinical trials that enroll patients with DMD at a sufficiently young age to benefit from the 
potential protective actions of ARBs will be necessary to compare the therapeutic 
potential of ARBs and ACEIs in these fragile hearts. Data from our center show that the 
small proportion of patients currently receiving ARB treatment may already be too old to 
benefit maximally from early myocardial preservation by ARBs, so any comparisons 
based on data from patients who started their ARB treatment after the onset of 
cardiomyopathic symptoms should be made very cautiously. 
In summary, we have presented data demonstrating that ARB treatment has a 
unique capacity to save cardiomyocytes from injury rather than just mitigating 
remodeling after their loss. These results support a shift in clinical practice toward using 
ARBs as a first-line therapy before 10 years of age for any child diagnosed with DMD, 
considering the certainty that virtually all of them will develop cardiomyopathy by their 
late teens. ARBs are safe, relatively well-tolerated, and readily available drugs that may 
hold the key to significant improvements in prognosis and quality of life for these 
patients, only requiring some adjustments to their clinical application.  
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Summary  
Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disease 
that causes progressive muscle wasting and cardiomyopathy. This X-linked disease 
results from mutations in the dystrophin gene and primarily affects males, with most 
cases being passed via the X-chromosome from a mother who carries the mutation. The 
loss of dystrophin causes widespread cellular pathology that leads to the loss of healthy 
myocytes, thus great effort has been invested in gene-targeted therapies that may 
restore dystrophin expression in striated muscle. Preclinical studies show that some of 
these approaches result in a mosaic pattern of dystrophin-expressing and dystrophin-
null myocardium, raising the question of what extent of dystrophin restoration is sufficient 
to rescue the heart from DMD-related pathology. Female carrier hearts can provide 
insights into this question, due to their mosaic dystrophin expression pattern resulting 
from random X-inactivation.  
In the present study, a mouse model of DMD carriers was used to model 
myocardial injury resulting from isoproterenol-induced stress in hearts partially 
expressing dystrophin. Carrier mice were derived either from dystrophic mothers or 
dystrophic fathers breeding with a wild type mate. Our results revealed that, despite 
expressing ~57% dystrophin, Carrier hearts are significantly susceptible to acute 
cardiomyocyte injury induced by one or repeated high doses of isoproterenol. 
Importantly, Carrier survival after cardiac injury depended on their parental genotypes, 
as only Carrier mice derived from dystrophic mothers showed mortality. These findings 
indicate that dystrophin expression in just over half of the heart may still leave the heart 
with marked vulnerability to injury. Additionally, the differential survival observed in mice 
expressing the same dystrophin levels underscores a need for better understanding of 
the impact of other factors, including epigenetic, developmental, and environmental 
influences, on this vulnerability in the dystrophic heart.    
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1. Introduction 
Duchenne muscular dystrophy (DMD) is a progressive muscle wasting disease 
that involves the heart, resulting in clinically significant cardiomyopathy [3,5,6,148,189]. 
The DMD gene locus on the X-chromosome encodes the protein dystrophin, which plays 
a critical role in healthy muscle cells by bolstering membrane integrity and serving as a 
signaling scaffold [52,190–193]. The loss of dystrophin leads to myocyte necrosis, 
fibrosis, skeletal muscle wasting, and cardiomyopathy, culminating in premature death 
from cardiorespiratory failure. Due to its X-linked origin, DMD occurs almost exclusively 
in males at a rate of roughly 1:5000, and in the majority of cases, it is passed down from 
a mother that carries one mutated copy of the gene [8,10,11]. Virtually all patients with 
DMD over 18 years of age display overt clinical signs of cardiomyopathy, including 
cardiac fibrosis, ventricular dilation, and reduced contractile function [3,24]. The 
devastating cardiac pathology caused by DMD has been recognized since its earliest 
descriptions, including an 1836 report by Conte and Gioja about two brothers who had 
progressive debilitating muscle weakness, and the oldest of whom evidently suffered 
from cardiomyopathy at the time of death [3,14]. The natural history of the disease often 
terminated with death from cardiorespiratory failure in the late teens or early 20’s. With 
advancements in symptomatic respiratory therapies and pharmacological management, 
DMD patient lifespans have extended into the 30’s or early 40’s, magnifying the 
incidence of heart failure in this patient population [1,25].  
In recent years, a variety of potential new therapies aiming to enable dystrophin 
expression in dystrophic muscle have emerged from preclinical work, with a few of them 
now entering the clinical arena. Some of these therapeutic strategies, like antisense 
oligonucleotide-mediated exon skipping and CRISPR-Cas9 gene editing, can restore the 
expression of the endogenous DMD gene [161,162,179,180,182]. Conversely, micro-
dystrophin gene therapy aims to replace the endogenous gene with a highly truncated 
but functional substitute that has been scaled down to its essential components 
[29,170,171]. These potential therapies hold great promise, and they have all been 
shown to induce dystrophin expression in both the skeletal muscle and the heart in 
preclinical studies. However, successful cardiomyocyte transduction continues to be a 
major obstacle to their cardiac efficiency. In preclinical work, these approaches have 
often displayed a mosaic pattern of transduction in the heart, with clusters of 
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cardiomyocytes that still lack dystrophin adjacent to those that now express it 
[161,164,180,183,257].  
This mosaic dystrophin expression pattern is reminiscent of that seen in DMD 
carrier hearts, who harbor one intact copy of the DMD gene and one disease-causing 
copy that carries a mutation resulting in the loss of dystrophin. Because of the 
requirement for two X-chromosomes for carrier status, DMD carriers are genetically 
female. Due to X-inactivation around the mid-gestational point in embryonic 
development, female cell nuclei have near-exclusive gene expression from a single X-
chromosome [258].  This genetic composition results in a nearly uniform distribution of 
dystrophin-positive myofibers in skeletal muscle, since each fiber is comprised of many 
independent nuclei that contribute to the overall expression profile of the cell. In contrast, 
each cardiomyocyte develops with a single nucleus, and any nuclear division that occurs 
after X-inactivation maintains the X-inactivation status of the original nucleus [259]. For 
this reason, the expression profile of any given cardiomyocyte generally depends on 
only one X-chromosome, giving rise to the mosaic pattern of positive and negative 
dystrophin expression in DMD carrier hearts.  
In animal models, DMD carrier hearts have been shown to have roughly 50% 
dystrophin-positive cardiomyocytes [32]. With gene therapy on a DMD background, the 
relative proportions of dystrophin-positive and dystrophin-negative myocytes vary widely 
in the heart, often on the basis of drug or virus dose or any modifications to the delivery 
aimed at enhancing cardiac uptake [161,162,164]. As these developing therapies move 
into clinical trials and become available to DMD patients, it becomes increasingly 
important to determine how much dystrophin expression is sufficient to rescue the heart 
in order to establish dosing. DMD carrier hearts represent a useful preclinical model to 
evaluate whether approximately 50% dystrophin-positive myocardium will be sufficient to 
reduce susceptibility to injury in treated dystrophic hearts.  
Observations in patients with DMD suggest that episodes of elevated cardiac 
stress and injury may underlie the progressive nature of DMD cardiomyopathy, indicated 
by transient periods of angina and elevated serum cardiac troponins in the contexts of 
surgery or other cardiac stress. We have previously shown that the β-adrenergic 
receptor agonist isoproterenol (Iso) may represent an appropriate model of episodic 
cardiac injury in dystrophic mice, based on elevations in serum cardiac troponins and 
lesion localization in the mdx mouse heart injured by a high dose of Iso [31]. Previous 
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work by Yue et al. had used low doses of Iso to investigate the impact of transient 
cardiac stress in mouse DMD carrier hearts [32]. This study showed extensive protection 
from cardiac stress-induced injury in DMD carrier hearts compared to dystrophin-null 
mdx female hearts after a brief 12-hour course of three low-dose Iso injections. 
However, we had been unable to induce a similar degree of cardiac damage to that 
reported by Yue et al. using the low-dose Iso protocol, and found contrasting results 
after inducing injury with high-dose Iso. Additionally, we set out to determine if the 
degree of susceptibility to injury in the DMD carrier hearts would remain relatively similar 
in the context of a multiple-day repeated cardiac stressor. Here we present the findings 
that DMD carrier hearts with ~57% dystrophin-positive myocardium display significant 
vulnerability to Iso-induced myocardial injury and mortality, and that the parental origin of 
the mutated DMD gene determines the degree of protection afforded by partial 
dystrophin expression.  
 
2. Methods 
2.1. Animals  
The wild type control strain C57BL/10SnJ (C10), the dystrophic strain 
C57BL/10ScSn-Dmdmdx/J (mdx), and the heterozygous offspring of their crosses (Carrier) 
were bred and maintained at the University of Minnesota. To limit genetic drift within this 
colony, breed stock were purchased from Jackson Laboratories every 5-6 generations. 
All mice were 4-6 months of age at the time of experiments and were housed in static 
cages with a 12-hour light-dark cycle. Since only female animals can be heterozygous 
with respect to X-chromosome genes like DMD, all mice used in this study were female. 
All animal procedures were approved by the University of Minnesota Institutional Animal 
Care and Use Committee and performed in compliance with all relevant laws and 
regulations. To enable the detection of epigenetic effects on experimental outcomes, two 
groups of DMD Carrier mice were generated with either maternal (CarrierM) or paternal 
(CarrierP) inheritance of the disease-causing DMD allele. CarrierM mice were born to 
mdx dams and C10 sires, and CarrierP mice were born to C10 dams and mdx sires.  
 
2.2. Low-dose isoproterenol challenge 
(-)-Isoproterenol hydrochloride (Iso; Sigma #I6504) was dissolved in saline to a 
concentration of 0.2 mg/ml and sterile filtered into a foil-wrapped glass vial prior to 
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injection. The sterile Iso solution was stored at 4˚C for no more than 3 days, and any 
solution developing discoloration, indicative of degradation, was discarded. Mice 
received 3 IP bolus injections of 0.35 mg/kg Iso each in volumes of 40-60 µl adjusted for 
body weight, with 6 hours between the first two injections and 3 hours between the 
second and the third injection, as previously described by Yue et al. [32]. Mice were 
sacrificed and hearts were harvested 30 hours after the first Iso injection.  
 
2.3. High-dose isoproterenol challenge 
Iso was dissolved in sterile saline to a concentration of 6 mg/ml, and otherwise 
handled as described in section 2.2. Mice received a single IP bolus injection of 10 
mg/kg Iso in volumes of 40-60 µl adjusted for body weight, as previously described [31]. 
Hearts were harvested 30 hours after the Iso injection.  
 
2.4. Repeated high-dose isoproterenol challenge 
Iso was prepared and handled as described in section 2.2. Mice received up to 
14 injections of 10 mg/kg isoproterenol over the course of 5 days, delivered as 3 daily IP 
injections at 8am, 12pm, and 4pm. Hearts from mice that succumbed to the challenge 
were harvested at the time of discovery, and all survivors were sacrificed at 2pm on the 
5th day. Mice that displayed marked and progressive lethargy or morbidity indicative of a 
decline toward death were euthanized in compliance with the animal use protocol.  
 
2.5. Histopathology 
At the time of harvest, hearts were cut in half along the short axis, and the apical 
halves were embedded in OCT blocks for histology. Heart section slides were prepared 
as previously described [31], and all tissues were unfixed at the time of staining. The 
following antibodies and reagents were used for immunofluorescence staining: goat 
serum for blocking (Jackson ImmunoResearch # 005-000-121, 10%), rabbit dystrophin 
monoclonal antibody (Abcam #ab218198, 1:300), goat anti-rabbit IgG (H+L) highly 
cross-adsorbed Alexa Fluor Plus 647 secondary antibody (Invitrogen #A32733, 1:200), 
Alexa Fluor 555 goat anti-mouse IgG secondary antibody with minimal cross-reactivity 
(Biolegend # 405324, 1:150), WGA Alexa Fluor 488 conjugate (ThermoFisher # 
W11261, 5µg/ml), and ProLong Gold antifade mountant with DAPI (ThermoFisher # 
P36934). The blocking, primary antibody, and secondary antibody incubation steps were 
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all carried out at room temperature for 1 hour, separated by three 5-minute washes in 
fresh PBS.  
The following reagents were used for Sirius Red Fast Green (SRFG) staining: 
1.2% picric acid solution (Ricca #R5860000), Direct Red 80 (Sigma #365548), Fast 
Green FCF (Sigma #F7252), Formula 83 clearing solvent (CBG Biotech F83), and 
organic mounting medium (CBG Biotech MM83). Slides were first fixed for 3 hours in 
snap chilled acetone at -20˚C before staining, then rehydrated in 70% ethanol followed 
by two changes of tap water. The tissue was then stained for 25 minutes in SRFG dye 
solution of picric acid, 0.1% Direct Red 80, and 0.1% Fast Green FCF. Staining was 
followed by 3 washes in tap water, then dehydration in 70% ethanol, 100% ethanol, and 
Formula 83 before coverslipping.  
All imaging was performed using NIS Elements software on a Nikon Eclipse Ni-E 
upright epifluorescent microscope with a motorized stage. For dystrophin and IgG lesion 
analysis, whole heart montages were collected as a stack of four fluorescent channels at 
a resolution of 0.92 µm/pixel. For evaluation of fibrosis, SRFG-stained sections were 
imaged as brightfield montages at a resolution of 0.85 µm/pixel.  
 
2.6. Histological analysis 
Dystrophin was quantified histologically on whole heart montages in Fiji using the 
threshold function [219]. An Alexa Fluor Plus 647 secondary antibody was chosen for 
dystrophin staining due to strong fluorophore signal and low background signal in the 
heart in that wavelength range, providing for an excellent signal-to-noise ratio and 
facilitating this thresholding approach. (Note: the coloration used in the figures 
represents the choice of optimal colors for depiction rather than the original wavelengths 
used for imaging). Dystrophin+ pixel area was divided by total heart section area as 
measured using the WGA signal. In wild type hearts, this method produced values with a 
range of 45.4-49.2% with a mean and standard error of 46.9±0.3%, reflecting strong 
consistency. All dystrophin measurements from individual hearts were then normalized 
to this wild type dystrophin mean value to determine the relative percentage of 
dystrophin expression in each heart compared to wild type hearts. The small number of 
revertant dystrophin+ myocytes present in all mdx hearts enabled the selection of an 
appropriate threshold for representing positive dystrophin signal in overwhelmingly 
dystrophin– images.  
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IgG+ injury area was determined using whole heart montages in Fiji by 
subtracting the WGA channel (staining extracellular matrix) from the IgG channel to 
better distinguish intra-myocyte IgG signal. The resulting IgG image was then 
thresholded to measure total lesion area, and normalized to total heart section area. 
Only hearts from mice that survived until the 30-hour sacrifice timepoint were analyzed 
for IgG+ injury area, due to the technical difficulty of quantifying the poorly-defined early 
injury present in hearts that succumb earlier in the time course.  
Fibrosis was analyzed in whole heart montages of SRFG-stained sections using 
the color threshold function in Fiji. Areas containing Sirius Red-stained collagen were 
quantified by measuring the pixel area corresponding to a red hue above a minimum 
saturation threshold. Total heart section area was represented by the full range of hues 
above the same minimum saturation threshold, and fibrosis was calculated as the Sirius 
Red area normalized to total heart area. Only hearts from mice that survived the 
repeated Iso challenge were used for fibrosis quantification following the challenge. 
Hearts that succumbed earlier in the challenge displayed a complex mix of degenerating 
myocytes with acute IgG+ injury and the fibrosis that was in the process of replacing 
them, and were thus difficult to quantify for total damaged area. 
 
2.7. Statistics 
All statistical analyses were performed using Prism 7 (GraphPad Software). 
Dystrophin and injury levels were compared across groups using one-way ANOVA with 
Holm-Sidak post-hoc test. Survival after a single high-dose Iso injection was compared 
using the Chi-square test, and survival over time in the repeated Iso challenge was 
compared using a log-rank test with the Bonferroni correction to adjust for multiple 
comparisons.  
 
3. Results 
3.1. DMD Carrier heart dystrophin expression does not depend on parental origin of the 
disease allele. 
Two breeding strategies were used to generate DMD Carrier mice, producing 
maternal (CarrierM) and paternal (CarrierP) female DMD Carriers from mdx dams and 
mdx sires, respectively (Fig. 4.1A). Both strategies resulted in the same degree of 
dystrophin expression in the Carrier hearts, as measured by histological quantification. 
 72 
 
Both groups displayed dystrophin+ signal in approximately 57% of the area 
corresponding to full dystrophin expression seen in wild type (WT) hearts, regardless of 
maternal or paternal origin of the disease-causing allele (56.8±3.7% in CarrierP and 
57.6±3.4% in CarrierM; Fig. 4.1B). The pattern of dystrophin expression was confirmed to 
be mosaic, with large adjacent regions of dystrophin+ and dystrophin– cardiomyocytes 
(Fig. 4.1D), in agreement with previously published work [32]. The range of quantified 
dystrophin levels in Carrier hearts represents real biological variability, rather than any 
artifact of histological processing, with the lowest-expressing heart having 40.0% 
dystrophin and the highest-expressing heart having 78.4% dystrophin relative to WT 
hearts (Fig. 4.1E). The levels of dystrophin expression was not litter-dependent, as mice 
expressing high levels of dystrophin and others expressing lower levels were found in 
the same litter.  
The presence or absence of dystrophin expression did not affect heart weights at 
baseline, as no significant differences were detected in heart weights between WT, mdx, 
and Carrier female mice, although Carrier hearts trended toward being slightly smaller 
(123.3±1.2 mg vs. 123.3±2.0 mg vs. 118.1±1.8 mg, respectively; p=0.07). The absence 
of a significant difference was confirmed by normalizing heart weight in mg to tibial 
length in mm to account for body size (Fig. 4.1C; p=0.21).  
 
3.2. DMD Carrier hearts display intermediate susceptibility to Iso-induced injury that 
partially depends on parental origin. 
Previously, Yue et al. showed that 3 sequential IP injections of the β-adrenergic 
receptor agonist isoproterenol (Iso), each at a low dose of 0.35 mg/kg and staggered 
over a 12-hour period before sacrifice, induced injury in approximately 11% of the mdx 
heart area, but only 2% of the Carrier heart area and negligible injury in wild type hearts 
[32]. Our attempt to replicate this result with the same Iso dosing protocol instead 
yielded significantly lower myocardial damage in mdx and Carrier mice. Three sequential 
Iso injections at a dose of 0.35 mg/kg each induced injury in less than 1% of the hearts 
in each group, with the mdx injury approximately 2-fold greater than injury in both wild 
type and Carrier hearts (Fig. 4.2A). The injured IgG+ myocytes in Carrier hearts were 
largely devoid of dystrophin (Fig. 4.2 B and D), but this was also true in wild type hearts, 
suggesting that cardiomyocyte injury likely precipitates the dystrophin loss as a 
consequence of proteolysis [31]. 
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In an effort to recapitulate the higher level of injury in mdx hearts presented by 
Yue et al., a protocol based on a single bolus IP injection of high-dose (10 mg/kg) Iso 
was used to induce cardiac injury [31]. This dose revealed 10-fold higher injury in mdx 
hearts compared to WT hearts, and an intermediate susceptibility to injury in DMD 
Carrier hearts (Fig. 4.2C). Surprisingly, 21% (4 of 19) of DMD Carrier mice born to mdx 
dams and WT sires (CarrierM) displayed spontaneous mortality after the single Iso 
injection, while Carriers derived from mdx sires and WT dams (CarrierP) all survived until 
sacrifice, and only 1 of 24 mdx females died (Fig. 4.2C).  
Surviving Carrier mice displayed damaged myocardial area that was significantly 
higher than in WT hearts and significantly lower than in mdx hearts, indicating 
intermediate susceptibility to a single bout of injury (Fig. 4.2C). As before, the majority of 
injured IgG+ cardiomyocytes lacked dystrophin, although the rare injured myocyte could 
be found with some dystrophin expression (Fig. 4.2D).   
 
3.3. DMD Carriers are highly susceptible to repeated bouts of high-dose Iso, but display 
divergent survival.  
To determine if hearts with 50% dystrophin expression would continue to show 
partial protection in the face of repeated bouts of adrenergic stress with high-dose Iso, 
WT, Carrier, and mdx mice received 14 doses of 10mg/kg Iso over a span of 5 days 
before sacrifice (Fig. 4.3A). As in the case of a single bolus Iso injection, parental origin 
of the null DMD allele had a significant influence on survival. Among CarrierM mice, 31% 
succumbed to the repeated Iso challenge, reflecting nearly identical mortality as mdx 
mice (38%). However, all CarrierP mice and WT mice survived the challenge (Fig. 4.3B).  
Survivors of the challenge were analyzed for cardiac fibrosis area to reflect the 
amount of myocardium lost during the challenge. Carrier mice were found to have 
equally high levels of cardiac damage as mdx mice, regardless of maternal or paternal 
origin of the disease-causing allele (Fig. 4.3C). Carrier hearts showed similar distribution 
of replacement fibrosis as dystrophic hearts, with large lesions scattered randomly 
throughout the myocardium, including subepicardial regions, in contrast to the 
endocardial localization of WT heart lesions (Fig. 4.3D).  
 
 
  
 74 
 
 
 
Figure 4.1: DMD Carrier hearts display mosaic dystrophin expression throughout the 
myocardium. 
(A) Heterozygous DMD Carrier mice were generated from two different crosses. 
Paternal Carrier (CarrierP) mice were bred from mdx fathers and wild type (C57Bl/10) 
mothers, maternal Carrier (CarrierM) mice were derived from mdx mothers and wild type 
fathers. (B) Histological quantification of dystrophin+ signal in Carrier hearts normalized 
to dystrophin+ signal in wild type (C10) hearts. Both types of Carriers express dystrophin 
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in ~57% of the heart area (n=7-13 per group). (C) Heart weights were not different 
between C10, Carrier, and mdx mice at baseline when normalized to tibial length to 
control for body size (n=6-14 per group; p=0.21). (D) Representative images of 
dystrophin distribution in C10, Carrier, and mdx hearts. Magnified images show the 
mosaic distribution of dystrophin+ and dystrophin– myocytes in Carrier hearts. Magnified 
image scale = 0.5´0.5 mm. (E) Representative images of biological variability in 
dystrophin expression in carrier hearts, ranging from 40.0-78.4%.  
 
 
 
 
  
 76 
 
 
Figure 4.2: DMD Carrier susceptibility to cardiac injury is significant and partially 
dependent on allelic parental origin.  
(A) Three injections of low-dose Iso (0.35 mg/kg each) induced slight injury in C10, 
Carrier, and mdx hearts 30 hours after the first Iso injection, with 2-fold higher injury area 
in mdx hearts (n = 6-9 per group; # p=0.04 vs. mdx). (B) Representative images of 
hearts 30 hours after starting a course of 3 low-dose Iso injections, showing slight IgG+ 
(red) cardiomyocyte injury. Most injured cardiomyocytes are lacking dystrophin (green), 
including in wild type hearts; white arrows indicate injured myocytes displaying 
dystrophin signal. (C) A single injection of high-dose Iso (10 mg/kg) caused widespread 
lesions in Carrier and mdx hearts, and mortality in 21% of CarrierM mice (n=17-24 per 
group; § p=0.027). Among survivors, both groups of Carriers displayed significantly 
higher injury than C10 hearts, and CarrierP hearts displayed significantly lower injury 
than mdx (n=10-14 per group; * p=0.04 vs. C10; *** p<0.001 vs. C10; # p=0.04 vs. mdx; 
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### p<0.001 vs mdx). (D) Representative images of dystrophin distribution in wild type, 
Carrier, and mdx hearts. Magnified images demonstrate the mosaic distribution of 
dystrophin+ and dystrophin– cardiomyocytes in Carrier hearts. Magnified image scale = 
0.3´0.3 mm. 
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Figure 4.3: DMD Carriers are highly susceptibility to cardiac injury with repeated bouts of 
injurious stimulation. 
(A) The repeated Iso challenge is comprised of 14 injections of high-dose (10 mg/kg) Iso 
over the span of 5 days. (B) All of the C10 and CarrierP mice survived the repeated Iso 
challenge, but 31% of CarrierM and 38% of mdx mice died during the challenge (* 
p=0.01; ** p=0.005). (C) Among survivors, repeated high-dose Iso caused similarly 
extensive replacement fibrosis in the hearts of Carrier and mdx mice, which was 
significantly higher than C10 injury (n=6-17 per group; ** p=0.01; *** p<0.001). (D) 
Representative images of fibrosis in wild type (C10), Carrier, and mdx hearts after 
repeated injury with high-dose Iso. Fibrosis is red, and intact myocardium is green.   
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4. Discussion 
DMD has been described in the literature for nearly 200 years as a devastating, 
progressive disease that wastes away skeletal muscle and causes heart disease. In the 
intervening decades, clinical advances that include symptomatic respiratory therapies 
and scoliosis correction have markedly extended lifespans, but only modest strides have 
been made in treating DMD cardiomyopathy [1,25]. A new wave of emerging gene-
targeted therapies holds the promise of potentially correcting the underlying defect in 
DMD by restoring dystrophin expression, but the efficacy of these approaches in treating 
the heart remains unknown. A major obstacle to maximizing the cardiac benefits of these 
corrective strategies lies in differences in tissue transduction between the heart and 
skeletal muscle that can result in hindered cardiac efficiency. In preclinical studies of 
antisense-mediated exon skipping, CRISPR-Cas9 gene editing, and micro-dystrophin 
gene delivery have resulted in incomplete cardiac dystrophin restoration, leaving a 
mosaic pattern of dystrophin-positive and dystrophin-negative myocardium 
[161,162,164]. A similar distribution of dystrophin is seen in the hearts of DMD carriers 
who have one normal allele and one null allele of the X-chromosomal DMD gene, due to 
random X-inactivation throughout the myocardium.  
In the present study, we have used the mouse model of DMD carriers to 
determine whether dystrophin expression in approximately half of the heart can protect 
the remaining myocardium in the context of single or repeated bouts of workload-
induced cardiac stress. We reported that Carrier mice display intermediate susceptibility 
to a single bout of high-dose Iso-induced injury relative to wild type and dystrophin-null 
hearts, but they sustain the same degree of injury as dystrophic hearts with repeated 
injurious Iso stimulation. Importantly, the comparison between Carriers derived from two 
different breeding schemes revealed the surprising finding that mortality following Iso 
varies in relation to the parent from whom the dystrophin-null allele is inherited. 
Specifically, although all Carriers derived from mdx fathers and wild type mothers 
survived the Iso-induced stress, Carrier mice from mdx mothers and wild type fathers 
showed 21% mortality after a single dose and 31% mortality after repeated doses of Iso, 
despite similar dystrophin expression.  
Many of the findings presented here do not align with those reported by Yue et 
al. in 2004, including the susceptibility to injury observed in carrier mouse hearts and the 
divergent phenotypes of carriers from the two different breeding strategies [32]. Many of 
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these differences may be related to the isoproterenol dose, which is the largest deviation 
in experimental details between previous and current work. In our hands, the low dose of 
Iso (0.35 mg/kg) previously used in the 2004 study was inadequate to cause more than 
1-2% injury in mdx hearts, thus we turned to the high dose of Iso (10 mg/kg) that our 
previous work is based on to recapitulate widespread injury in dystrophic hearts. It is 
unclear what factors underlie the large differences in susceptibility observed in the two 
studies. While the mice in the present study were 1-3 months older, this is unlikely to 
account for their increased resilience. Another possible explanation may lie in the use of 
Evans Blue dye by Yue et al. in contrast to IgG staining used in the current study. 
Although both measures reflect cardiomyocyte permeability to serum proteins, Evans 
Blue dye was injected 12 hours ahead in the earlier work, and may have exerted mild 
cytotoxic effects that were subsequently amplified by Iso-induced stress. A multitude of 
other unknown factors could also contribute to the overall effect of Iso in conscious 
animals, including injection timing relative to light/dark cycles, single or group housing, 
handling during the study, and other environmental influences. 
The critical implication of these results for DMD therapies is that the degree of 
protection from mortality in partially dystrophin-expressing hearts likely depends on 
additional factors besides dystrophin levels. Although average dystrophin levels were 
nearly identical in the hearts of both groups of this Carrier mouse model, their response 
to high cardiac workload appears to be altered through a mechanism that significantly 
affects their vulnerability and survival.  This mechanism is beyond the scope of this work, 
but it may be related to epigenetic differences causing divergent expression of genes 
involved in cardiac resilience, or it may stem from different in utero environments 
belonging to healthy and dystrophic mothers. The differences in vulnerability may also 
involve a more complex behavioral basis, like differential interactions between healthy 
and dystrophic mothers with their heterozygous offspring, leading to differences in 
psychosocial stresses. This suggests that in human patients, a variety of factors could 
influence the degree of therapeutic correction that is sufficient to prevent lethal heart 
failure, potentially including polymorphisms in other genes, maternal and paternal 
epigenetic imprinting, and even environmental or dietary factors.  
Phenotypic diversity stemming from complex factors besides dystrophin is readily 
evident in human DMD patients and DMD carriers. Marked phenotypic variability with 
respect to the degree of cardiac and respiratory disease severity has been documented 
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in multiple sets of brothers diagnosed with the same DMD-causing mutation, without 
clear evidence of what may cause the divergence [260]. Furthermore, the cardiac and 
respiratory phenotypes in any given patient may progress independently of each other, 
and with trajectories that are not predictable based on the disease-causing mutation, in a 
phenomenon referred to as phenotypic discordance [261]. Likewise, human carriers of 
DMD have been documented to have variable skeletal muscle and cardiac phenotypes 
that were not overtly linked to their underlying mutation [262,263]. In fact, the reported 
incidence of cardiomyopathic symptoms in DMD carriers ranges from <10% to nearly 
50%, reflecting the high variability of the carrier cardiac phenotype [20,262]. Regardless 
of the variability in symptomology, current guidelines recommend routine monitoring of 
carrier cardiac function, reflecting the understanding that DMD carriers are at high risk 
for developing cardiomyopathy [6,20,264]. Together with the preclinical findings 
presented here, these observations in human patients underscore the notion that the 
therapeutic efficacy of partial dystrophin restoration in the heart is difficult to predict.  
Current evidence points to the strong possibility that the restoration of dystrophin 
in roughly half of in the heart may be sufficient to steer the course of the disease away 
from heart failure in some patients, but not in others. Further preclinical and clinical 
research will need to be directed at determining the factors that contribute the overall 
outcomes in partially dystrophin-replete hearts. Additionally, the hearts of human 
patients undergoing gene-targeted therapies should continue to be carefully monitored 
using the latest available guidelines to evaluate the potential need for additional 
therapeutic interventions with pharmacological therapies like angiotensin receptor 
blockers or ACE inhibitors.  
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Summary 
Muscular dystrophies are a genetically diverse group of muscle wasting 
diseases. Sarcoglycanopathies belong to the category of autosomal recessive Limb-
girdle muscular dystrophies (LGMD), with many clinical cases featuring early onset, 
progressive degeneration of skeletal muscles, and significant cardiomyopathy. The 
sarcoglycan complex is a heterotetrameric member of the dystrophin glycoprotein 
complex, which is critical in maintaining myocyte membrane integrity. The loss of the 
sarcoglycans induces high membrane permeability, leading to myocyte death, fibrosis, 
and cardiomyopathy. Individual mutations in four different sarcoglycan genes have been 
documented to give rise to LGMD with a Duchenne-like disease course and severity. 
Among the sarcoglycanopathies, the absence of β-sarcoglycan is associated with 
particularly early onset and high rates of cardiac involvement.  
The β-sarcoglycan-null mouse (βsg-/-), a model of LGMD2E, displays a 
progressive cardiac phenotype that can be exacerbated by stressing the heart. The β-
adrenergic receptor agonist isoproterenol (Iso, 10 mg/kg) was used to induce cardiac 
stress and injury in βsg-/- mice. A single dose of Iso caused early cardiac injury and 
fibrosis in 10-24% of the heart area in βsg-/- mice. Surprisingly, male βsg-/- hearts 
displayed 2.1-fold higher cardiomyocyte injury and 2.2-fold higher fibrosis compared to 
female hearts. Chronic and acute treatments with the angiotensin receptor blocker 
losartan markedly reduced cardiac damage and hypertrophy in male βsg-/- hearts, but 
had no significant effect in female hearts. Due to the sex-dependence of this protective 
effect, losartan treatment of βsg-/- mice resulted in the elimination of sex differences in 
Iso-induced cardiac injury.  
Here we report a striking sex difference in susceptibility to cardiac injury in mice 
lacking the sarcoglycan complex, and demonstrate that angiotensin receptor blockade 
reduces cardiac damage in male hearts, abolishing the sex difference. These findings 
suggest that angiotensin receptor signaling contributes to exacerbation of cardiac injury 
in these dystrophic hearts in a sex-dependent manner.  
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1. Introduction 
Muscular dystrophies are a genetically heterogeneous group of progressive 
muscle wasting diseases with variable cardiac involvement. Limb-girdle muscular 
dystrophy (LGMD) is a large and diverse category of muscular dystrophies, with LGMD 
type 2 representing the subgroup with an autosomal recessive mode of inheritance. 
Several of the diseases from this group feature clinically significant cardiomyopathy 
[265]. Among these, the sarcoglycanopathies are particularly remarkable for presenting 
with a degree of muscle deterioration and heart disease similar in severity to Duchenne 
muscular dystrophy (DMD) [266,267].  
The four primary sarcoglycanopathies are LGMD2C, 2D, 2E, and 2F, all arising 
from mutations resulting in the absence of one or more proteins that constitute the 
heterotetrameric sarcoglycan complex [268]. The sarcoglycans are important members 
of the larger dystrophin-glycoprotein complex (DGC), which plays a critical role in 
maintaining sarcolemmal integrity by serving as the node between the intracellular 
stabilizing protein dystrophin and the extracellular anchoring protein laminin [193,269]. 
Although the transmembrane sarcoglycan complex does not interact directly with either 
dystrophin or laminin, the loss of this complex can have grave consequences for the 
skeletal muscle and heart tissue. The loss of α-sarcoglycan may leave the rest of the 
sarcoglycan complex intact, explaining the observation that the associated pathology is 
often milder [269,270]. However, the absence of β-, δ-, or γ-sarcoglycan can deplete the 
whole sarcoglycan complex, precipitating childhood onset of pathological effects that 
may include muscle weakness, myocyte necrosis, fibrosis, loss of ambulation, heart 
failure, and premature death from cardiorespiratory insufficiency [266,271,272]. The loss 
of β-sarcoglycan appears to be the most devastating, as indicated by the age of onset, 
severity of the disease, and proportion of cardiac involvement [265,270,271]. Because 
some patients completely lack one or more of the sarcoglycans but others retain partial 
expression of the mutated protein, the phenotypic range of sarcoglycanopathies is large, 
perhaps analogous to that of Duchenne and Becker muscular dystrophies combined 
[271,272]. Sarcoglycanopathies have been estimated to have a prevalence of roughly 1 
in 180,000, and account for up to 68% of patients with the more aggressive childhood-
onset autosomal recessive LGMD, but only ~10% of the milder adult-onset cases 
[270,273].  
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The β-sarcoglycan-null mouse (βsg-/-) is a preclinical model of LGMD2E that 
displays progressive muscle degeneration and cardiac fibrosis [274–276]. Earlier work 
characterizing this mouse model demonstrated total loss of the sarcoglycan complex 
and the associated protein sarcospan with retention of other DGC components, in 
parallel with similar observations in human patient biopsies [275,277,278]. The cardiac 
phenotype of the βsg-/- mouse can be accelerated by increasing stress on the heart to 
induce acute myocardial injury and its conversion to fibrosis. The β-adrenergic receptor 
agonist isoproterenol (Iso) has been successfully used for this purpose by our group and 
several others, triggering increases in cardiac contractility and heart rate that produce 
scattered clusters of injured cardiomyocytes [31,32,77]. These areas of myocardial 
injury, detectable acutely by imaging cardiomyocyte uptake of endogenous serum 
proteins (IgG or Evans blue dye-bound albumin), are subsequently replaced within a few 
days by fibrotic lesions [31]. In earlier work, we have shown that the hearts of mdx mice, 
a popular model of DMD, are significantly susceptible to acute Iso-induced injury, but 
this susceptibility is markedly reduced by treatment with the angiotensin II type 1 
receptor (AT1R) blocker losartan [31]. Because the phenotypes of DMD and LGMD2E 
display many similarities in both human patients and mouse models, we set out to 
determine whether this therapeutic effect may be recapitulated in the absence of β-
sarcoglycan.  
In the present study, we aimed to assess the susceptibility of βsg-/- hearts to 
acute Iso-induced injury, evaluate the conversion of these myocardial wounds to the 
fibrotic scar, and determine whether global blockade of AT1R may ameliorate these 
processes. Here we report a sex-dependent beneficial effect of losartan on acute injury 
and fibrosis reduction in male βsg-/- mouse hearts but not female hearts, underscoring 
the surprising discovery that cardiac vulnerability and the benefits of AT1R blockade 
diverge by sex in this mouse model.  
 
2. Methods 
2.1. Animals  
β-sarcoglycan-null (βsg-/-) mice were bred at the University of Minnesota from 
breeding pairs obtained from the Jackson Laboratory. Mice were 4-6 months of age 
during all isoproterenol studies. Because LGMD2E is an autosomal disease, both male 
and female mice were used for these studies. All animal procedures were approved by 
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the University of Minnesota Institutional Animal Care and Use Committee and performed 
in compliance with all relevant laws and regulations. 
 
2.2. VCD Study 
The degree of ovarian hormone influence on cardiac injury was investigated by 
inducing chemical ovarian senescence in a group of female mice using vinylcyclohexene 
dioxide (VCD) [279–281]. The VCD was purchased from Synquest Laboratories (#2209-
1-08) and prepared to a concentration of 64 ng/ml in sesame oil, as described elsewhere 
[280]. Starting at 1-2 months of age, the mice received daily injections of 160 mg/kg 
VCD or sesame oil vehicle, in volumes of 35-60 µl adjusted for body weight, for 15 days. 
Mice entered the studies and were sacrificed 40-70 days from the end of their VCD 
injection course. A significant reduction in uterine weights after VCD treatment compared 
to vehicle-treated littermates and untreated female mice confirmed that VCD had the 
intended effect of diminishing ovarian hormone production (75.4±4.3 mg control vs. 
52.9±2.6 mg with VCD; p<0.001). All VCD-treated mice remained healthy throughout the 
study.  
 
2.3. Isoproterenol Studies 
(-)-Isoproterenol hydrochloride (Iso; Sigma #I6504) was prepared and delivered 
as previous described, as a single IP injection of 10 mg/kg per mouse [31]. Hearts were 
harvested at timepoints of 30 hours and 1 month after the injection.  
 
2.4. Acute Losartan Studies 
A group of βsg-/- mice was assigned to receive acute treatment with losartan 
starting 1 hour before the Iso injection, as previous described [31]. Briefly, a sterile 
losartan solution was prepared from a crushed generic losartan tablet dissolved in 
saline, and delivered as four intermittent IP injections totaling 160 mg/kg over the course 
of the 30-hour timeframe. The injections began 1 hour before Iso and ended 7 hours 
before the 30-hour heart harvest, without interrupting the dark cycle. Dosing was based 
on the half-lives of losartan and its major active metabolite (EXP3174), and intended to 
minimize the troughs in drug serum levels between the loading dose and the time of 
sacrifice with minimal disruptions to the mice.  
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2.5. Pretreatment Losartan Studies 
To investigate further protective effects that may arise after pretreatment, an 
additional group of βsg-/- mice was assigned to drink losartan dissolved in water for 2 
weeks prior to Iso-induced injury. Losartan water was prepared from a crushed generic 
tablet and given at a concentration of 600 mg/L in 2.5% dextrose, with an average 
consumed dose of 80 mg/kg daily. Losartan-containing water was replaced 3 times per 
week, and each mouse was weighed before and after the pretreatment.  
The physical discomfort experienced by mice following Iso administration can 
interrupt their water intake for 1-2 days, so the mode of drug delivery was switched from 
the drinking water to IP injections for a period of 30 hours after Iso to maintain 
therapeutic drug levels. On the 15th day after the start of pretreatment, mice received 
fresh tap water and a single a single 10mg/kg Iso injection. For the next 30 hours, the 
pretreated mice received booster injections of losartan as described in section 2.3 above 
and elsewhere previously [31]. A subset of βsg-/- mice was sacrificed for the heart 
harvest 30 hours after the Iso injection. The rest were placed back on the same losartan 
treatment in the drinking water for 1 month after the Iso injection, and then sacrificed for 
the heart harvest.  
 
2.6. Histopathology 
Only the hearts of mice that survived to their 30-hour and 1-month timepoints 
were used for quantification of injury area for each timepoint, as we have shown cardiac 
injury to undergo changes in appearance and total area during this time. The mortality 
rate in any given sex and treatment group was no greater than 10%, thus this is not 
expected to significantly skew the results.  
Histopathology studies were carried out as previously described, using 7 µm 
slices of unfixed frozen hearts [31]. The following reagents were used for IF staining: 
goat serum for blocking (Jackson ImmunoResearch # 005-000-121, 10%), goat anti-
mouse IgG (H+L) secondary antibody (Invitrogen #R37121, 1:200), WGA AlexaFluor 
conjugate (ThermoFisher, 5µg/ml), and ProLong Gold Antifade Mountant with DAPI 
(ThermoFisher). After blocking, staining was performed as a single step at room 
temperature for 1 hour, flanked by three 5-minute washes in PBS.  
The following reagents were used for Sirius Red Fast Green (SRFG) staining: 
1.2% picric acid solution (Ricca #R5860000), Direct Red 80 (Sigma #365548), Fast 
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Green FCF (Sigma #F7252), Formula 83 clearing solvent (CBG Biotech F83), and 
organic mounting medium (CBG Biotech MM83). Slides were fixed for 3 hours in chilled 
acetone at -20˚C before staining, then rehydrated in 70% ethanol followed by two 
changes of tap water. The rehydrated slides were stained for 25 minutes in rocking 
SRFG dye solution of picric acid, 0.1% Direct Red 80, and 0.1% Fast Green FCF. The 
slides were then rinsed in 3 changes of tap water, and dehydrated in 70% ethanol, 100% 
ethanol, and Formula 83 before applying organic mounting medium and coverslips.  
 
2.7. Microscopy and Image Analysis 
All imaging was performed in NIS Elements software on a Nikon Eclipse Ni-E 
upright epifluorescent microscope with a motorized stage. Whole heart montages of 
acute injury were collected as a stack of three fluorescent channels at a resolution of 
0.92 µm/pixel.  
IgG-positive injury area was determined using Fiji by subtracting the WGA 
channel (staining extracellular matrix) from the IgG channel to better distinguish intra-
myocyte IgG signal [219]. This injury area was then quantified by thresholding the 
resulting IgG image for total lesion area, and normalizing it to total heart section area. 
SRFG-stained sections were collected as brightfield whole heart montages at a 
resolution of 0.85 µm/pixel. Fibrosis was analyzed in these images using the color 
threshold function in Fiji. Areas containing Sirius Red-stained collagen were measured 
by counting the pixel area corresponding to a red hue above a minimum saturation 
threshold. Total heart area was represented by the number of pixels with any hue above 
the minimum saturation threshold, and fibrosis was calculated as the Sirius Red area 
normalized to total heart area. 
 
2.8. In Vivo Hemodynamic Assay 
Left ventricular catheterization was performed as described previously 
[200,202,282]. Briefly, mice were induced and maintained at a surgical plane of 
anesthesia with isoflurane. Temperature was maintained at 37°C throughout the 
procedure. A bilateral thoracotomy was performed to expose the apex of the heart. The 
pericardium was removed, and a 1.4 Fr pressure-volume catheter was inserted into the 
left ventricle via an apical stab incision created using a 25g needle. An intravenous 
catheter was placed in the external jugular vein and 10% albumin-supplemented saline 
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was infused to a final volume of 5 µl/g body weight. This infusion was delivered during a 
10-minute equilibration period. At the end of this equilibration period, baseline 
hemodynamics parameters were collected. Dobutamine was then infused (42µg/kg/min) 
to assess cardiac reserve. After 5 minutes of dobutamine infusion, hemodynamic 
parameters were collected again. 
 
2.9. Statistics 
All statistical analyses were performed using Prism 7 (GraphPad Software). 
Comparisons between βsg-/- males, βsg-/- females, and VCD-treated βsg-/- females were 
made using one-way ANOVA with Sidak post-hoc test. Hemodynamic parameters were 
compared using two-way ANOVA for repeated measures. All other comparisons were 
made using regular two-way ANOVA with Sidak post-hoc test. All graphs display the 
mean with standard error.  
 
3. Results 
3.1. The amount of Iso-induced injury in βsg-/- hearts depends on sex but not on ovarian 
hormones. 
A single injection of isoproterenol (Iso) induced extensive and scattered injury in 
βsg-/- male and female hearts harvested 30 hours after the injection. Interestingly, the 
cardiac injury area was 2.1-fold greater in male than female βsg-/- hearts, and the 
depletion of ovarian hormones with VCD did not alter female susceptibility to Iso-induced 
cardiac injury (Fig. 5.1A).  
Quantification of fibrosis in hearts harvested 1 month after Iso-induced injury 
revealed a similar 2.2-fold sex difference between male and female cardiac fibrosis. 
Again, the degree of Iso-induced fibrosis was nearly identical in all female βsg-/- mice, 
regardless of VCD treatment (Fig. 5.1B). Notably, some βsg-/- male hearts displayed 
ventricular dilation at the time of sacrifice 1 month after Iso (Fig. 5.1C), reflecting the 
dilated cardiomyopathy that has been documented in LGMD2E patients.  
In vivo cardiac catheterization in male and female βsg-/- mice revealed that the 
sex differences in cardiac injury are not a reflection of different cardiac performance at 
baseline or under adrenergic stimulation. The short-lived β1-adrenergic receptor agonist 
dobutamine, infused to evaluate the responsiveness of βsg-/- hearts to catecholamine 
stimulation, induced similar increases in heart rate, ejection fraction, and contractility in 
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βsg-/- hearts of both sexes, and neither sex showed a change in lusitropy with adrenergic 
stimulation (Fig. 5.2).  
 
3.2. Losartan reduces early injury in βsg-/- male hearts and eliminates the sex difference.  
Broadly, βsg-/- mice treated with the angiotensin receptor blocker (ARB) losartan 
displayed reductions in cardiac susceptibility to injury, and the losartan treatment 
benefits were not significantly different between acute treatment started 1 hour before 
Iso and chronic pretreatment given for 2 weeks before Iso (Fig. 5.3 A-C).  
When compared to βsg-/- mice that had only received Iso, the combined group of 
losartan-treated βsg-/- males from both treatment regimens displayed a striking 64% 
reduction in early cardiomyocyte injury present 30 hours after the Iso injection. In 
contrast, cardiac injury in female βsg-/- hearts treated with losartan trended toward a 
modest reduction of approximately 40% that did not reach statistical significance 
(p=0.12, Fig. 5.3D). Importantly, the protective effect of losartan on early cardiac injury 
was significantly greater in βsg-/- males and erased the sex difference in cardiac injury 
(interaction p=0.002, Fig. 5.3D).  
 
3.3. Chronic losartan treatment after injury selectively benefits male βsg-/- hearts. 
Within the group that continued to receive losartan in the drinking water for 1 
month after Iso-induced injury, the treatment only ameliorated cardiac remodeling in 
male βsg-/- hearts, without a significant effect in female hearts (Fig 5.4). Heart weights 
normalized to body weight demonstrated that, on average, male βsg-/- hearts were 
hypertrophied 1 month after Iso-induced injury, and losartan prevented this increase in 
heart size (p<0.001; Fig. 5.4B). In contrast, female heart weights did not increase 
significantly 1 month after Iso-induced cardiac injury, and the trend toward a modest 
reduction in heart weight with losartan did not reach statistical significance (p=0.09; 
interaction p=0.05; Fig. 5.4B).  
Quantification of cardiac fibrosis showed that βsg-/- male hearts chronically 
treated with losartan had a 46% reduction in Iso-induced cardiac fibrosis, but female 
cardiac fibrosis was nearly identical with and without losartan (interaction p=0.01; Fig. 
5.4C). As with acute injury, these discordant effects resulted in the elimination of sex 
differences in cardiac remodeling after Iso-induced injury in losartan-treated βsg-/- hearts.  
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Figure 5.1: βsg-/- hearts show significant vulnerability to Iso-induced injury that varies  
by sex. 
(A) Iso-induced early myocardial injury area, reflected in cardiomyocyte uptake of 
endogenous mouse IgG, was 2.2-fold larger in male than female βsg-/- hearts. Female 
cardiac injury was not altered by VCD treatment, which causes early ovarian 
senescence (n=12-16 per group; *** p<0.001). (B) 1 month after Iso-induced injury, 
cardiac fibrosis was 2.2-fold higher in male βsg-/- hearts than female hearts, and female 
cardiac fibrosis was unaffected by VCD treatment (n=9-13 per group; *** p<0.001). (C) 
Representative images of cardiac injury distribution in βsg-/- male and female hearts after 
one injection of Iso. Images of early myocardial injury (top) and cardiac fibrosis (bottom) 
both show lesions in red and total heart area in green. 
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Figure 5.2: βsg-/- hearts of both sexes show similar performance at rest and with 
adrenergic stimulation. 
Cardiac functional parameters were measured in vivo in anesthetized mice at rest and 
under adrenergic stimulation with dobutamine. These parameters show that βsg-/- male 
and female hearts have similar cardiac function and adrenergic responsiveness, as 
demonstrated by heart rate (A), ejection fraction (B), maximal rate of contraction (C), and 
maximal rate of relaxation (D). All parameters except for the relaxation rate (D) showed 
a significant main effect of stimulation (p<0.001), and none of the parameters showed a 
main effect of sex or a significant interaction by two-way ANOVA (n=6-7 per group).  
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Figure 5.3: Losartan reduces early injury triggered by Iso in βsg-/- hearts and eliminates 
the sex difference. 
(A) Acute losartan treatment was initiated by injection 1 hour before Iso, and was 
maintained with booster injections until the 30-hour sacrifice. (B) Chronic losartan 
pretreatment began 2 weeks before the Iso injection in the drinking water, and was 
maintained after Iso with booster injections until sacrifice. (C) The amount of Iso-induced 
early cardiac injury in losartan-treated mice was not altered significantly based on the 
length of the losartan treatment course (p>0.05 for sex, treatment type, and interaction; 
n=8-12 per group). (D) The combined group of male βsg-/- mice treated with losartan 
showed 64% lower early cardiac injury compared to male hearts without losartan. The 
combined group of female βsg-/- mice treated with losartan trended toward a modest 
reduction in early cardiac injury that was not statistically significant. The sex-dependence 
of losartan’s effect on cardiac damage resulted in the loss of the sex difference in 
losartan-treated mice (n=15-22; *** p<0.001; interaction p=0.002). The untreated βsg-/- 
male and female injury data are reproduced from Fig. 1A. (E) Representative images of 
cardiac injury in βsg-/- male and female hearts treated with losartan after one injection of 
Iso, with myocardial damage shown in red and the total heart area shown in green. 
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Figure 5.4: Chronic losartan treatment reduces cardiac fibrosis and normalizes heart 
weight in male βsg-/- mice. 
(A) The effects of losartan on cardiac remodeling after injury were assessed in mice 
pretreated with losartan for 2 weeks before Iso, and maintained on losartan treatment in 
the water for 1 month after Iso. During the 30-hour period immediately after Iso, the mice 
received plain tap water and injected losartan boosters to ensure maintenance of 
therapeutic levels (inset). (B) Male βsg-/- hearts were significantly enlarged 1 month after 
Iso-induced injury, and chronic losartan treatment normalized heart weights in male  
βsg-/- mice. Female hearts did not change in size significantly after Iso administration, 
with or without losartan (n=6-11 per group; * p=0.02, ** p=0.003, *** p<0.001; interaction 
p=0.05). (C) 1 month after Iso-induced injury, losartan treatment caused 46% lower 
cardiac fibrosis in male βsg-/- hearts, compared to untreated mice. No detectable effect 
on cardiac fibrosis was observed in female hearts (n=8-13 per group; ** p=0.001, *** 
p<0.001; interaction p=0.01). The untreated βsg-/- male and female fibrosis data are 
reproduced from Fig. 1B. (D) Representative images of cardiac fibrosis 1 month after 
one injection of Iso in βsg-/- male and female hearts treated with losartan. Fibrosis is 
shown in red and the total heart area shown in green.  
 
 
  
base 1 mo
Iso
1 mo
Iso+Los
3
4
5
6
7
H
W
/B
W
βsg M
** ***
*
βsg F
Iso
 on
ly
Iso
 on
ly
Iso
+L
os
Iso
+L
os
0
10
20
30
40
50
%
 S
iri
us
 R
ed
0.82p=
***
**
βsg M
βsg F
Iso
Losartan in water 30 hrs
Los boosters
Iso
& water change
water change
sacrifice
2 weeks
Losartan in water
1 month
DB Heart Weight Cardiac FibrosisC Sirius Red
Fast G
reen
βsg-/- male +Los βsg-/- female +Los
A
1 mo
Iso only
1 mo
Iso Los
 95 
 
4. Discussion 
The severity of the cardiomyopathy noted in many patients and preclinical 
models with sarcoglycanopathies underscores the importance of identifying cardiac-
directed therapies that may help these vulnerable hearts. In recent work, we identified 
AT1R blockade as a potential treatment strategy for preventing the accumulation of early 
myocardial injury in the mouse model of DMD, which shares many features with 
LGMD2E [31,271]. In the present study, we aimed to evaluate the potential benefits of 
treatment with the ARB losartan for preventing workload-induced injury in β-sarcoglycan-
null mouse hearts. While the protective effects of ARB treatment were partially 
substantiated in this work, they are confounded by a striking sex difference manifesting 
as enhanced cardiac resilience in dystrophic female mice. Specifically, male βsg-/- hearts 
were roughly twice as susceptible as female hearts to early cardiomyocyte injury and the 
fibrosis that replaces those cardiomyocytes, and losartan treatment served to eliminate 
the sex differences through disproportionate protection in male hearts. These results 
suggest that any degree of protection that is afforded to male βsg-/- hearts by AT1R 
blockade may already be present in female βsg-/- hearts without additional treatments.  
The marked rarity of LGMD2E, combined with the phenotypic variability 
stemming from incomplete loss of β-sarcoglycan in some of the patients, significantly 
complicates the evaluation of any potential sex differences in the cardiac phenotype of 
human LGMD2E patients. One recent study set out to evaluate the phenotypic 
characteristics of the largest cohort of LGMDE2 patients yet, and included 16 male and 
16 female patients, with a severe phenotype observed in 7 and 8 of each group, 
respectively [271]. However, this classification was based on loss of ambulation, and the 
observations related to cardiomyopathy were not reported in relation to biological sex, 
precluding any conclusions about cardiac sex-based differences. The large intra-group 
variability in cardiac injury in the present study required sizeable cohorts of genetically-
identical mice to detect the sex difference, despite its large effect size, thus the question 
of a sex difference in human sarcoglycan-null hearts may not be readily answerable.  
It is possible that the sex difference in cardiac resilience reported in this study 
only exists in mice, and may not reflect similar underlying differences in human patients. 
If this were the case, it highlights the question of the physiological differences that exist 
between female humans and mice that enable the female mice to be markedly protected 
despite the absence of the sarcoglycan complex. Interestingly, the existence of this 
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protective mechanism in female mice does not depend on ovarian hormones, suggesting 
that it may represent a potential basis for therapeutics that could be used to protect the 
hearts of male and female sarcoglycanopathy patients. In clinical practice and preclinical 
work, female protection from the more aggressive features of various acquired 
cardiovascular diseases has been consistently documented, including in contexts of 
myocardial injury, heart failure, and hypertension [283–290]. Although estrogen has 
been linked to many of these protective effects, some known instances of female 
resilience and protection do not depend on estrogen, and estrogen-independent 
protective mechanisms may represent promising targets for therapeutic development for 
all sexes [284,287,291,292]  
Previous reports have detailed numerous sex differences in the renin-angiotensin 
system, most notably with respect to angiotensin receptors and responses to 
angiotensin II [293–296]. Importantly, the overall trend in the literature suggests that 
female physiology may be skewed in favor of protective features of the angiotensin 
system. However, until recently, it has been a common practice to only include males in 
preclinical animal studies, potentially due to the assumption that female reproductive 
cycling introduces excessive variability, or perhaps due to observing a confounding sex 
difference [297]. In previous work, activation of AT1R with angiotensin II has been 
extensively documented to induce many pathological effects in the cardiovascular 
system and elsewhere [80,83,84,231,232], although it is less clear how many of these 
conclusions were based on studies of males. The finding that AT1R blockade nullified the 
existing sex difference in cardiac susceptibility in these mice, combined with reports of 
pathological processes activated by AT1R signaling, suggests that less injurious 
angiotensin signaling could underlie some aspects of female resilience.  
Although sex differences complicate the interpretation of losartan’s benefits in the 
present study, the protective effect of AT1R blockade on early Iso-induced myocardial 
injury has been confirmed in male βsg-/- mice. Furthermore, we have shown here that 
this protection persists chronically with ongoing treatment, resulting in amelioration of 
cardiac remodeling and fibrosis that occur after myocardial damage. These observations 
should be used to inform the course of treatment of LGMD2E in clinical settings, with a 
possible goal of starting treatment with ARBs as early as reasonable to intervene in the 
early disease processes in the heart. The first gene therapy aiming to completely replace 
the absent β-sarcoglycan gene by an AAV-delivered vector has recently moved into a 
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clinical trial with promising preliminary results, but its cardiac efficiency has not yet been 
assessed in human patients [276,298]. There is a risk that the restoration of the cardiac 
sarcoglycan complex may be incomplete in patient hearts after gene therapy, which may 
occur as a consequence of efforts to identify the lowest effective AAV dose for achieving 
sufficient skeletal muscle correction. In this case, patients with partial sarcoglycan 
restoration may remain subject to underlying disease processes that could jeopardize 
their hearts in the absence of additional therapeutic interventions, analogously to 
LGMD2E patients who have been shown to develop cardiomyopathy even in the context 
of partial endogenous β-sarcoglycan expression and mild skeletal muscle disease 
[271,272]. Future work should aim to shed light on any potential sex differences in the 
cardiac phenotype of sarcoglycanopathy patients, and continue to investigate the 
protective capacity of AT1R blockade in their hearts.  
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
  
This dissertation represents a body of work driven by the pursuit of insights into 
the dysfunctional processes underlying dystrophic cardiomyopathy and the interventions 
that may limit these processes. These studies were carried out with the understanding 
that small mammalian models of complex progressive diseases represent a compromise 
between the desire for clear mechanistic answers and the importance of physiological 
relevance to human disease. This compromise means that many of the conclusions and 
future directions arising from this work should be tested at additional tiers of complexity. 
More reductionist systems, such as ex vivo hearts and isolated cardiomyocytes, may 
allow for clearer characterization of cellular features, processes, and causal relationships 
with less potential for compensatory confounding effects. Conversely, only careful 
clinical research will be able to assess parallels between these models and human 
patients to determine whether the findings reported here are applicable to the ultimate 
goal of treating disease in human patients.  
 
1. Conclusions  
 The work described here has centered on the exploration of cardiac vulnerability 
in mouse models of muscular dystrophies, with the goal of identifying relationships or 
interventions that can help shape the management of these diseases in human patients. 
Because the most severe muscular dystrophies are diseases of childhood and early 
adulthood, the use of young adult mice enabled the study of cardiac disease without 
concerns about aging as a confounding factor, but it presented the problem of only 
modest cardiac involvement in these mice. For this reason, this work has relied on the 
induction of cardiac stress with the β-adrenergic receptor agonist isoproterenol to 
produce the kind of myocardial injury that may accumulate intermittently in human 
patient hearts during bouts of high cardiac stress. This adrenergic stress model is 
thought to be relevant to perioperative cardiac stresses in dystrophic patients, with 
procedures requiring anesthesia and resulting in bouts of elevated cardiac stress being a 
regular part of treatment [6,216]. Additionally, periods of chest pain accompanied by 
serum cardia troponin elevations have been documented in DMD patients, in parallel 
with effects of isoproterenol documented in our earlier work [30,31,252] 
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One major finding arising from this injury model is the robust capacity of 
angiotensin receptor blockers to limit the extent of cardiomyocyte injury when given in 
advance of the injurious stimulus. ARBs like losartan, along with ACE inhibitors, have 
been understood to benefit failing and injured hearts by modifying transcriptional profiles 
that drive adverse cardiac remodeling. The effects of angiotensin II signaling through 
AT1R include the transcriptional activation of pro-fibrotic gene programs that contribute 
to myocyte hypertrophy, myocyte death, fibrosis, and functional decline. The more 
immediate, signaling-based effects of AT1R activation are less often addressed, but the 
results described here suggest that acute AT1R signaling may represent an important 
mechanism underlying myocardial injury in the dystrophic heart. In males of two different 
genetic models of muscular dystrophy, the reduction in Iso-induced cardiomyocyte injury 
was similarly robust if they were treated with losartan for two weeks or only 1 hour 
before isoproterenol. This suggests that the effects of transcriptional changes are not 
needed for this mechanism of protection at the time of injury, and it may instead depend 
predominantly on blocking rapid signal transduction downstream of AT1R. NADPH 
oxidase is a potential candidate for mediating this effect, as the activation of AT1R 
signaling has been linked to ROS production via NADPH oxidase 2 [80,83,84]. Neither 
an acute or chronic treatment course with an ACE inhibitor had an effect on early cardiac 
injury, indicating that the inhibition of angiotensin’s pathological contribution to injury is 
more effective with direct receptor blockade. Two primary implications can be derived 
from this finding for further investigation. The first is the potentially causal role for 
reactive oxygen species produced by NADPH oxidase, a downstream effector of AT1R 
signaling, in the expansion of dystrophic myocardial injury. The second is the possibility 
that dystrophic heart disease in human patients may be effectively delayed by the use 
ARBs, in place of the more popular ACE inhibitors, at a sufficiently young age to precede 
initial cardiac damage.  
Another major conclusion stemming from this work is the discovery of significant 
cardiac vulnerability and even Iso-induced mortality in female DMD carrier mice. Based 
on earlier preclinical work with partial cardiac transduction of micro-dystrophin therapies, 
combined with a previous study showing a lack of cardiac disease indicators in DMD 
carrier mice, the extent of Iso-induced injury in dystrophin-mosaic carrier hearts was 
surprising. Even more surprising was the observation that survival after isoproterenol 
was highly divergent between the carrier mice bred from mdx males and those bred from 
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mdx females. The mechanisms that may underlie this difference based on parental 
genotypes are likely very complex and represent an interesting target for future studies. 
However, the observation that hearts with similar levels of dystrophin expression may 
show discordant vulnerability reveals a new layer of complexity in addressing the 
question of how much genetic correction or replacement is sufficient in the dystrophin-
null heart. A number of gene-targeted therapies in development and in trials for DMD 
aim to restore skeletal muscle and cardiac dystrophin expression, including antisense 
oligonucleotide exon skipping, AAV micro-dystrophin therapies, and CRISPR/Cas9 gene 
editing. However, preclinical work has shown that these approaches may produce a 
mosaic pattern of transduction in the heart, with clusters of cardiomyocytes that lack 
dystrophin adjacent to those expressing it [161,164,180,183,257]. This resulting pattern 
is comparable to mosaic DMD carrier hearts, and human carriers of DMD have been 
documented to display a varied incidence of cardiac symptoms (<10% to nearly 50%) 
that were not overtly linked to their underlying mutation [20,262,263]. Based on these 
observations, the finding that mosaic expression of dystrophin in ~50% of the heart may 
be insufficient to rescue the myocardium merits careful investigation.  
 A third major conclusion of this work is the possibility that sex-based alterations 
in physiological processes that underlie dystrophic heart injury may partially overlap with 
the benefits of AT1R blockade. In dystrophic mice lacking the sarcoglycan complex, male 
hearts displayed over 2-fold higher Iso-induced cardiomyocyte injury and subsequent 
fibrosis compared to female heart. However, ARB treatment selectively benefitted the 
male mice without any significant protection in dystrophic female mice, abolishing the 
sex differences in early injury, fibrosis, and hypertrophy in sarcoglycan-null hearts. In 
light of previously reported sex differences in the renin-angiotensin system in humans 
and animal models, this finding supports the possibility of an endogenous mechanism 
that may mitigate angiotensin’s effects in female mouse hearts in the absence of ARB 
treatment.  
A central theme in this collection of work has been the exacerbation of existing 
cardiac vulnerability in dystrophic mouse hearts using isoproterenol, a drug that 
activates endogenous β-adrenergic receptors. This adrenergic stimulation produces a 
response akin to “fight-or-flight” by approximating a robust upsurge in sympathetic 
nervous system activation, which drives sharp increases in cardiac contractility and heart 
rate. The increased workload on the myocardium is presumed to be the predominant 
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cause of the cardiac damage presented here. However, many other factors could 
contribute to the injury processes and mortality that follow isoproterenol administration, 
including influences from the vascular, renal, immune, and central nervous systems.  
 
2. Future Directions  
 Future work aiming to build upon the results reported here should continue to 
probe the cellular processes that drive myocardial injury after Iso stimulation and 
investigate how these conclusions are relevant to human dystrophic patients.   
 The study of the mechanistic effects of AT1R blockade in ex vivo working hearts, 
cardiac papillary muscle preparations, or isolated cardiomyocytes would enable the 
detection of reactive oxygen species production by dystrophic myocardium, as well as 
any functional changes that may accompany ARB treatment. Furthermore, the 
comparison of ARB effects on ROS production in whole hearts compared to 
cardiomyocytes may shed light on the potential role of non-myocyte cardiac cells. The 
pursuit of similar experiments in hearts from male and female sarcoglycan-null mice 
would shed light on any differences in ROS accumulation that may exist without ARB 
blockade, and reveal whether ARB treatment equalizes any such differences in male 
and female hearts. Furthermore, efforts to recapitulate the benefits of losartan by 
inhibiting NADPH oxidase or increasing antioxidant defenses could support or refute the 
hypothesis that NADPH oxidase-mediated ROS production drives the deleterious effects 
of angiotensin that are blocked by losartan. This work would help define the link between 
AT1R and cardiomyocyte injury, determining whether ROS is the mediator of non-
transcriptional AT1R effects that exacerbate myocardial injury.  
 Investigation of the clinical relevance of this ARB-mediated cardiac injury 
prevention should begin in patients with DMD or genetically-diagnosed 
sarcoglycanopathies before 10 years of age, with ARB treatment in place of ACE 
inhibitor treatment. Clinical studies have shown similar efficacy of both drug classes in 
treating heart failure in general and DMD cardiomyopathy in particular, and ARBs are 
also better-tolerated than ACE inhibitors, resulting in minimal risk to patients. The 
comparison of patients treated with ARBs from a young age to those treated with ACE 
inhibitors or other non-ARB treatments can shed light on any significant differences in 
the degree of benefits afforded by the different treatment options.  
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 To address cardiac vulnerability and the influence of non-dystrophin factors in 
DMD carrier hearts, RNAseq comparing hearts from wild type, dystrophic, and carrier 
mice could be used to generate hypotheses in preclinical work. Differences in a variety 
of epigenetic influences between maternal and paternal DMD carriers should become 
evident in assessing the transcriptome of their hearts. This approach could reveal the 
differentially-expressed genes that modify cardiac vulnerability in hearts with mosaic 
dystrophin expression, potentially contributing to the development and implementation of 
cardiac gene-targeted therapies in DMD. Furthermore, human DMD carriers should 
continue to be monitored and characterized in clinical work to improve understanding of 
the phenotype of partial dystrophin expression.  
 Most importantly, future work must aim to continue improving approaches for 
evaluating cardiac health and function in dystrophic hearts, and utilizing those 
approaches to improve understanding of the cardiac phenotype in carriers of DMD and 
patients with Becker muscular dystrophy. The landscape of DMD cardiomyopathy is on 
the precipice of significant changes, as gene-targeted therapies aim to restore truncated 
dystrophin expression that may have discordant efficiency in the heart and skeletal 
muscle. The treatment of dystrophic patients with AAV-delivered replacement genes has 
shown very promising early results in human trials. Limitations of this approach have 
historically included immunogenicity, pre-existing neutralizing immunity, and the 
challenges of producing sufficient amounts of virus for human dosing. However, recent 
work has made progress in addressing these limitations, and earlier dosing of human 
patients at a young age will require less virus than the dosing of older children and 
adolescents patients. Because of the encouraging trajectory of AAV gene therapy, it 
seems inevitable that it will play a major role in shaping the future of muscular 
dystrophies. With the possibility of sustained ambulation and physical activity in 
dystrophic patients comes an increased need to ensure that the heart can keep up. The 
hearts of wheelchair-bound patients are subject to a very different set of demands than 
the hearts of patients who may remain ambulatory for the duration of their adult lives, 
thus future efforts must be directed at optimizing the cardiac efficacy of gene therapies 
along with the pursuit of correcting skeletal muscle.  
  
 
  
 103 
 
REFERENCES 
1.  Eagle, M.; Baudouin, S. V; Chandler, C.; Giddings, D.R.; Bullock, R.; Bushby, K. 
Survival in Duchenne muscular dystrophy: improvements in life expectancy since 
1967 and the impact of home nocturnal ventilation. Neuromuscul. Disord. 2002, 
12, 926–929. 
2.  Rafael-Fortney, J.A.; Chadwick, J.A.; Raman, S. V. Duchenne muscular dystrophy 
mice and men: Can understanding a genetic cardiomyopathy inform treatment of 
other myocardial diseases? Circ. Res. 2016, 118, 1059–1061. 
3.  Nigro, G.; Comi, L.I.; Politano, L.; Bain, R.J.I. The incidence and evolution of 
cardiomyopathy in Duchenne muscular dystrophy. Int. J. Cardiol. 1990, 26, 271–
277. 
4.  Spurney, C.F.; Shimizu, R.; Morgenroth, L.P.; Kolski, H.; Gordish-Dressman, H.; 
Clemens, P.R.; Cregan, M.; Goude, E.; Glick, M.; Johnson, L.; et al. CINRG 
Duchenne Natural History Study demonstrates insufficient diagnosis and 
treatment of cardiomyopathy in Duchenne muscular dystrophy. Muscle and Nerve 
2014, 50, 250–256. 
5.  McNally, E.M.; Kaltman, J.R.; Benson, D.W.; Canter, C.E.; Cripe, L.H.; Duan, D.; 
Finder, J.D.; Hoffman, E.P.; Judge, D.P.; Kertesz, N.; et al. Contemporary cardiac 
issues in Duchenne muscular dystrophy. Circulation 2015, 131, 1590–1598. 
6.  Birnkrant, D.J.; Bushby, K.; Bann, C.M.; Alman, B.A.; Apkon, S.D.; Blackwell, A.; 
Case, L.E.; Cripe, L.H.; Hadjiyannakis, S.; Olson, A.K.; et al. Diagnosis and 
management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone 
health, and orthopaedic management. Lancet Neurol. 2018, 17, 347–361. 
7.  Kamdar, F.; Garry, D.J. Dystrophin-Deficient Cardiomyopathy. J. Am. Coll. 
Cardiol. 2016, 67, 2533–2546. 
8.  Bladen, C.L.; Salgado, D.; Monges, S.; Foncuberta, M.E.; Kekou, K.; Kosma, K.; 
Dawkins, H.; Lamont, L.; Roy, A.J.; Chamova, T.; et al. The TREAT-NMD DMD 
Global Database: analysis of more than 7,000 Duchenne muscular dystrophy 
mutations. Hum. Mutat. 2015, 36, 395–402. 
9.  Flanigan, K.M. Duchenne and Becker Muscular Dystrophies. In Swaiman’s 
Pediatric Neurology; Elsevier Inc., 2017; pp. e2482–e2492. 
10.  Mendell, J.R.; Shilling, C.; Leslie, N.D.; Flanigan, K.M.; Gastier-foster, J.; Kneile, 
K.; Dunn, D.M.; Duval, B.; Aoyagi, A.; Hamil, C.; et al. Evidence-Based Path to 
Newborn Screening for Duchenne Muscular Dystrophy. Ann. Neurol. 2012, 71, 
304–313. 
11.  Mah, J.K.; Korngut, L.; Dykeman, J.; Day, L.; Pringsheim, T.; Jette, N. A 
systematic review and meta-analysis on the epidemiology of Duchenne and 
Becker muscular dystrophy. Neuromuscul. Disord. 2014, 24, 482–491. 
12.  Guiraud, S.; Aartsma-Rus, A.; Vieira, N.M.; Davies, K.E.; van Ommen, G.-J.B.; 
Kunkel, L.M. The Pathogenesis and Therapy of Muscular Dystrophies. Annu. Rev. 
Genomics Hum. Genet. 2015, 16, 281–308. 
13.  Nicolas, A.; Raguènès-Nicol, C.; Yaou, R. Ben; Hir, S.A. Le; Chéron, A.; Vié, V.; 
Claustres, M.; Leturcq, F.; Delalande, O.; Hubert, J.F.; et al. Becker muscular 
dystrophy severity is linked to the structure of dystrophin. Hum. Mol. Genet. 2015, 
24, 1267–1279. 
14.  Tyler, K.L. Origins and early descriptions of “Duchenne muscular dystrophy.” 
Muscle and Nerve 2003, 28, 402–422. 
15.  Torriani, M.; Townsend, E.; Thomas, B.J.; Bredella, M.A.; Ghomi, R.H.; Tseng, 
B.S. Lower leg muscle involvement in Duchenne muscular dystrophy: An MR 
 104 
 
imaging and spectroscopy study. Skeletal Radiol. 2012, 41, 437–445. 
16.  Birnkrant, D.J.; Bushby, K.; Bann, C.M.; Apkon, S.D.; Blackwell, A.; Colvin, M.K.; 
Cripe, L.H.; Herron, A.R.; Kennedy, A.; Kinnett, K.; et al. Diagnosis and 
management of Duchenne muscular dystrophy, part 3 : primary care, emergency 
management, psychosocial care, and transitions of care across the lifespan. 
Lancet Neurol. 2018, 17, 445–455. 
17.  Banihani, R.; Smile, S.; Yoon, G.; Dupuis, A.; Mosleh, M.; Snider, A.; McAdam, L. 
Cognitive and neurobehavioral profile in boys with duchenne muscular dystrophy. 
J. Child Neurol. 2015, 30, 1472–1482. 
18.  Tandon, A.; Villa, C.R.; Hor, K.N.; Jefferies, J.L.; Gao, Z.; Towbin, J.A.; Wong, 
B.L.; Mazur, W.; Fleck, R.J.; Sticka, J.J.; et al. Myocardial fibrosis burden predicts 
left ventricular ejection fraction and is associated with age and steroid treatment 
duration in Duchenne muscular dystrophy. J. Am. Heart Assoc. 2015, 4, 1–8. 
19.  Hor, K.N.; Wansapura, J.; Markham, L.W.; Mazur, W.; Cripe, L.H.; Fleck, R.; 
Benson, D.W.; Gottliebson, W.M. Circumferential Strain Analysis Identifies Strata 
of Cardiomyopathy in Duchenne Muscular Dystrophy. A Cardiac Magnetic 
Resonance Tagging Study. J. Am. Coll. Cardiol. 2009, 53, 1204–1210. 
20.  Hor, K.N.; Mah, M.L.; Johnston, P.; Cripe, T.P.; Cripe, L.H. Advances in the 
diagnosis and management of cardiomyopathy in Duchenne muscular dystrophy. 
Neuromuscul. Disord. 2018, 28, 711–716. 
21.  Matsumura, T.; Saito, T.; Fujimura, H.; Shinno, S. Cardiac troponin I for accurate 
evaluation of cardiac status in myopathic patients. Brain Dev. 2007, 29, 496–501. 
22.  Ergul, Y.; Ekici, B.; Nisli, K.; Tatli, B.; Binboga, F.; Acar, G.; Ozmen, M.; 
Omeroglu, R.E. Evaluation of the North Star Ambulatory Assessment scale and 
cardiac abnormalities in ambulant boys with Duchenne muscular dystrophy. J. 
Paediatr. Child Health 2012, 48, 610–616. 
23.  Ramaciotti, C.; Iannaccone, S.T.; Scott, W.A. Myocardial cell damage in 
Duchenne muscular dystrophy. Pediatr. Cardiol. 2003, 24, 503–506. 
24.  Cheeran, D.; Khan, S.; Khera, R.; Bhatt, A.; Garg, S.; Grodin, J.L.; Morlend, R.; 
Araj, F.G.; Amin, A.A.; Thibodeau, J.T.; et al. Predictors of death in adults with 
Duchenne muscular dystrophy-associated cardiomyopathy. J. Am. Heart Assoc. 
2017, 6, 1–12. 
25.  Eagle, M.; Bourke, J.; Bullock, R.; Gibson, M.; Mehta, J.; Giddings, D.; Straub, V.; 
Bushby, K. Managing Duchenne muscular dystrophy - The additive effect of spinal 
surgery and home nocturnal ventilation in improving survival. Neuromuscul. 
Disord. 2007, 17, 470–475. 
26.  Rybakova, I.N.; Patel, J.R.; Ervasti, J.M. The dystrophin complex forms a 
mechanically strong link between the sarcolemma and costameric actin. J. Cell 
Biol. 2000, 150, 1209–1214. 
27.  Ervasti, J.M. Dystrophin, its interactions with other proteins, and implications for 
muscular dystrophy. Biochim. Biophys. Acta - Mol. Basis Dis. 2007, 1772, 108–
117. 
28.  Sharpe, K.M.; Premsukh, M.D.; Townsend, D. Alterations of dystrophin-
associated glycoproteins in the heart lacking dystrophin or dystrophin and 
utrophin. J. Muscle Res. Cell Motil. 2013, 34, 395–405. 
29.  Townsend, D.; Blankinship, M.J.; Allen, J.M.; Gregorevic, P.; Chamberlain, J.S.; 
Metzger, J.M. Systemic administration of micro-dystrophin restores cardiac 
geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 
2007, 15, 1086–1092. 
30.  Hor, K.N.; Johnston, P.; Kinnett, K.; Mah, M.L.; Stiver, C.; Markham, L.W.; Cripe, 
 105 
 
L.H. Progression of Duchenne Cardiomyopathy Presenting with Chest Pain and 
Troponin Elevation. J. Neuromuscul. Dis. 2017, 4, 307–314. 
31.  Meyers, T.A.; Heitzman, J.A.; Krebsbach, A.; Aufdembrink, L.M.; Hughes, R.; 
Bartolomucci, A.; Townsend, D. Acute AT1R blockade prevents isoproterenol-
induced injury in mdx hearts. J. Mol. Cell. Cardiol. 2019, 128, 51–61. 
32.  Yue, Y.; Skimming, J.W.; Liu, M.; Strawn, T.; Duan, D. Full-length dystrophin 
expression in half of the heart cells ameliorates β-isoproterenol-induced 
cardiomyopathy in mdx mice. Hum. Mol. Genet. 2004, 13, 1669–1675. 
33.  Olthoff, J.T.; Lindsay, A.; Abo-Zahrah, R.; Baltgalvis, K.A.; Patrinostro, X.; 
Belanto, J.J.; Yu, D.-Y.; Perrin, B.J.; Garry, D.J.; Rodney, G.G.; et al. Loss of 
peroxiredoxin-2 exacerbates eccentric contraction-induced force loss in 
dystrophin-deficient muscle. Nat. Commun. 2018, 9, 5104. 
34.  Han, R.; Bansal, D.; Miyake, K.; Muniz, V.P.; Weiss, R.M.; McNeil, P.L.; 
Campbell, K.P. Dysferlin-mediated membrane repair protects the heart from 
stress-induced left ventricular injury. J. Clin. Invest. 2007, 117, 1805–1813. 
35.  Cai, C.; Masumiya, H.; Weisleder, N.; Matsuda, N.; Nishi, M.; Hwang, M.; Ko, J.K.; 
Lin, P.; Thornton, A.; Zhao, X.; et al. MG53 nucleates assembly of cell membrane 
repair machinery. Nat. Cell Biol. 2009, 11, 56–64. 
36.  Zhang, C.; Chen, B.; Wang, Y.; Guo, A.; Tang, Y.; Khataei, T.; Shi, Y.; Kutschke, 
W.J.; Zimmerman, K.; Weiss, R.M.; et al. MG53 is dispensable for T-tubule 
maturation but critical for maintaining T-tubule integrity following cardiac stress. J. 
Mol. Cell. Cardiol. 2017, 112, 123–130. 
37.  Vanhoutte, D.; Schips, T.G.; Kwong, J.Q.; Davis, J.; Tjondrokoesoemo, A.; Brody, 
M.J.; Sargent, M.A.; Kanisicak, O.; Yi, H.; Gao, Q.Q.; et al. Thrombospondin 
expression in myofibers stabilizes muscle membranes. Elife 2016, 5, 1–33. 
38.  Brody, M.J.; Vanhoutte, D.; Schips, T.G.; Boyer, J.G.; Bakshi, C. V.; Sargent, 
M.A.; York, A.J.; Molkentin, J.D. Defective Flux of Thrombospondin-4 through the 
Secretory Pathway Impairs Cardiomyocyte Membrane Stability and Causes 
Cardiomyopathy. Mol. Cell. Biol. 2018, 38, 1–14. 
39.  Harris, E.; Bladen, C.L.; Mayhew, A.; James, M.; Bettinson, K.; Moore, U.; Smith, 
F.E.; Rufibach, L.; Cnaan, A.; Goebel, D.X.B.; et al. The clinical outcome study for 
dysferlinopathy: An international multicenter study. Neurol. Genet. 2016, 2, e89. 
40.  He, B.; Tang, R.H.; Weisleder, N.; Xiao, B.; Yuan, Z.; Cai, C.; Zhu, H.; Lin, P.; 
Qiao, C.; Li, J.; et al. Enhancing muscle membrane repair by gene delivery of 
MG53 ameliorates muscular dystrophy and heart failure inδ-sarcoglycan-deficient 
hamsters. Mol. Ther. 2012, 20, 727–735. 
41.  Weisleder, N.; Takizawa, N.; Lin, P.; Wang, X.; Cao, C.; Zhang, Y.; Tan, T.; 
Ferrante, C.; Zhu, H.; Chen, P.J.; et al. Recombinant MG53 protein modulates 
therapeutic cell membrane repair in treatment of muscular dystrophy. Sci. Transl. 
Med. 2012, 4, 139ra85. 
42.  Houang, E.M.; Bates, F.S.; Sham, Y.Y.; Metzger, J.M. All-Atom Molecular 
Dynamics-Based Analysis of Membrane-Stabilizing Copolymer Interactions with 
Lipid Bilayers Probed under Constant Surface Tensions. J. Phys. Chem. B 2017, 
121, 10657–10664. 
43.  Houang, E.M.; Sham, Y.Y.; Bates, F.S.; Metzger, J.M. Muscle membrane integrity 
in Duchenne muscular dystrophy: Recent advances in copolymer-based muscle 
membrane stabilizers. Skelet. Muscle 2018, 8, 1–19. 
44.  Townsend, D.; Turner, I.; Yasuda, S.; Martindale, J.; Davis, J.; Shillingford, M.; 
Kornegay, J.N.; Metzger, J.M. Chronic administration of membrane sealant 
prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. J. Clin. 
 106 
 
Invest. 2010, 120, 1140–1150. 
45.  Yasuda, S.; Townsend, D.; Michele, D.E.; Favre, E.G.; Day, S.M.; Metzger, J.M. 
Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005, 
436, 1025–1029. 
46.  Houang, E.M.; Haman, K.J.; Filareto, A.; Perlingeiro, R.C.; Bates, F.S.; Lowe, 
D.A.; Metzger, J.M. Membrane-stabilizing copolymers confer marked protection to 
dystrophic skeletal muscle in vivo. Mol. Ther. - Methods Clin. Dev. 2015, 2, 
15042. 
47.  Townsend, D.; Yasuda, S.; Metzger, J. Cardiomyopathy of Duchenne muscular 
dystrophy: pathogenesis and prospect of membrane sealants as a new 
therapeutic approach. Expert Rev. Cardiovasc. Ther. 2007, 5, 99–109. 
48.  Ryan, T.; Phrixus Pharmaceuticals Inc. NCT03558958: Safety and Efficacy of P-
188 NF in DMD Patients. 2018. 
49.  Vallejo-Illarramendi, A.; Toral-Ojeda, I.; Aldanondo, G.; López de Munain, A. 
Dysregulation of calcium homeostasis in muscular dystrophies. Expert Rev. Mol. 
Med. 2014, 16, e16. 
50.  Williams, I.A.; Allen, D.G. Intracellular calcium handling in ventricular myocytes 
from mdx mice. Am. J. Physiol. Circ. Physiol. 2007, 292, H846–H855. 
51.  Johnstone, V.P.A.; Viola, H.M.; Hool, L.C. Dystrophic cardiomyopathy—potential 
role of calcium in pathogenesis, treatment and novel therapies. Genes (Basel). 
2017, 8. 
52.  Allen, D.G.; Whitehead, N.P. Duchenne muscular dystrophy - What causes the 
increased membrane permeability in skeletal muscle? Int. J. Biochem. Cell Biol. 
2010, 43, 290–294. 
53.  Lorin, C.; Vögeli, I.; Niggli, E. Dystrophic cardiomyopathy: Role of TRPV2 
channels in stretch-induced cell damage. Cardiovasc. Res. 2015, 106, 153–162. 
54.  Allen, D.G.; Whitehead, N.P.; Yeung, E.W. Mechanisms of stretch-induced 
muscle damage in normal and dystrophic muscle: Role of ionic changes. J. 
Physiol. 2005, 567, 723–735. 
55.  Koenig, X.; Rubi, L.; Obermair, G.J.; Cervenka, R.; Dang, X.B.; Lukacs, P.; 
Kummer, S.; Bittner, R.E.; Kubista, H.; Todt, H.; et al. Enhanced currents through 
L-type calcium channels in cardiomyocytes disturb the electrophysiology of the 
dystrophic heart. Am. J. Physiol. Heart Circ. Physiol. 2014, 306, H564–H573. 
56.  Viola, H.M.; Davies, S.M.K.; Filipovska, A.; Hool, L.C. L-type Ca 2+ channel 
contributes to alterations in mitochondrial calcium handling in the mdx ventricular 
myocyte. Am. J. Physiol. Circ. Physiol. 2013, 304, H767–H775. 
57.  Sadeghi, A.; Doyle, A.D.; Johnson, B.D. Regulation of the cardiac L-type Ca2+ 
channel by the actin-binding proteins alpha-actinin and dystrophin. Am. J. Physiol. 
Cell Physiol. 2002, 282, C1502-11. 
58.  Andersson, D.C.; Marks, A.R. Fixing ryanodine receptor Ca2+ leak – A novel 
therapeutic strategy for contractile failure in heart and skeletal muscle. Drug 
Discov. Today Dis. Mech. 2010, 7, e151–e157. 
59.  Fauconnier, J.; Thireau, J.; Reiken, S.; Cassan, C.; Richard, S.; Matecki, S.; 
Marks, A.R.; Lacampagne, A. Leaky RyR2 trigger ventricular arrhythmias in 
Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. 2010, 107, 1559–1564. 
60.  Bellinger, A.M.; Reiken, S.; Carlson, C.; Mongillo, M.; Liu, X.; Rothman, L.; 
Matecki, S.; Lacampagne, A.; Marks, A.R. Hypernitrosylated ryanodine receptor 
calcium release channels are leaky in dystrophic muscle. Nat. Med. 2009, 15, 
325–330. 
61.  Sarma, S.; Li, N.; van Oort, R.J.; Reynolds, C.; Skapura, D.G.; Wehrens, X.H.T. 
 107 
 
Genetic inhibition of PKA phosphorylation of RyR2 prevents dystrophic 
cardiomyopathy. Proc. Natl. Acad. Sci. 2010, 107, 13165–13170. 
62.  Wang, Q.; Wang, W.; Wang, G.; Rodney, G.G.; Wehrens, X.H.T. Crosstalk 
between RyR2 oxidation and phosphorylation contributes to cardiac dysfunction in 
mice with Duchenne muscular dystrophy. J. Mol. Cell. Cardiol. 2015, 89, 177–184. 
63.  Voit, A.; Patel, V.; Pachon, R.; Shah, V.; Bakhutma, M.; Kohlbrenner, E.; McArdle, 
J.J.; Dell’Italia, L.J.; Mendell, J.R.; Xie, L.H.; et al. Reducing sarcolipin expression 
mitigates Duchenne muscular dystrophy and associated cardiomyopathy in mice. 
Nat. Commun. 2017, 8, 1068. 
64.  Rohman, M.S.; Emoto, N.; Takeshima, Y.; Yokoyama, M.; Matsuo, M. Decreased 
mAKAP, ryanodine receptor, and SERCA2a gene expression in mdx hearts. 
Biochem. Biophys. Res. Commun. 2003, 310, 228–235. 
65.  Shin, J.; Tajrishi, M.M.; Ogura, Y.; Kumar, A. Wasting mechanisms in muscular 
dystrophy. Int. J. Biochem. Cell Biol. 2013, 45, 2266–2279. 
66.  Zatz, M.; Starling, A. Calpains and Disease. N. Engl. J. Med. 2005, 352, 2413–
2423. 
67.  Letavernier, E.; Zafrani, L.; Perez, J.; Letavernier, B.; Haymann, J.P.; Baud, L. 
The role of calpains in myocardial remodelling and heart failure. Cardiovasc. Res. 
2012, 96, 38–45. 
68.  Freitas, A.C.S.; Figueiredo, M.J.; Campos, E.C.; Soave, D.F.; Ramos, S.G.; 
Tanowitz, H.B.; Celes, M.R.N. Activation of both the calpain and ubiquitin-
proteasome systems contributes to septic cardiomyopathy through dystrophin 
loss/disruption and mTOR inhibition. PLoS One 2016, 11, 1–14. 
69.  Shoshan-Barmatz, V.; De, S.; Meir, A. The Mitochondrial Voltage-Dependent 
Anion Channel 1, Ca2+ Transport, Apoptosis, and Their Regulation. Front. Oncol. 
2017, 7, 1–12. 
70.  Glancy, B.; Balaban, R.S. Role of mitochondrial Ca 2+ in the regulation of cellular 
energetics. Biochemistry 2012, 51, 2959–7293. 
71.  Lemasters, J.J.; Theruvath, T.P.; Zhong, Z.; Nieminen, A.L. Mitochondrial calcium 
and the permeability transition in cell death. Biochim. Biophys. Acta - Bioenerg. 
2009, 1787, 1395–1401. 
72.  Kyrychenko, V.; Poláková, E.; Janíček, R.; Shirokova, N. Mitochondrial 
dysfunctions during progression of dystrophic cardiomyopathy. Cell Calcium 2015, 
58, 186–195. 
73.  Millay, D.P.; Sargent, M.A.; Osinska, H.; Baines, C.P.; Barton, E.R.; Vuagniaux, 
G.; Sweeney, H.L.; Robbins, J.; Molkentin, J.D. Genetic and pharmacologic 
inhibition of mitochondrial-dependent necrosis attenuates muscular dystrophy. 
Nat. Med. 2008, 14, 442–447. 
74.  Gonzalez, D.R.; Treuer, A. V; Lamirault, G.; Mayo, V.; Cao, Y.; Dulce, R.A.; Hare, 
J.M. NADPH oxidase-2 inhibition restores contractility and intracellular calcium 
handling and reduces arrhythmogenicity in dystrophic cardiomyopathy. Am. J. 
Physiol. - Hear. Circ. Physiol. 2014, 307, H710–H721. 
75.  Prosser, B.L.; Ward, C.W.; Lederer, W.J. X-ROS signaling: Rapid mechano-
chemo transduction in heart. Science 2011, 333, 1440–1445. 
76.  Loehr, J.A.; Wang, S.; Cully, T.R.; Pal, R.; Larina, I. V; Larin, K. V; Rodney, G.G. 
NADPH oxidase mediates microtubule alterations and diaphragm dysfunction in 
dystrophic mice. Elife 2018, 7, 1–19. 
77.  Strakova, J.; Dean, J.D.; Sharpe, K.M.; Meyers, T.A.; Odom, G.L.; Townsend, D. 
Dystrobrevin increases dystrophin’s binding to the dystrophin-glycoprotein 
complex and provides protection during cardiac stress. J. Mol. Cell. Cardiol. 2014, 
 108 
 
76, 106–115. 
78.  Belanto, J.J.; Olthoff, J.T.; Mader, T.L.; Chamberlain, C.M.; Nelson, D.M.; 
McCourt, P.M.; Talsness, D.M.; Gundersen, G.G.; Lowe, D.A.; Ervasti, J.M. 
Independent variability of microtubule perturbations associated with 
dystrophinopathy. Hum. Mol. Genet. 2016, 25, 4951–4961. 
79.  Matecki, S.; Fauconnier, J.; Lacampagne, A. Reactive Oxygen Species and 
Muscular Dystrophy. Syst. Biol. Free Radicals Antioxidants 2014, 3055–3072. 
80.  Dikalov, S.I.; Nazarewicz, R.R. Angiotensin II-Induced Production of Mitochondrial 
Reactive Oxygen Species: Potential Mechanisms and Relevance for 
Cardiovascular Disease. Antioxid. Redox Signal. 2013, 19, 1085–1094. 
81.  Allen, D.G.; Whitehead, N.P.; Froehner, S.C. Absence of Dystrophin Disrupts 
Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric 
Oxide in the Development of Muscular Dystrophy. Physiol. Rev. 2015, 96, 253–
305. 
82.  Prosser, B.L.; Khairallah, R.J.; Ziman, A.P.; Ward, C.W.; Lederer, W.J. X-ROS 
signaling in the heart and skeletal muscle: Stretch-dependent local ROS regulates 
[Ca2+]i. J. Mol. Cell. Cardiol. 2013, 58, 172–181. 
83.  Münzel, T.; Gori, T.; Keaney, J.F.; Maack, C.; Daiber, A. Pathophysiological role 
of oxidative stress in systolic and diastolic heart failure and its therapeutic 
implications. Eur. Heart J. 2015, 36, 2555–2564. 
84.  Choi, H.; Leto, T.L.; Hunyady, L.; Catt, K.J.; Yun, S.B.; Sue, G.R. Mechanism of 
angiotensin II-induced superoxide production in cells reconstituted with 
angiotensin type 1 receptor and the components of NADPH oxidase. J. Biol. 
Chem. 2008, 283, 255–267. 
85.  Spurney, C.F.; Sali, A.; Guerron, A.D.; Iantorno, M.; Yu, Q.; Gordish-Dressman, 
H.; Rayavarapu, S.; Van Der Meulen, J.; Hoffman, E.P.; Nagaraju, K. Losartan 
decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-
deficient mdx mice. J. Cardiovasc. Pharmacol. Ther. 2011, 16, 87–95. 
86.  Lee, E.-M.; Kim, D.-Y.; Kim, A.-Y.; Lee, E.-J.; Kim, S.-H.; Lee, M.-M.; Sung, S.-E.; 
Park, J.-K.; Jeong, K.-S. Chronic effects of losartan on the muscles and the 
serologic profiles of mdx mice. Life Sci. 2015, 143, 35–42. 
87.  Brenman, J.E.; Chao, D.S.; Xia, H.; Aldape, K.; Bredt, D.S. Nitric oxide synthase 
complexed with dystrophin and absent from skeletal muscle sarcolemma in 
Duchenne muscular dystrophy. Cell 1995, 82, 743–752. 
88.  Martin, E.A.; Barresi, R.; Byrne, B.J.; Tsimerinov, E.I.; Scott, B.L.; Walker, A.E.; 
Gurudevan, S. V.; Anene, F.; Elashoff, R.M.; Thomas, G.D.; et al. Tadalafil 
alleviates muscle ischemia in patients with becker muscular dystrophy. Sci. 
Transl. Med. 2012, 4, 162ra155. 
89.  Thomas, G.D.; Sander, M.; Lau, K.S.; Huang, P.L.; Stull, J.T.; Victor, R.G. 
Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-
deficient skeletal muscle. Proc. Natl. Acad. Sci. 1998, 95, 15090–15095. 
90.  Johnson, E.K.; Zhang, L.; Adams, M.E.; Phillips, A.; Freitas, M.A.; Froehner, S.C.; 
Green-Church, K.B.; Montanaro, F. Proteomic analysis reveals new cardiac-
specific dystrophin-associated proteins. PLoS One 2012, 7, e43515. 
91.  Bia, B.L.; Cassidy, P.J.; Young, M.E.; Rafael-Fortney, J.A.; Leighton, B.; Davies, 
K.E.; Radda, G.K.; Clarke, K. Decreased myocardial nNOS, increased iNOS and 
abnormal ECGs in mouse models of duchenne muscular dystrophy. J. Mol. Cell. 
Cardiol. 1999, 31, 1857–1862. 
92.  Ramachandran, J.; Schneider, J.S.; Crassous, P.-A.; Zheng, R.; Gonzalez, J.P.; 
Xie, L.-H.; Beuve, A.; Fraidenraich, D.; Peluffo, R.D. Nitric oxide signalling 
 109 
 
pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine 
transporters. Biochem. J. 2012, 449, 133–142. 
93.  Garbincius, J.F.; Michele, D.E. Dystrophin–glycoprotein complex regulates muscle 
nitric oxide production through mechanoregulation of AMPK signaling. Proc. Natl. 
Acad. Sci. 2015, 112, 13663–13668. 
94.  Balligand, J.L.; Ungureanu-Longrois, D.; Simmons, W.W.; Pimental, D.; Malinski, 
T.A.; Kapturczak, M.; Taha, Z.; Lowenstein, C.J.; Davidoff, A.J.; Kelly, R.A.; et al. 
Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes. 
Characterization and regulation of iNOS expression and detection of iNOS activity 
in single cardiac myocytes in vitro. J. Biol. Chem. 1994, 269, 27580–27588. 
95.  Altamirano, F.; López, J.R.; Henríquez, C.; Molinski, T.; Allen, P.D.; Jaimovich, E. 
Increased resting intracellular calcium modulates NF-κB-dependent inducible 
nitric-oxide synthase gene expression in dystrophic mdx skeletal myotubes. J. 
Biol. Chem. 2012, 287, 20876–20887. 
96.  Kanai, A.J.; Pearce, L.L.; Clemens, P.R.; Birder, L.A.; VanBibber, M.M.; Choi, S.-
Y.; de Groat, W.C.; Peterson, J. Identification of a neuronal nitric oxide synthase 
in isolated cardiac mitochondria using electrochemical detection. Proc. Natl. Acad. 
Sci. 2002, 98, 14126–14131. 
97.  Massion, P.B.; Feron, O.; Dessy, C.; Balligand, J.-L. Nitric oxide and cardiac 
function: ten years after, and continuing. Circ. Res. 2003, 93, 388–398. 
98.  Adamo, C.M.; Dai, D.-F.F.; Percival, J.M.; Minami, E.; Willis, M.S.; Patrucco, E.; 
Froehner, S.C.; Beavo, J.A. Sildenafil reverses cardiac dysfunction in the mdx 
mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. 2010, 107, 
19079–19083. 
99.  Khairallah, M.; Khairallah, R.J.; Young, M.E.; Allen, B.G.; Gillis, M.A.; Danialou, 
G.; Deschepper, C.F.; Petrof, B.J.; Des Rosiers, C. Sildenafil and cardiomyocyte-
specific cGMP signaling prevent cardiomyopathic changes associated with 
dystrophin deficiency. Proc. Natl. Acad. Sci. 2008, 105, 7028–7033. 
100.  Sander, M.; Chavoshan, B.; Harris, S.A.; Iannaccone, S.T.; Stull, J.T.; Thomas, 
G.D.; Victor, R.G. Functional muscle ischemia in neuronal nitric oxide synthase-
deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. 
Natl. Acad. Sci. 2000, 97, 13818–13823. 
101.  Leung, D.G.; Herzka, D.A.; Thompson, W.R.; He, B.; Bibat, G.; Tennekoon, G.; 
Russell, S.D.; Schuleri, K.H.; Lardo, A.C.; Kass, D.A.; et al. Sildenafil does not 
improve cardiomyopathy in Duchenne/Becker muscular dystrophy. Ann. Neurol. 
2014, 76, 541–549. 
102.  Chung, H.S.; Kim, G.E.; Holewinski, R.J.; Venkatraman, V.; Zhu, G.; Bedja, D.; 
Kass, D.A.; Van Eyk, J.E. Transient receptor potential channel 6 regulates 
abnormal cardiac S-nitrosylation in Duchenne muscular dystrophy. Proc. Natl. 
Acad. Sci. 2017, 114, E10763–E10771. 
103.  Lai, Y.; Zhao, J.; Yue, Y.; Wasala, N.B.; Duan, D. Partial restoration of cardiac 
function with ΔPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. 
Hum. Mol. Genet. 2014, 23, 3189–3199. 
104.  Wehling-Henricks, M.; Jordan, M.C.; Roos, K.P.; Deng, B.; Tidball, J.G. 
Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a 
neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 
2005, 14, 1921–1933. 
105.  Wehling-Henricks, M.; Tidball, J.G. Neuronal nitric oxide synthase-rescue of 
dystrophin/utrophin double knockout mice does not require nNOS localization to 
the cell membrane. PLoS One 2011, 6, e25071. 
 110 
 
106.  Hor, K.N.; Taylor, M.D.; Al-Khalidi, H.R.; Cripe, L.H.; Raman, S. V; Jefferies, J.L.; 
O’Donnell, R.; Benson, D.W.; Mazur, W. Prevalence and distribution of late 
gadolinium enhancement in a large population of patients with Duchenne 
muscular dystrophy: Effect of age and left ventricular systolic function. J. 
Cardiovasc. Magn. Reson. 2013, 15, 1–9. 
107.  Kong, P.; Christia, P.; Frangogiannis, N.G. The pathogenesis of cardiac fibrosis. 
Cell. Mol. Life Sci. 2014, 71, 549–574. 
108.  Porter, K.E.; Turner, N.A. Cardiac fibroblasts: At the heart of myocardial 
remodeling. Pharmacol. Ther. 2009, 123, 255–278. 
109.  Heras-Bautista, C.O.; Mikhael, N.; Lam, J.; Shinde, V.; Katsen-Globa, A.; 
Dieluweit, S.; Molcanyi, M.; Uvarov, V.; Jütten, P.; Sahito, R.G.A.; et al. 
Cardiomyocytes facing fibrotic conditions re-express extracellular matrix 
transcripts. Acta Biomater. 2019, 89, 180–192. 
110.  Ma, Y.; Mouton, A.J.; Lindsey, M.L. Cardiac macrophage biology in the steady-
state heart, the aging heart, and following myocardial infarction. Transl. Res. 
2018, 191, 15–28. 
111.  Chadwick, J.A.; Swager, S.A.; Lowe, J.; Welc, S.S.; Tidball, J.G.; Gomez-
Sanchez, C.E.; Gomez-Sanchez, E.P.; Rafael-Fortney, J.A. Myeloid cells are 
capable of synthesizing aldosterone to exacerbate damage in muscular 
dystrophy. Hum. Mol. Genet. 2016, 25, 5167–5177. 
112.  Rafael-Fortney, J.A.; Chimanji, N.S.; Schill, K.E.; Martin, C.D.; Murray, J.D.; 
Ganguly, R.; Stangland, J.E.; Tran, T.; Xu, Y.; Canan, B.D.; et al. Early treatment 
with lisinopril and spironolactone preserves cardiac and skeletal muscle in 
Duchenne muscular dystrophy mice. Circulation 2011, 124, 582–588. 
113.  Rodriguez, E.K.; Hunter, W.C.; Royce, M.J.; Leppo, M.K.; Douglas, A.S.; 
Weisman, H.F. A method to reconstruct myocardial sarcomere lengths and 
orientations at transmural sites in beating canine hearts. Am. J. Physiol. Circ. 
Physiol. 2017, 263, H293–H306. 
114.  Dasgupta, C.; Zhang, L. Angiotensin II receptors and drug discovery in 
cardiovascular disease. Drug Discov. Today 2011, 16, 22–34. 
115.  Iwanami, J.; Mogi, M.; Iwai, M.; Horiuchi, M. Inhibition of the renin–angiotensin 
system and target organ protection. Hypertens. Res. 2009, 32, 229–237. 
116.  Kawai, T.; Forrester, S.J.; O’Brien, S.; Baggett, A.; Rizzo, V.; Eguchi, S. AT1 
receptor signaling pathways in the cardiovascular system. Pharmacol. Res. 2017, 
125, 4–13. 
117.  Duboc, D.; Meune, C.; Lerebours, G.; Devaux, J.Y.; Vaksmann, G.; Bécane, H.M. 
Effect of perindopril on the onset and progression of left ventricular dysfunction in 
Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 2005, 45, 855–857. 
118.  Duboc, D.; Meune, C.; Pierre, B.; Wahbi, K.; Eymard, B.; Toutain, A.; Berard, C.; 
Vaksmann, G.; Weber, S.; Bécane, H.M. Perindopril preventive treatment on 
mortality in Duchenne muscular dystrophy: 10 years’ follow-up. Am. Heart J. 
2007, 154, 596–602. 
119.  Eichhorn, E.; Domanski, M.; Krause-Steinrauf, H.; Anderson, J. A trial of the beta-
blocker bucindolol in patients with advanced chronic heart failure. ACC Curr. J. 
Rev. 2001, 344, 1659–1667. 
120.  Meyers, T.A.; Heitzman, J.A.; Townsend, D. Acute myocardial injury in mdx hearts 
ameliorated by ARB but not ACE inhibitor treatment. Submitted 2019. 
121.  Bangalore, S.; Fakheri, R.; Toklu, B.; Ogedegbe, G.; Weintraub, H.; Messerli, F.H. 
Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in 
Patients Without Heart Failure? Insights from 254,301 Patients from Randomized 
 111 
 
Trials. Mayo Clin. Proc. 2016, 91, 51–60. 
122.  Pitt, B.; Poole-Wilson, P.A.; Segal, R.; Martinez, F.A.; Dickstein, K.; Camm, A.J.; 
Konstam, M.A.; Riegger, G.; Klinger, G.H.; Neaton, J.; et al. Effect of losartan 
compared with captopril on mortality in patients with symptomatic heart failure: 
randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 
2000, 355, 1582–1587. 
123.  Allen, H.D.; Flanigan, K.M.; Thrush, P.T.; Viollet-Callendret, L.; Dvorchik, I.; Yin, 
H.; Canter, C.E.; Connolly, A.M.; Parrish, M.; McDonald, C.M.; et al. A 
Randomized, Double-Blind Trial of Lisinopril and Losartan for the Treatment of 
Cardiomyopathy in Duchenne Muscular Dystrophy. PLoS Curr. Muscular 
Dystrophy 2013, 5. 
124.  Hollenberg, N.K.; Fisher, N.D.L.; Price, D.A. Pathways for angiotensin II 
generation in intact human tissue: Evidence from comparative pharmacological 
interruption of the renin system. Hypertension 1998, 32, 387–392. 
125.  Uehara, Y.; Miura, S.; Yahiro, E.; Saku, K. Non-ACE Pathway-induced 
Angiotensin II Production. Curr. Pharm. Des. 2013, 19, 3054–3059. 
126.  Basu, R.; Poglitsch, M.; Yogasundaram, H.; Thomas, J.; Rowe, B.H.; Oudit, G.Y. 
Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J. 
Am. Coll. Cardiol. 2017, 69, 805–819. 
127.  Zou, Y.; Akazawa, H.; Qin, Y.; Sano, M.; Takano, H.; Minamino, T.; Makita, N.; 
Iwanaga, K.; Zhu, W.; Kudoh, S.; et al. Mechanical stress activates angiotensin II 
type 1 receptor without the involvement of angiotensin II. Nat. Cell Biol. 2004, 6, 
499–506. 
128.  Takezako, T.; Unal, H.; Karnik, S.S.; Node, K. Structure-Function Basis of 
Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for 
Active-State Angiotensin II Type 1 Receptors. Mol. Pharmacol. 2015, 88, 488–
501. 
129.  Chow, B.S.M.; Allen, T.J. Angiotensin II type 2 receptor (AT2R) in renal and 
cardiovascular disease. Clin. Sci. 2016, 130, 1307–1326. 
130.  Pavo, N.; Goliasch, G.; Wurm, R.; Novak, J.; Strunk, G.; Gyöngyösi, M.; Poglitsch, 
M.; Säemann, M.D.; Hülsmann, M. Low- and high-renin heart failure phenotypes 
with clinical implications. Clin. Chem. 2018, 64, 597–608. 
131.  Viollet, L.; Thrush, P.T.; Flanigan, K.M.; Mendell, J.R.; Allen, H.D. Effects of 
angiotensin-converting enzyme inhibitors and/or beta blockers on the 
cardiomyopathy in Duchenne muscular dystrophy. Am. J. Cardiol. 2012, 110, 98–
102. 
132.  Wagner, S.; Maier, L.S.; Bers, D.M. Role of Sodium and Calcium Dysregulation in 
Tachyarrhythmias in Sudden Cardiac Death. Circ. Res. 2015, 16, 1956–1970. 
133.  Triposkiadis, F.; Karayannis, G.; Giamouzis, G.; Skoularigis, J.; Louridas, G.; 
Butler, J. The Sympathetic Nervous System in Heart Failure. Physiology, 
Pathophysiology, and Clinical Implications. J. Am. Coll. Cardiol. 2009, 54, 1747–
1762. 
134.  Kajimoto, H.; Ishigaki, K.; Okumura, K.; Tomimatsu, H.; Nakazawa, M.; Saito, K.; 
Osawa, M.; Nakanishi, T. Beta-Blocker Therapy for Cardiac Dysfunction in 
Patients With Muscular Dystrophy. Circ. J. 2006, 70, 991–994. 
135.  Matsumura, T.; Tamura, T.; Kuru, S.; Kikuchi, Y.; Kawai, M. Carvedilol can 
Prevent Cardiac Events in Duchenne Muscular Dystrophy. Intern. Med. 2010, 49, 
1357–1363. 
136.  Raman, S. V.; Hor, K.N.; Mazur, W.; Halnon, N.J.; Kissel, J.T.; He, X.; Tran, T.; 
Smart, S.; McCarthy, B.; Taylor, M.D.; et al. Eplerenone for early cardiomyopathy 
 112 
 
in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled 
trial. Lancet. Neurol. 2015, 14, 153–161. 
137.  Heier, C.R.; Yu, Q.; Fiorillo, A.A.; Tully, C.B.; Tucker, A.; Mazala, D.A.; 
Uaesoontrachoon, K.; Srinivassane, S.; Damsker, J.M.; Hoffman, E.P.; et al. 
Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic 
cardiomyopathy. Life Sci. Alliance 2019, 2, e201800186. 
138.  Janssen, P.M.L.; Murray, J.D.; Schill, K.E.; Rastogi, N.; Schultz, E.J.; Tran, T.; 
Raman, S. V.; Rafael-Fortney, J.A. Prednisolone attenuates improvement of 
cardiac and skeletal contractile function and histopathology by lisinopril and 
spironolactone in the mdx mouse model of duchenne muscular dystrophy. PLoS 
One 2014, 9, e88360. 
139.  Raman, S. V.; Hor, K.N.; Mazur, W.; He, X.; Kissel, J.T.; Smart, S.; McCarthy, B.; 
Roble, S.L.; Cripe, L.H. Eplerenone for early cardiomyopathy in Duchenne 
muscular dystrophy: results of a two-year open-label extension trial. Orphanet J. 
Rare Dis. 2017, 12, 1–5. 
140.  Griggs, R.C.; Herr, B.E.; Reha, A.; Elfring, G.; Atkinson, L.; Cwik, V.; Mccoll, E.; 
Tawil, R.; Pandya, S.; Mcdermott, M.P.; et al. Corticosteroids in Duchenne 
muscular dystrophy: Major variations in practice. Muscle and Nerve 2013, 48, 27–
31. 
141.  Hoffman, E.P.; Reeves, E.; Damsker, J.; Nagaraju, K.; McCall, J.M.; Connor, 
E.M.; Bushby, K. Novel Approaches to Corticosteroid Treatment in Duchenne 
Muscular Dystrophy. Phys. Med. Rehabil. Clin. N. Am. 2012, 23, 821–828. 
142.  Bauer, R.; Straub, V.; Blain, A.; Bushby, K.; MacGowan, G.A. Contrasting effects 
of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of 
dystrophin-deficient cardiomyopathy. Eur. J. Heart Fail. 2009, 11, 463–471. 
143.  Schram, G.; Fournier, A.; Leduc, H.; Dahdah, N.; Therien, J.; Vanasse, M.; Khairy, 
P. All-cause mortality and cardiovascular outcomes with prophylactic steroid 
therapy in Duchenne muscular dystrophy. J. Am. Coll. Cardiol. 2013, 61, 948–
954. 
144.  Markham, L.W.; Spicer, R.L.; Khoury, P.R.; Wong, B.L.; Mathews, K.D.; Cripe, 
L.H. Steroid therapy and cardiac function in duchenne muscular dystrophy. 
Pediatr. Cardiol. 2005, 26, 768–771. 
145.  Barber, B.J.; Andrews, J.G.; Lu, Z.; West, N.A.; Meaney, F.J.; Price, E.T.; Gray, 
A.; Sheehan, D.W.; Pandya, S.; Yang, M.; et al. Oral corticosteroids and onset of 
cardiomyopathy in Duchenne muscular dystrophy. J. Pediatr. 2013, 163, 1080-
1084.e1. 
146.  Silversides, C.K.; Webb, G.D.; Harris, V.A.; Biggar, D.W. Effects of deflazacort on 
left ventricular function in patients with Duchenne muscular dystrophy. Am. J. 
Cardiol. 2003, 91, 769–772. 
147.  Raman, S. V.; Cripe, L.H. Glucocorticoid Therapy for Duchenne Cardiomyopathy: 
A Hobson’s Choice? J. Am. Heart Assoc. 2015, 4, 1–3. 
148.  Spurney, C.F. Cardiomyopathy of Duchenne muscular dystrophy: current 
understanding and future directions. Muscle Nerve 2011, 44, 8–19. 
149.  Heier, C.R.; Damsker, J.M.; Yu, Q.; Dillingham, B.C.; Huynh, T.; Van der Meulen, 
J.H.; Sali, A.; Miller, B.K.; Phadke, A.; Scheffer, L.; et al. VBP15, a novel anti-
inflammatory and membrane-stabilizer, improves muscular dystrophy without side 
effects. EMBO Mol. Med. 2013, 5, 1569–1585. 
150.  Rodrigues, M.; Echigoya, Y.; Fukada, S.; Yokota, T. Current Translational 
Research and Murine Models For Duchenne Muscular Dystrophy. J. 
Neuromuscul. Dis. 2016, 3, 29–48. 
 113 
 
151.  Berko, B.A.; Swift, M. X-Linked dilated cardiomyopathy. N. Engl. J. Med. 1985, 
316, 1186–1191. 
152.  Ferlini, A.; Sewry, C.; Melis, M.A.; Mateddu, A.; Muntoni, F. X-linked dilated 
cardiomyopathy and the dystrophin gene. Neuromuscul. Disord. 1999, 9, 339–
346. 
153.  Nakamura, A. X-linked dilated cardiomyopathy: A cardiospecific phenotype of 
dystrophinopathy. Pharmaceuticals 2015, 8, 303–320. 
154.  Kaspar, R.W.; Allen, H.D.; Ray, W.C.; Alvarez, C.E.; Kissel, J.T.; Pestronk, A.; 
Weiss, R.B.; Flanigan, K.M.; Mendell, J.R.; Montanaro, F. Analysis of dystrophin 
deletion mutations predicts age of cardiomyopathy onset in becker muscular 
dystrophy. Circ. Cardiovasc. Genet. 2009, 2, 544–551. 
155.  Namgoong, J.H.; Bertoni, C. Clinical potential of ataluren in the treatment of 
Duchenne muscular dystrophy. Degener. Neurol. Neuromuscul. Dis. 2016, 6, 37–
48. 
156.  Welch, E.M.; Barton, E.R.; Zhuo, J.; Tomizawa, Y.; Friesen, W.J.; Trifillis, P.; 
Paushkin, S.; Patel, M.; Trotta, C.R.; Hwang, S.; et al. PTC124 targets genetic 
disorders caused by nonsense mutations. Nature 2007, 447, 87–91. 
157.  Ebrahimi-Fakhari, D.; Dillmann, U.; Flotats-Bastardas, M.; Poryo, M.; Abdul-
Khaliq, H.; Shamdeen, M.G.; Mischo, B.; Zemlin, M.; Meyer, S. Off-Label Use of 
Ataluren in Four Non-ambulatory Patients With Nonsense Mutation Duchenne 
Muscular Dystrophy: Effects on Cardiac and Pulmonary Function and Muscle 
Strength. Front. Pediatr. 2018, 6, 316. 
158.  Lu, Q.L.; Rabinowitz, A.; Chen, Y.C.; Yokota, T.; Yin, H.; Alter, J.; Jadoon, A.; 
Bou-Gharios, G.; Partridge, T. Systemic delivery of antisense oligoribonucleotide 
restores dystrophin expression in body-wide skeletal muscles. Proc. Natl. Acad. 
Sci. 2005, 102, 198–203. 
159.  Yokota, T.; Lu, Q.L.; Partridge, T.; Kobayashi, M.; Nakamura, A.; Takeda, S.; 
Hoffman, E. Efficacy of systemic morpholino exon-skipping in duchenne dystrophy 
dogs. Ann. Neurol. 2009, 65, 667–676. 
160.  Nguyen, Q.; Yokota, T. Antisense oligonucleotides for the treatment of 
cardiomyopathy in Duchenne muscular dystrophy. Am. J. Transl. Res. 2019, 11, 
1202–1218. 
161.  Wu, B.; Lu, P.; Benrashid, E.; Malik, S.; Ashar, J.; Doran, T.J.; Lu, Q.L. Dose-
dependent restoration of dystrophin expression in cardiac muscle of dystrophic 
mice by systemically delivered morpholino. Gene Ther. 2010, 17, 132–140. 
162.  Yin, H.; Moulton, H.M.; Seow, Y.; Boyd, C.; Boutilier, J.; Iverson, P.; Wood, M.J.A. 
Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic 
muscle and cardiac dystrophin expression and function. Hum. Mol. Genet. 2008, 
17, 3909–3918. 
163.  Betts, C.; Saleh, A.F.; Arzumanov, A.A.; Hammond, S.M.; Godfrey, C.; 
Coursindel, T.; Gait, M.J.; Wood, M.J. Pip6-PMO, A New Generation of Peptide-
oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for 
DMD Treatment. Mol. Ther. Nucleic Acids 2012, 1, e38. 
164.  Echigoya, Y.; Nakamura, A.; Nagata, T.; Urasawa, N.; Lim, K.R.Q.; Trieu, N.; 
Panesar, D.; Kuraoka, M.; Moulton, H.M.; Saito, T.; et al. Effects of systemic 
multiexon skipping with peptide-conjugated morpholinos in the heart of a dog 
model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U. S. A. 2017, 114, 
4213–4218. 
165.  Mendell, J.R.; Goemans, N.; Lowes, L.P.; Alfano, L.N.; Berry, K.; Shao, J.; Kaye, 
E.M.; Mercuri, E. Longitudinal effect of eteplirsen versus historical control on 
 114 
 
ambulation in Duchenne muscular dystrophy. Ann. Neurol. 2016, 79, 257–271. 
166.  Echevarría, L.; Aupy, P.; Goyenvalle, A. Exon-skipping advances for Duchenne 
muscular dystrophy. Hum. Mol. Genet. 2018, 27, R163–R172. 
167.  McNally, E.M.; Wyatt, E.J. Mutation-based therapy for duchenne muscular 
dystrophy: Antisense treatment arrives in the clinic. Circulation 2017, 136, 979–
981. 
168.  Chamberlain, J.R.; Chamberlain, J.S. Progress toward Gene Therapy for 
Duchenne Muscular Dystrophy. Mol. Ther. 2017, 25, 1125–1131. 
169.  Duan, D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular 
Dystrophy. Mol. Ther. 2018, 26, 2337–2356. 
170.  Shin, J.H.; Nitahara-Kasahara, Y.; Hayashita-Kinoh, H.; Ohshima-Hosoyama, S.; 
Kinoshita, K.; Chiyo, T.; Okada, H.; Okada, T.; Takeda, S. Improvement of cardiac 
fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction. 
Gene Ther. 2011, 18, 910–919. 
171.  Gregorevic, P.; Allen, J.M.; Minami, E.; Blankinship, M.J.; Haraguchi, M.; Meuse, 
L.; Finn, E.; Adams, M.E.; Froehner, S.C.; Murry, C.E.; et al. rAAV6-
microdystrophin preserves muscle function and extends lifespan in severely 
dystrophic mice. Nat. Med. 2006, 12, 787–789. 
172.  Wang, B.; Li, J.; Fu, F.H.; Chen, C.; Zhu, X.; Zhou, L.; Jiang, X.; Xiao, X. 
Construction and analysis of compact muscle-specific promoters for AAV vectors. 
Gene Ther. 2008, 15, 1489–1499. 
173.  Salva, M.Z.; Himeda, C.L.; Tai, P.W.L.; Nishiuchi, E.; Gregorevic, P.; Allen, J.M.; 
Finn, E.E.; Nguyen, Q.G.; Blankinship, M.J.; Meuse, L.; et al. Design of tissue-
specific regulatory cassettes for high-level rAAV-mediated expression in skeletal 
and cardiac muscle. Mol. Ther. 2007, 15, 320–329. 
174.  Hakim, C.H.; Wasala, N.B.; Pan, X.; Kodippili, K.; Yue, Y.; Zhang, K.; Yao, G.; 
Haffner, B.; Duan, S.X.; Ramos, J.; et al. A Five-Repeat Micro-Dystrophin Gene 
Ameliorated Dystrophic Phenotype in the Severe DBA/2J-mdx Model of 
Duchenne Muscular Dystrophy. Mol. Ther. - Methods Clin. Dev. 2017, 6, 216–
230. 
175.  Louis Jeune, V.; Joergensen, J.A.; Hajjar, R.J.; Weber, T. Pre-existing Anti–
Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy. Hum. 
Gene Ther. Methods 2013, 24, 59–67. 
176.  Chicoine, L.G.; Montgomery, C.L.; Bremer, W.G.; Shontz, K.M.; Griffin, D.A.; 
Heller, K.N.; Lewis, S.; Malik, V.; Grose, W.E.; Shilling, C.J.; et al. Plasmapheresis 
eliminates the negative impact of AAV antibodies on microdystrophin gene 
expression following vascular delivery. Mol. Ther. 2014, 22, 338–347. 
177.  Min, Y.-L.; Bassel-Duby, R.; Olson, E.N. CRISPR Correction of Duchenne 
Muscular Dystrophy. Annu. Rev. Med. 2018, 70, 239–255. 
178.  Lim, K.R.Q.; Yoon, C.; Yokota, T. Applications of CRISPR/Cas9 for the treatment 
of Duchenne muscular dystrophy. J. Pers. Med. 2018, 8, E38. 
179.  Nelson, C.E.; Hakim, C.H.; Ousterout, D.G.; Thakore, P.I.; Moreb, E.A.; 
Castellanos Rivera, R.M.; Madhavan, S.; Pan, X.; Ran, F.A.; Yan, W.X.; et al. In 
vivo genome editing improves muscle function in a mouse model of Duchenne 
muscular dystrophy. Science 2016, 351, 403–407. 
180.  Amoasii, L.; Li, H.; Sanchez-Ortiz, E.; Caballero, D.; Harron, R.; Massey, C.; 
Shelton, J.; Piercy, R.; Olson, E.N. Gene editing restores dystrophin expression in 
a canine model of Duchenne muscular dystrophy. Science 2018, 362, 86–91. 
181.  Amoasii, L.; Long, C.; Li, H.; Mireault, A.A.; Shelton, J.M.; Sanchez-Ortiz, E.; 
McAnally, J.R.; Bhattacharyya, S.; Schmidt, F.; Grimm, D.; et al. Single-cut 
 115 
 
genome editing restores dystrophin expression in a new mouse model of 
muscular dystrophy. Sci. Transl. Med. 2017, 9, 1–11. 
182.  Bengtsson, N.E.; Hall, J.K.; Odom, G.L.; Phelps, M.P.; Andrus, C.R.; Hawkins, 
R.D.; Hauschka, S.D.; Chamberlain, J.R.J.S.J.R.; Chamberlain, J.R.J.S.J.R. 
Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates 
pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat. 
Commun. 2017, 8, 1–9. 
183.  Hakim, C.H.; Wasala, N.B.; Nelson, C.E.; Wasala, L.P.; Yue, Y.; Louderman, J.A.; 
Lessa, T.B.; Dai, A.; Zhang, K.; Jenkins, G.J.; et al. AAV CRISPR editing rescues 
cardiac and muscle function for 18 months in dystrophic mice. JCI Insight 2018, 3, 
1–13. 
184.  Xu, L.; Lau, Y.S.; Gao, Y.; Li, H.; Han, R. Life-Long AAV-Mediated CRISPR 
Genome Editing in Dystrophic Heart Improves Cardiomyopathy without Causing 
Serious Lesions in mdx Mice. Mol. Ther. 2019, 27, 1–8. 
185.  Nelson, C.E.; Wu, Y.; Gemberling, M.P.; Oliver, M.L.; Waller, M.A.; Bohning, J.D.; 
Robinson-Hamm, J.N.; Bulaklak, K.; Castellanos Rivera, R.M.; Collier, J.H.; et al. 
Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular 
dystrophy. Nat. Med. 2019, 25, 427–432. 
186.  Long, C.; Amoasii, L.; Mireault, A.A.; McAnally, J.R.; Li, H.; Sanchez-Ortiz, E.; 
Bhattacharyya, S.; Shelton, J.M.; Bassel-Duby, R.; Olson, E.N. Postnatal genome 
editing partially restores dystrophin expression in a mouse model of muscular 
dystrophy. Science 2016, 351, 400–403. 
187.  Fu, Y.; Foden, J.A.; Khayter, C.; Maeder, M.L.; Reyon, D.; Joung, J.K.; Sander, 
J.D. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in 
human cells. Nat. Biotechnol. 2013, 31, 822–826. 
188.  Kleinstiver, B.P.; Pattanayak, V.; Prew, M.S.; Tsai, S.Q.; Nguyen, N.T.; Zheng, Z.; 
Joung, J.K. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-
wide off-target effects. Nature 2016, 529, 490–495. 
189.  Muntoni, F. Cardiomyopathy in muscular dystrophies. Curr. Opin. Neurol. 2003, 
16, 577–583. 
190.  Hoffman, E.P.; Brown, R.H.; Kunkel, L.M. Dystrophin: the protein product of the 
Duchene muscular dystrophy locus. Cell 1987, 51, 919–928. 
191.  Hoffman, E.P.; Kunkel, L.M. Dystrophin abnormalities in Duchenne/Becker 
muscular dystrophy. Neuron 1989, 2, 1019–1029. 
192.  Campbell, K.P.; Ervasti, J.M. Dystrophin and the membrane skeleton. Curr. Opin. 
Cell Biol. 1993, 5, 82–87. 
193.  Ervasti, J.M.; Sonnemann, K.J. Biology of the Striated Muscle Dystrophin-
Glycoprotein Complex. Int. Rev. Cytol. 2008, 265, 191–225. 
194.  Wagner, K.R. Approaching a New Age in Duchenne Muscular Dystrophy 
Treatment. Neurotherapeutics 2008, 5, 583–591. 
195.  Chamberlain, J.S.; Metzger, J.; Reyes, M.; Townsend, D.; Faulkner, J.A. 
Dystrophin-deficient mdx mice display a reduced life span and are susceptible to 
spontaneous rhabdomyosarcoma. FASEB J. 2007, 21, 2195–2204. 
196.  Birnkrant, D.J.; Bushby, K.; Bann, C.M.; Apkon, S.D.; Blackwell, A.; Brumbaugh, 
D.; Case, L.E.; Clemens, P.R.; Hadjiyannakis, S.; Pandya, S.; et al. Diagnosis and 
management of Duchenne muscular dystrophy, part 1 : diagnosis, and 
neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional 
management. Lancet Neurol. 2018, 17, 251–267. 
197.  Bulfield, G.; Siller, W.G.; Wight, P.A.; Moore, K.J. X chromosome-linked muscular 
dystrophy (mdx) in the mouse. Proc. Natl. Acad. Sci. 1984, 81, 1189–1192. 
 116 
 
198.  Ryder-Cook, A.S.; Sicinski, P.; Thomas, K.; Davies, K.E.; Worton, R.G.; Barnard, 
E.A.; Darlison, M.G.; Barnard, P.J. Localization of the mdx mutation within the 
mouse dystrophin gene. EMBO J. 1988, 7, 3017–3021. 
199.  McGreevy, J.W.; Hakim, C.H.; McIntosh, M.A.; Duan, D. Animal models of 
Duchenne muscular dystrophy: from basic mechanisms to gene therapy. Dis. 
Model. Mech. 2015, 8, 195–213. 
200.  Meyers, T.A.; Townsend, D. Early right ventricular fibrosis and reduction in 
biventricular cardiac reserve in the dystrophin-deficient mdx heart. Am. J. Physiol. 
- Hear. Circ. Physiol. 2015, 308, H303–H315. 
201.  Spurney, C.F.; Guerron, A.D.; Yu, Q.; Sali, A.; van der Meulen, J.H.; Hoffman, 
E.P.; Nagaraju, K. Membrane sealant Poloxamer P188 protects against 
isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC 
Cardiovasc. Disord. 2011, 11, 20. 
202.  Townsend, D.; Yasuda, S.; McNally, E.M.; Metzger, J.M. Distinct 
pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or 
the sarcoglycan complex. FASEB J. 2011, 25, 3106–3114. 
203.  Heydemann, A.; Ceco, E.; Lim, J.E.; Hadhazy, M.; Ryder, P.; Moran, J.L.; Beier, 
D.R.; Palmer, A.A.; McNally, E.M. Latent TGF-β – binding protein 4 modifies 
muscular dystrophy in mice. J. Clin. Invest. 2009, 119, 3703–3712. 
204.  Lorts, A.; Schwanekamp, J.A.; Baudino, T.A.; McNally, E.M.; Molkentin, J.D. 
Deletion of periostin reduces muscular dystrophy and fibrosis in mice by 
modulating the transforming growth factor-β pathway. Proc. Natl. Acad. Sci. 2012, 
109, 10978–10983. 
205.  Cohn, R.D.; Erp, C. Van; Habashi, J.P.; Soleimani, A.A.; Klein, E.C.; Lisi, M.T.; 
Gamradt, M.; Rhys, C.M.; Holm, T.M.; Loeys, B.L.; et al. Angiotensin II type 1 
receptor blockade attenuates TGF- b – induced failure of muscle regeneration in 
multiple myopathic states. 2007, 13, 204–211. 
206.  Tidball, J.G.; Wehling-Henricks, M. The role of free radicals in the 
pathophysiology of muscular dystrophy. J. Appl. Physiol. 2007, 102, 1677–1686. 
207.  Williams, I.A.; Allen, D.G. The role of reactive oxygen species in the hearts of 
dystrophin-deficient mdx mice. Am. J. Physiol. - Hear. Circ. Physiol. 2007, 293, 
H1969–H1977. 
208.  Whitehead, N.P.; Pham, C.; Gervasio, O.L.; Allen, D.G. N-Acetylcysteine 
ameliorates skeletal muscle pathophysiology in mdx mice. J. Physiol. 2008, 586, 
2003–2014. 
209.  Russo, V.; Papa, A.A.; Williams, E.A.; Rago, A.; Palladino, A.; Politano, L.; Nigro, 
G. ACE inhibition to slow progression of myocardial fibrosis in muscular 
dystrophies. Trends Cardiovasc. Med. 2018, 28, 330–337. 
210.  de Senzi Moraes Pinto, R.; Ferretti, R.; Moraes, L.H.R.; Neto, H.S.; Marques, 
M.J.; Minatel, E. N-Acetylcysteine treatment reduces TNF-α levels and 
myonecrosis in diaphragm muscle of mdx mice. Clin. Nutr. 2013, 32, 472–475. 
211.  Guiraud, S.; Davies, K.E. Pharmacological advances for treatment in Duchenne 
muscular dystrophy. Curr. Opin. Pharmacol. 2017, 34, 36–48. 
212.  Markham, L.W.; Michelfelder, E.C.; Border, W.L.; Khoury, P.R.; Spicer, R.L.; 
Wong, B.L.; Benson, D.W.; Cripe, L.H. Abnormalities of Diastolic Function 
Precede Dilated Cardiomyopathy Associated with Duchenne Muscular Dystrophy. 
J. Am. Soc. Echocardiogr. 2006, 19, 865–871. 
213.  McNally, E.M. New Approaches in the Therapy of Cardiomyopathy in Muscular 
Dystrophy. Annu. Rev. Med. 2007, 58, 75–88. 
214.  Kirchmann, C.; Kececioglu, D.; Korinthenberg, R.; Dittrich, S. Echocardiographic 
 117 
 
and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-
Kiener muscular dystrophies. Pediatr. Cardiol. 2005, 26, 66–72. 
215.  Tuttle, R.R.; Mills, J. Dobutamine: Development of a new catecholamine to 
selectively increase cardiac contractility. Circ. Res. 1975, 36, 185–196. 
216.  Schmidt, G.N.; Burmeister, M.-A.; Lilje, C.; Wappler, F.; Bischoff, P. Acute heart 
failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br. J. 
Anaesth. 2003, 90, 800–804. 
217.  Tamaki, T.; Nishiyama, A.; Kimura, S.; Aki, Y.; Yoshizumi, M.; Houchi, H.; Morita, 
K.; Abe, Y. EXP3174: The Major Active Metabolite of Losartan. Cardiovasc. Drug 
Rev. 1997, 15, 122–136. 
218.  Lo, M.W.; Goldberg, M.R.; McCrea, J.B.; Lu, H.; Furtek, C.I.; Bjornsson, T.D. 
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active 
metabolite EXP3174 in humans. Clin. Pharmacol. Ther. 1995, 58, 641–649. 
219.  Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, 
T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: an open-source 
platform for biological-image analysis. Nat. Methods 2012, 9, 676–682. 
220.  R Core Team R: A Language and Environment for Statistical Computing 2014. 
221.  Junqueira, L.C.U.; Bignolas, G.; Brentani, R.R. Picrosirius staining plus 
polarization microscopy, a specific method for collagen detection in tissue 
sections. Histochem. J. 1979, 11, 447–455. 
222.  Lattouf, R.; Younes, R.; Lutomski, D.; Naaman, N.; Godeau, G.; Senni, K.; 
Changotade, S. Picrosirius Red Staining: A Useful Tool to Appraise Collagen 
Networks in Normal and Pathological Tissues. J. Histochem. Cytochem. 2014, 62, 
751–758. 
223.  Rich, L.; Whittaker, P. Collagen and Picrosirius red staining : a polarized light 
assessment of fibrillar hue and spatial distribution. Brazilian J. Morphol. Sci. 2005, 
22, 97–104. 
224.  Junqueira, L.C.U.; Montes, G.S.; Sanchez, E.M. The influence of tissue section 
thickness on the study of collagen by the Picrosirius-polarization method. 
Histochemistry 1982, 74, 153–156. 
225.  Dayan, D.; Hiss, Y.; Hirshberg, A.; Bubis, J.J.; Wolman, M. Are the polarization 
colors of Picrosirius red-stained collagen determined only by the diameter of the 
fibers? Histochemistry 1989, 93, 27–29. 
226.  Hermiston, M.L.; Xu, Z.; Weiss, A. CD45: A Critical Regulator of Signaling 
Thresholds in Immune Cells. Annu. Rev. Immunol. 2003, 21, 107–37. 
227.  Patties, I.; Haagen, J.; Dörr, W.; Hildebrandt, G.; Glasow, A. Late inflammatory 
and thrombotic changes in irradiated hearts of C57BL/6 wild-type and 
atherosclerosis-prone ApoE-deficient mice. Strahlentherapie und Onkol. 2015, 
191, 172–179. 
228.  Barros, M.H.M.; Hauck, F.; Dreyer, J.H.; Kempkes, B.; Niedobitek, G. 
Macrophage polarisation: An immunohistochemical approach for identifying M1 
and M2 macrophages. PLoS One 2013, 8, e80908. 
229.  Raggi, F.; Pelassa, S.; Pierobon, D.; Penco, F.; Gattorno, M.; Novelli, F.; Eva, A.; 
Varesio, L.; Giovarelli, M.; Bosco, M.C. Regulation of human Macrophage M1-M2 
Polarization Balance by hypoxia and the Triggering receptor expressed on 
Myeloid cells-1. Front. Immunol. 2017, 8, 1097. 
230.  Genin, M.; Clement, F.; Fattaccioli, A.; Raes, M.; Michiels, C. M1 and M2 
macrophages derived from THP-1 cells differentially modulate the response of 
cancer cells to etoposide. BMC Cancer 2015, 15, 1–14. 
231.  Kharraz, Y.; Guerra, J.; Pessina, P.; Serrano, A.L.; Munoz-Canoves, P. 
 118 
 
Understanding the process of fibrosis in Duchenne muscular dystrophy. Biomed 
Res. Int. 2014, 2014, 1–11. 
232.  Rosenkranz, S. TGF-β1 and angiotensin networking in cardiac remodeling. 
Cardiovasc. Res. 2004, 63, 423–432. 
233.  Munger, M.A. Use of Angiotensin receptor blockers in cardiovascular protection: 
Current evidence and future directions. Pharm. Ther. 2011, 36, 22–40. 
234.  Sukumaran, V.; Watanabe, K.; Veeraveedu, P.T.; Thandavarayan, R.A.; 
Gurusamy, N.; Ma, M.; Yamaguchi, K.; Suzuki, K.; Kodama, M.; Aizawa, Y. 
Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in 
rats with dilated cardiomyopathy. Hypertens. Res. 2010, 33, 695–702. 
235.  Khan, R.; Sheppard, R. Fibrosis in heart disease: Understanding the role of 
transforming growth factor-β1 in cardiomyopathy, valvular disease and 
arrhythmia. Immunology 2006, 118, 10–24. 
236.  Heydemann, A.; Huber, J.M.; Kakkar, R.; Wheeler, M.T.; McNally, E.M. Functional 
nitric oxide synthase mislocalization in cardiomyopathy. J. Mol. Cell. Cardiol. 
2004, 36, 213–223. 
237.  Flanigan, K.M.; Ceco, E.; Lamar, K.-M.; Kaminoh, Y.; Dunn, D.M.; Mendell, J.R.; 
King, W.M.; Pestronk, A.; Florence, J.M.; Mathews, K.D.; et al. LTBP4 genotype 
predicts age of ambulatory loss in duchenne muscular dystrophy. Ann. Neurol. 
2013, 73, 481–488. 
238.  Cozzoli, A.; Liantonio, A.; Conte, E.; Cannone, M.; Massari, A.M.; Giustino, A.; 
Scaramuzzi, A.; Pierno, S.; Mantuano, P.; Capogrosso, R.F.; et al. Angiotensin II 
modulates mouse skeletal muscle resting conductance to chloride and potassium 
ions and calcium homeostasis via the AT1 receptor and NADPH oxidase. Am. J. 
Physiol. - Cell Physiol. 2014, 307, C634–C647. 
239.  Bedard, K.; Krause, K.-H. The NOX family of ROS-generating NADPH oxidases: 
physiology and pathophysiology. Physiol. Rev. 2007, 87, 245–313. 
240.  Ismail, H.M.; Scapozza, L.; Ruegg, U.T.; Dorchies, O.M. Diapocynin, a dimer of 
the NADPH oxidase inhibitor apocynin, reduces ROS production and prevents 
force loss in eccentrically contracting dystrophic muscle. PLoS One 2014, 9, 
e110708. 
241.  Yang, J.; Zhang, X.; Yu, X.; Tang, W.; Gan, H. Renin-Angiotensin system 
activation accelerates atherosclerosis in experimental renal failure by promoting 
endoplasmic reticulum stress-related inflammation. Int. J. Mol. Med. 2017, 39, 
613–621. 
242.  Yao, Y.; Li, Y.; Zeng, X.; Ye, Z.; Li, X.; Zhang, L. Losartan Alleviates Renal 
Fibrosis and Inhibits Endothelial-to-Mesenchymal Transition (EMT) Under High-
Fat Diet-Induced Hyperglycemia. Front. Pharmacol. 2018, 9, 1213. 
243.  Fujisaka, S.; Usui, I.; Kanatani, Y.; Ikutani, M.; Takasaki, I.; Tsuneyama, K.; 
Tabuchi, Y.; Bukhari, A.; Yamazaki, Y.; Suzuki, H.; et al. Telmisartan improves 
insulin resistance and modulates adipose tissue macrophage polarization in high-
fat-fed mice. Endocrinology 2011, 152, 1789–1799. 
244.  Yamamoto, S.; Yancey, P.G.; Zuo, Y.; Ma, L.-J.; Kaseda, R.; Fogo, A.B.; 
Ichikawa, I.; Linton, M.F.; Fazio, S.; Kon, V. Macrophage polarization by 
angiotensin II-type 1 receptor aggravates renal injury-acceleration of 
atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011, 31, 2856–2864. 
245.  Westermeier, F.; Bustamante, M.; Pavez, M.; Garcia, L.; Chiong, M.; Ocaranza, 
M.P.; Lavandero, S. Novel players in cardioprotection: Insulin like growth factor-1, 
angiotensin-(1-7) and angiotensin-(1-9). Pharmacol. Res. 2015, 101, 41–55. 
246.  Chappell, M.C.; Marshall, A.C.; Alzayadneh, E.M.; Shaltout, H.A.; Diz, D.I. Update 
 119 
 
on the angiotensin converting enzyme 2-angiotensin (1-7)-Mas receptor axis: fetal 
programing, sex differences, and intracellular pathways. Front. Endocrinol. 
(Lausanne). 2014, 4, 201. 
247.  Santos, R.A. Angiotensin-(1-7). Hypertension 2014, 63, 1138–1147. 
248.  Manolis, A.J.; Marketou, M.E.; Gavras, I.; Gavras, H. Cardioprotective properties 
of bradykinin: role of the B2 receptor. Hypertens. Res. 2010, 33, 772–777. 
249.  Hartman, J.C. The role of bradykinin and nitric oxide in the cardioprotective action 
of ACE inhibitors. Ann. Thorac. Surg. 1995, 60, 789–792. 
250.  Bish, L.T.; Yarchoan, M.; Sleeper, M.M.; Gazzara, J.A.; Morine, K.J.; Acosta, P.; 
Barton, E.R.; Sweeney, H.L. Chronic Losartan Administration Reduces Mortality 
and Preserves Cardiac but Not Skeletal Muscle Function in Dystrophic Mice. 
PLoS One 2011, 6, e20856. 
251.  Blain, A.; Greally, E.; Laval, S.H.; Blamire, A.M.; MacGowan, G. a.; Straub, V.W. 
Absence of Cardiac Benefit with Early Combination ACE Inhibitor and Beta 
Blocker Treatment in mdx Mice. J. Cardiovasc. Transl. Res. 2015, 8, 198–207. 
252.  Thrush, P.T.; Flanigan, K.M.; Mendell, J.R.; Raman, S. V.; Daniels, C.J.; Allen, 
H.D. Visual Diagnosis: Chest Pain in a Boy With Duchenne Muscular Dystrophy 
and Cardiomyopathy. Pediatr. Rev. 2014. 
253.  Lowe, J.; Wodarcyk, A.J.; Floyd, K.T.; Rastogi, N.; Schultz, E.J.; Swager, S. a.; 
Chadwick, J. a.; Tran, T.; Raman, S. V.; Janssen, P.M.L.; et al. The Angiotensin 
Converting Enzyme Inhibitor Lisinopril Improves Muscle Histopathology but not 
Contractile Function in a Mouse Model of Duchenne Muscular Dystrophy. J. 
Neuromuscul. Dis. 2015, 2, 257–268. 
254.  Romero, C.A.; Orias, M.; Weir, M.R. Novel RAAS agonists and antagonists: 
clinical applications and controversies. Nat. Rev. Endocrinol. 2015, 11, 242–252. 
255.  Kostenis, E.; Milligan, G.; Christopoulos, A.; Sanchez-Ferrer, C.F.; Heringer-
Walther, S.; Sexton, P.M.; Gembardt, F.; Kellett, E.; Martini, L.; Vanderheyden, P.; 
et al. G-protein-coupled receptor Mas is a physiological antagonist of the 
angiotensin II type 1 receptor. Circulation 2005, 111, 1806–1813. 
256.  Acuña, M.J.; Pessina, P.; Olguin, H.; Cabrera, D.; Vio, C.P.; Bader, M.; Muñoz-
canoves, P.; Santos, R.A.; Cabello-verrugio, C.; Brandan, E. Restoration of 
muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of 
TGF-β signalling. Hum. Mol. Genet. 2014, 23, 1237–1249. 
257.  Yue, Y.; Li, Z.; Harper, S.Q.; Davisson, R.L.; Chamberlain, J.S.; Duan, D. 
Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein 
complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 
2003, 108, 1626–1632. 
258.  Viggiano, E.; Ergoli, M.; Picillo, E.; Politano, L. Determining the role of skewed X-
chromosome inactivation in developing muscle symptoms in carriers of Duchenne 
muscular dystrophy. Hum. Genet. 2016, 135. 
259.  Kalantry, S. Recent advances in X-chromosome inactivation. J. Cell. Physiol. 
2011, 226, 1714–1718. 
260.  Birnkrant, D.J.; Ashwath, M.L.; Noritz, G.H.; Merrill, M.C.; Shah, T.A.; Crowe, 
C.A.; Bahler, R.C. Cardiac and pulmonary function variability in Duchenne/Becker 
muscular dystrophy: a n initial report. J. Child Neurol. 2010, 25, 1110–1115. 
261.  Jin, J.B.; Carter, J.C.; Sheehan, D.W.; Birnkrant, D.J. Cardiopulmonary 
phenotypic discordance is common in Duchenne muscular dystrophy. Pediatr. 
Pulmonol. 2019, 54, 186–193. 
262.  Oosterwijk, J.; Majoor-Krakauer, D.; Leschot, N.; Wilde, A.; de Visser, M.; Ippel, 
P.; van der Wouw, P.; Bakker, E.; Van Essen, A.; Brunner, H.; et al. Signs and 
 120 
 
symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy 
among carriers in the Netherlands: a cohort study. Lancet 2002, 353, 2116–2119. 
263.  Florian, A.; Rösch, S.; Bietenbeck, M.; Engelen, M.; Stypmann, J.; Waltenberger, 
J.; Sechtem, U.; Yilmaz, A. Cardiac involvement in female Duchenne and Becker 
muscular dystrophy carriers in comparison to their first-degree male relatives: A 
comparative cardiovascular magnetic resonance study. Eur. Heart J. Cardiovasc. 
Imaging 2016, 17, 326–333. 
264.  Politano, L.; Nigro, V.; Nigro, G.; Petretta, V.R.; Passamano, L.; Papparella, S.; Di 
Somma, S.; Comi, L.I. Development of cardiomyopathy in female carriers of 
Duchenne and Becker muscular dystrophies. J. Am. Med. Assoc. 1996, 275, 
1335–1338. 
265.  Guglieri, M.; Magri, F.; D’Angelo, M.G.; Prelle, A.; Morandi, L.; Rodolico, C.; 
Cagliani, R.; Mora, M.; Fortunato, F.; Bordoni, A.; et al. Clinical, molecular, and 
protein correlations in a large sample of genetically diagnosed Italian limb girdle 
muscular dystrophy patients. Hum. Mutat. 2008, 29, 258–266. 
266.  Duggan, D.J.; Gorospe, J.R.; Fanin, M.; Hoffman, E.P.; Angelini, C. Mutations in 
the sarcoglycan genes in patients with myopathy. N. Engl. J. Med. 1997, 336, 
618–624. 
267.  Fanin, M.; Melacini, P.; Boito, C.; Pegoraro, E.; Angelini, C. LGMD2E patients risk 
developing dilated cardiomyopathy. Neuromuscul. Disord. 2003, 13, 303–309. 
268.  Nigro, V.; Savarese, M. Genetic basis of limb-girdle muscular dystrophies: The 
2014 update. Acta Myol. 2014, 33, 1–12. 
269.  Allikian, M.J.; McNally, E.M. Processing and Assembly of the Dystrophin 
Glycoprotein Complex. Traffic 2007, 8, 177–183. 
270.  Fanin, M.; Duggan, D.J.; Mostacciuolo, M.L.; Martinello, F.; Freda, M.P.; Soraru, 
G.; Trevisan, C.P.; Hoffman, E.P.; Angelini, C. Genetic epidemiology of muscular 
dystrophies resulting from sarcoglycan gene mutations. J. Med. Genet. 1997, 34, 
973–977. 
271.  Semplicini, C.; Dahlqvist, J.R.; Stojkovic, T.; Bello, L.; Ambrosio, P.D.; Eymard, B.; 
Politano, L.; Laforêt, P. Clinical and genetic spectrum in limb-girdle muscular 
dystrophy type 2E. Neurology 2015, 84, 1772–81. 
272.  Barresi, R.; Di Blasi, C.; Negri, T.; Brugnoni, R.; Vitali, A.; Felisari, G.; Salandi, A.; 
Daniel, S.; Cornelio, F.; Morandi, L.; et al. Disruption of heart sarcoglycan 
complex and severe cardiomyopathy caused by beta sarcoglycan mutations. J. 
Med. Genet. 2000, 37, 102–107. 
273.  Pegoraro, E.; Hoffman, E.P. Limb-Girdle Muscular Dystrophy Overview. 
GeneReviews® 1993, 1–27. 
274.  Durbeej, M.; Cohn, R.D.; Hrstka, R.F.; Moore, S.A.; Allamand, V.; Davidson, B.L.; 
Williamson, R.A.; Campbell, K.P. Disruption of the beta-sarcoglycan gene reveals 
pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol. Cell 
2000, 5, 141–151. 
275.  Araishi, K.; Sasaoka, T.; Imamura, M.; Noguchi, S.; Hama, H.; Wakabayashi, E.; 
Yoshida, M.; Hori, T.; Ozawa, E. Loss of the sarcoglycan complex and sarcospan 
leads to muscular dystrophy in β-sarcoglycan-deficient mice. Hum. Mol. Genet. 
1999, 8, 1589–1598. 
276.  Pozsgai, E.R.; Griffin, D.A.; Heller, K.N.; Mendell, J.R.; Rodino-Klapac, L.R. β-
Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E 
mice. Gene Ther. 2015, 23, 57–66. 
277.  Bonnemann, C.G.; Modi, R.; Noguchi, S.; Mizuno, Y.; Yoshida, M.; Gussoni, E.; 
McNally, E.M.; Duggan, D.J.; Angelini, C.; Hoffman, E.P. Beta-sarcoglycan (A3b) 
 121 
 
mutations cause autosomal recessive muscular dystrophy with loss of the 
sarcoglycan complex. Nat Genet 1995, 11, 266–273. 
278.  Coral-vazquez, R.; Cohn, R.D.; Moore, S. a; Hill, J. a; Weiss, R.M.; Davisson, 
R.L.; Straub, V.; Barresi, R.; Bansal, D.; Hrstka, R.F.; et al. Disruption of the 
Sarcoglycan – Sarcospan Complex in Vascular Smooth Muscle : A Novel 
Mechanism for Cardiomyopathy and Muscular Dystrophy. Animals 1999, 98, 465–
474. 
279.  Hoyer, P.B.; Devine, P.J.; Hu, X.; Thompson, K.E.; Sipes, I.G. Ovarian Toxicity of 
4-Vinylcyclohexene Diepoxide: A Mechanistic Model. Toxicol. Pathol. 2001, 29, 
91–99. 
280.  Chen, H.; Perez, J.N.; Constantopoulos, E.; McKee, L.; Regan, J.; Hoyer, P.B.; 
Brooks, H.L.; Konhilas, J. A Method to Study the Impact of Chemically-induced 
Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice. J. Vis. Exp. 
2014, 1–8. 
281.  Greising, S.M.; Carey, R.S.; Blackford, J.E.; Dalton, L.E.; Kosir, A.M.; Lowe, D.A. 
Estradiol treatment, physical activity, and muscle function in ovarian-senescent 
mice. Exp. Gerontol. 2011, 46, 685–93. 
282.  Townsend, D. Measuring Pressure Volume Loops in the Mouse. JoVE 2016, 
e53810. 
283.  Guerra, S.; Leri, A.; Wang, X.; Finato, N.; Loreto, C. Di; Beltrami, C.A.; Kajstura, 
J.; Anversa, P. Myocyte Death in the Failing Human Heart Is Gender Dependent. 
New York 1999, 856–866. 
284.  Fukumoto, T.; Yamashita, N.; Tawa, M.; Ohkita, M.; Matsumura, Y. Sex 
differences in postischemic cardiac dysfunction and norepinephrine overflow in rat 
heart: the role of estrogen against myocardial ischemia-reperfusion damage via 
an NO-mediated mechanism. J. Cardiovasc. Pharmacol. 2012, 60, 269–75. 
285.  Cross, H.R.; Murphy, E.; Steenbergen, C. Ca(2+) loading and adrenergic 
stimulation reveal male/female differences in susceptibility to ischemia-reperfusion 
injury. Am. J. Physiol. Heart Circ. Physiol. 2002, 283, H481-9. 
286.  Chen, Q.; Williams, R.; Healy, C.L.; Wright, C.D.; Wu, S.C.; O’Connell, T.D. An 
association between gene expression and better survival in female mice following 
myocardial infarction. J. Mol. Cell. Cardiol. 2010, 49, 801–11. 
287.  Ji, H.; Zheng, W.; Wu, X.; Liu, J.; Ecelbarger, C.M.; Watkins, R.; Arnold, A.P.; 
Sandberg, K. Sex chromosome effects unmasked in angiotensin II-induced 
hypertension. Hypertension 2010, 55, 1275–1282. 
288.  Regitz-Zagrosek, V.; Oertelt-Prigione, S.; Seeland, U.; Hetzer, R. Sex and gender 
differences in myocardial hypertrophy and heart failure. Circ. J. 2010, 74, 1265–
1273. 
289.  Martínez-Sellés, M.; Domínguez, M.; Martínez, E.; Fernández, M.A.G.; García, E. 
Women with left ventricular ejection fraction ≤ 20% have better prognosis than 
men. Int. J. Cardiol. 2007, 120, 276–278. 
290.  Cavasin, M.A.; Tao, Z.; Menon, S.; Yang, X.-P. Gender differences in cardiac 
function during early remodeling after acute myocardial infarction in mice. Life Sci. 
2004, 75, 2181–2192. 
291.  Xue, B.; Pamidimukkala, J.; Lubahn, D.B.; Hay, M. Estrogen receptor-alpha 
mediates estrogen protection from angiotensin II-induced hypertension in 
conscious female mice. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H1770–
H1776. 
292.  Konhilas, J.P.; Leinwand, L. a The effects of biological sex and diet on the 
development of heart failure. Circulation 2007, 116, 2747–59. 
 122 
 
293.  Silva-Antonialli, M.M.; Tostes, R.C.A.; Fernandes, L.; Fior-Chadi, D.R.; Akamine, 
E.H.; Carvalho, M.H.C.; Fortes, Z.B.; Nigro, D. A lower ratio of AT1/AT2 receptors 
of angiotensin II is found in female than in male spontaneously hypertensive rats. 
Cardiovasc. Res. 2004, 62, 587–593. 
294.  Xue, Q.; Xiao, D.; Zhang, L. Estrogen Regulates Angiotensin II Receptor 
Expression Patterns and Protects the Heart from Ischemic Injury in Female Rats 
1. 2015, 93, 1–9. 
295.  Sampson, A.K.; Moritz, K.M.; Jones, E.S.; Flower, R.L.; Widdop, R.E.; Denton, 
K.M. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in 
arterial pressure attributable to chronic low-dose angiotensin II in female rats. 
Hypertension 2008, 52, 666–671. 
296.  Sullivan, J.C. Sex and the renin-angiotensin system: inequality between the sexes 
in response to RAS stimulation and inhibition. Am. J. Physiol. Regul. Integr. 
Comp. Physiol. 2008, 294, R1220-6. 
297.  Maric-Bilkan, C.; Arnold, A.P.; Taylor, D.A.; Dwinell, M.; Howlett, S.E.; Wenger, 
N.; Reckelhoff, J.F.; Sandberg, K.; Churchill, G.; Levin, E.; et al. Report of the 
National Heart, Lung, and Blood Institute Working Group on Sex Differences 
Research in Cardiovascular Disease: Scientific Questions and Challenges. 
Hypertension 2016, 802–807. 
298.  Pozsgai, E.R.; Griffin, D.A.; Heller, K.N.; Mendell, J.R.; Rodino-Klapac, L.R. 
Systemic AAV-Mediated β-Sarcoglycan Delivery Targeting Cardiac and Skeletal 
Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice. Mol. 
Ther. 2017, 25, 855–869. 
 
 
 
 
  
